PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
C12N 15/31, C07K 14/315, A61K 39/09, C12N 1/21

(11) International Publication Number:

WO 99/42588

A2 | (4

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/CA99/00114

(22) International Filing Date:

17 February 1999 (17.02.99)

(30) Priority Data:

60/075,425

20 February 1998 (20.02.98)

US

(71) Applicant (for all designated States except US): BIOCHEM VACCINS INC. [CA/CA]; 2323 boulevard du Parc Technologique, Sainte-Foy, Québec G1P 4R8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRODEUR, Bernard, R. [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). RIOUX, Clément [CA/CA]; 1012 Jean-Charles Cantin, Ville de Cap Rouge, Québec G1Y 2X1 (CA). BOYER, Martine [CA/CA]; Apt. 204, 25 des Mouettes, Beauport, Québec G1E 7G1 (CA). CHARLEBOIS, Isabelle [CA/CA]; 410 Mirabel, St-Nicolas, Québec G7A 2L5 (CA). HAMEL, Josée [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G rue Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9 (CA).

(74) Agents: CÔTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

(57) Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL Albania ES Spain LS Lesotho SI Slovenia AM Armenia FI Finland LT Lithuania SK Slovakia	
Tr Cintand 1 T Listuania CV Clayabic	
All Alliente	
AT Austria FR France LU Luxembourg SN Senegal	
AU Australia GA Gabon LV Latvia SZ Swazila:	nd
AZ Azerbaijan GB United Kingdom MC Monaco TD Chad	
BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo	
BB Barbados GH Ghana MG Madagascar TJ Tajikista	an
BE Belgium GN Guinea MK The former Yugoslav TM Turkme	nistan
BF Burkina Faso GR Greece Republic of Macedonia TR Turkey	
BG Bulgaria HU Hungary ML Mali TT Trinidac	d and Tobago
BJ Benin IE Ireland MN Mongolia UA Ukraine	
BR Brazil IL Israel MR Mauritania UG Uganda	
BY Belarus IS Iceland MW Malawi US United	States of America
CA Canada IT Italy MX Mexico UZ Uzbekis	stan
CF Central African Republic JP Japan NE Niger VN Viet Na	um .
CG Congo KE Kenya NL Netherlands YU Yugosla	avia
CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbab	we
CI Côte d'Ivoire KP Democratic People's NZ New Zealand	
CM Cameroon Republic of Korea PL Poland	
CN China KR Republic of Korea PT Portugal	
CU Cuba KZ Kazakstan RO Romania	
CZ Czech Republic LC Saint Lucia RU Russian Federation	
DE Germany LI Liechtenstein SD Sudan	
DK Denmark LK Sri Lanka SE Sweden	
EE Estonia LR Liberia SG Singapore	

GROUP B STREPTOCOCCUS ANTIGENS

5

FIELD OF THE INVENTION

The present invention is related to antigens, more particularly protein antigens of group B streptococcus (GBS)

10 bacterial pathogen which are useful as vaccine components for therapy and/or prophylaxis.

BACKGROUND OF THE INVENTION

15

Streptococcus are gram (+) bacteria that are differentiated by group specific carbohydrate antigens A through O found on their cell surface. Streptococcus groups are further distinguished by type-specific capsular polysaccharide

20 antigens. Several serotypes have been identified for the Group B streptococcus (GBS): Ia, Ib, II, III, IV, V, VI, VII and VIII. GBS also contains antigenic proteins known as "C-proteins" (alpha, beta, gamma and delta), some of which have been cloned.

25

30

35

Although GBS is a common component of the normal human vaginal and colonic flora this pathogen has long been recognized as a major cause of neonatal sepsis and meningitis, late-onset meningitis in infants, postpartum endometritis as well as mastitis in dairy herds. Expectant mothers exposed to GBS are at risk of postpartum infection and may transfer the infection to their baby as the child passes through the birth canal. Although the organism is sensitive to antibiotics, the high attack rate and rapid onset of sepsis in neonates and meningitis in infants results in high morbidity and mortality.

To find a vaccine that will protect individuals from GBS infection, researches have turned to the type-specific antigens. Unfortunately these polysaccharides have proven to be poorly immunogenic in humans and are restricted to the particular serotype from which the polysaccharide originates. Further, capsular polysaccharide elicit a T cell independent response i.e. no IgG production. Consequently capsular polysaccharide antigens are unsuitable as a vaccine component for protection against GBS infection.

Others have focused on the C-protein beta antigen which demonstrated immunogenic properties in mice and rabbit models. This protein was found to be unsuitable as a human vaccine because of its undesirable property of interacting with high affinity and in a non-immunogenic manner with the Fc region of human IgA. The C-protein alpha antigen is rare in type III serotypes of GBS which is the serotype responsible for most GBS mediated conditions and is therefore of little use as a vaccine component.

Therefore there remains an unmet need for GBS antigens that may be used as vaccine components for the prophylaxis and/or therapy of GBS infection.

SUMMARY OF THE INVENTION

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence selected from the group consisting of:

SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,

SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,

SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,

SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,

```
SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

In other aspects, there is provided vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and methods of producing polypeptides comprising culturing said host cells under conditions suitable for expression.

15 In yet another aspect, there is provided novel polypeptides encoded by polynucleotides of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

20

25

```
Figure la is the DNA sequence of clone 1 (SEQ ID NO :1) with corresponding amino acid sequences for open reading frames; figure 1b is the amino acid sequence SEQ ID NO: 2; figure 1c is the amino acid sequence SEQ ID NO: 3; figure 1d is the amino acid sequence SEQ ID NO: 4; figure 1e is the amino acid sequence SEQ ID NO: 5; figure 1f is the amino acid sequence SEQ ID NO: 6;
```

Figure 2a is the DNA sequence of clone 2 (SEQ ID NO :7) with corresponding amino acid sequences for open reading frames; figure 2b is the amino acid sequence SEQ ID NO: 8; figure 2c is the amino acid sequence SEQ ID NO: 9; figure 2d is the amino acid sequence SEQ ID NO:10; figure 2e is the amino acid sequence SEQ ID NO:11; figure 2f is the amino acid sequence SEQ ID NO:12;

```
Figure 3a is the DNA sequence of clone 3 (SEQ ID NO :13)
     with corresponding amino acid sequences for open reading
     frames;
     figure 3b is the amino acid sequence SEQ ID NO:14;
    figure 3c is the amino acid sequence SEQ ID NO:15;
    figure 3d is the amino acid sequence SEQ ID NO:16;
    figure 3e is the amino acid sequence SEQ ID NO:17;
    figure 3f is the amino acid sequence SEQ ID NO:18;
    figure 3g is the amino acid sequence SEQ ID NO:19;
    figure 3h is the amino acid sequence SEQ ID NO:20;
10
    figure 3i is the amino acid sequence SEQ ID NO:21;
    Figure 4a is the DNA sequence of clone 4 (SEQ ID NO :22)
    with corresponding amino acid sequences for open reading
15
    frames;
    figure 4b is the amino acid sequence SEQ ID NO:23;
    figure 4c is the amino acid sequence SEQ ID NO:24;
    figure 4d is the amino acid sequence SEQ ID NO:25;
    figure 4e is the amino acid sequence SEQ ID NO:26;
20
    Figure 5a is the DNA sequence of clone 5 (SEQ ID NO :27)
    with corresponding amino acid sequences for open reading
    frames:
    figure 5b is the amino acid sequence SEQ ID NO:28;
    figure 5c is the amino acid sequence SEQ ID NO:29;
25
    figure 5d is the amino acid sequence SEQ ID NO:30;
    figure 5e is the amino acid sequence SEQ ID NO:31;
    Figure 6a is the DNA sequence of clone 6 (SEQ ID NO :32);
    figure 6b is the amino acid sequence SEQ ID NO:33;
30
    figure 6c is the amino acid sequence SEQ ID NO:34;
    figure 6d is the amino acid sequence SEQ ID NO:35;
    figure 6e is the amino acid sequence SEQ ID NO:36;
    Figure 7a is the DNA sequence of clone 7 (SEQ ID NO :37);
35
    figure 7b is the amino acid sequence SEQ ID NO:38;
```

```
figure 7c is the amino acid sequence SEQ ID NO:39; figure 7d is the amino acid sequence SEQ ID NO:40; figure 7e is the amino acid sequence SEQ ID NO:41;
```

5 Figure 8 is the DNA sequence of a part of clone 7 including a signal sequence (SEQ ID NO :42);

Figure 9 is the DNA sequence of a part of clone 7 without a signal sequence (SEQ ID NO :43);

10 Figure 9a is the amino acid sequence (SEQ ID NO:44);

Figure 10 represents the distribution of anti-GBS ELISA titers in sera from CD-1 mice immunized with recombinant GBS protein corresponding to the SEQ ID NO:39.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel antigenic polypeptides of group B streptococcus (GBS) characterized by the amino acid sequence selected from the group consisting of:

SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,

SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,

SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,

SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,

15 SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

A preferred embodiment of the invention includes SEQ ID NO :39 and SEQ ID NO:44.

20

30

A further preferred embodiment of the invention is SEQ ID ${\tt NO}$:39.

A further preferred embodiment of the invention is SEQ ID NO :44.

As used herein, "fragments", "derivatives" or "analogs" of the polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural.

The terms «fragments», «derivatives» or «analogues» of polypeptides of the present invention also include polypeptides which are modified by addition, deletion,

substitution of amino acids provided that the polypeptides retain the capacity to induce an immune response.

By the term «conserved amino acid» is meant a substitution of one or more amino acids for another in which the antigenic determinant (including its secondary structure and hydropathic nature) of a given antigen is completely or partially conserved in spite of the substitution.

- For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, 15 the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) 20 amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- 25 Preferably, derivatives and analogs of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. More preferably polypeptides will have greater than 95% homology. In another 30 preferred embodiment, derivatives and analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10. Preferred substitutions are those known in the art as conserved i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional groups.

Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different GBS strains.

Also included are polypeptides which have fused thereto other compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for ease of purification; prepro- and pro- sequences; and (poly) saccharides.

Moreover, the polypeptides of the present invention can be modified by terminal -NH₂ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carbosy amidation, e.g. with ammonia or methylamine) to provide stability, increased hydrophobicity for linking or binding to a support or other molecule.

20

25

10

Also contemplated are hetero and homo polypeptide multimers of the polypeptide fragments, analogues and derivatives. These polymeric forms include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, gluteraldehyde or dimethyl-superimidate. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.

Preferably, a fragment, analog or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e. at least one epitope.

In order to achieve the formation of antigenic polymers

(i.e. synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like,

where the reagents being specific for thio groups. Therefore, the link between two mercapto groups of the different peptides may be a single bond or may be composed of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

In a particular embodiment, polypeptide fragments, analogs and derivatives of the invention do not contain a methionine (Met) starting residue. Preferably, polypeptides will not incorporate a leader or secretory sequence (signal sequence). The signal portion of a polypeptide of the invention may be determined according to established molecular biological techniques. In general, the polypeptide of interest may be isolated from a GBS culture and subsequently sequenced to determine the initial residue of the mature protein and therefor the sequence of the mature polypeptide.

- According to another aspect, there is provided vaccine compositions comprising one or more GBS polypeptides of the invention in admixture with a pharmaceutically acceptable carrier diluent or adjuvant.
- Suitable adjuvants include oils i.e. Freund's complete or incomplete adjuvant; salts i.e. AlK(SO₄)₂, AlNa(SO₄)₂, AlNH₄(SO₄)₂, Al(OH)₃, AlPO₄, silica, kaolin; saponin derivative; carbon polynucleotides i.e. poly IC and poly AU and also detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal immunity. Preferred adjuvants include QuilATM, AlhydrogelTM and AdjuphosTM. Vaccines of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or bucal or oral.

Vaccine compositions of the invention are used for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection, in particular.

- in particular group A streptococcus (pyogenes), group B streptococcus (GBS or agalactiae), dysgalactiae, uberis, nocardia as well as Staphylococcus aureus. General information about Streptococcus is available in Manual of Clinical Microbiology by P.R.Murray et al. (1995, 6th Edition,
- ASM Press, Washington, D.C.). More particularly group B streptococcus, agalactiae. In a particular embodiment vaccines are administered to those individuals at risk of GBS infection such as pregnant women and infants for sepsis, meningitis and pneumonia as well as immunocompromised
- individuals such as those with diabetes, liver disease or cancer. Vaccines may also have veterinary applications such as for the treatment of mastitis in cattle which is mediated by the above mentioned bacteria as well as *E.coli*.
- The vaccine of the present invention can also be used for the manufacture of a medicament used for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection, in particular group A streptococcus (pyogenes), group B streptococcus (GBS or agalactiae), dysgalactiae, uberis, nocardia as well as Staphylococcus aureus. More particularly group B
- Vaccine compositions are preferably in unit dosage form of about 0.001 to 100 µg/kg (antigen/body weight) and more preferably 0.01 to 10 µg/kg and most preferably 0.1 to 1 µg/kg 1 to 3 times with an interval of about 1 to 12 weeks intervals between immunizations, and more preferably 1 to 6

streptococcus, agalactiae.

weeks.

According to another aspect, there is provided polynucleotides encoding polypeptides of group B

- 5 streptococcus (GBS) characterized by the amino acid sequence selected from the group consisting of:
 - SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,
 - SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,
 - SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,
- 10 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,
 - SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24,
 - SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,
 - SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34,
 - SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,
- 15 SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

Preferred polynucleotides are those illustrated in figures la (SEQ ID NO: 1), 2a (SEQ ID NO: 7), 3a (SEQ ID NO: 13), 4a (SEQ ID NO: 22), 5a (SEQ ID NO: 27), 6a (SEQ ID NO: 32), 7a (SEQ ID NO: 37), 8 (SEQ ID NO: 42) and 9(SEQ ID NO: 43) which correspond to the open reading frames, encoding polypeptides of the invention.

- Preferred polynucleotides are those illustrated in figures la (SEQ ID NO: 1), 2a (SEQ ID NO: 7), 3a (SEQ ID NO: 13), 4a (SEQ ID NO: 22), 5a (SEQ ID NO: 27), 6a (SEQ ID NO: 32), 7a (SEQ ID NO: 37), 8 (SEQ ID NO: 42) and 9(SEQ ID NO: 43) and fragments, analogues and derivatives thereof.
 - More preferred polynucleotides of the invention are those illustrated in Figures 7 (SEQ ID NO : 37), 8 (SEQ ID NO : 42) and 9(SEQ ID NO : 43).
- Most preferred polynucleotides of the invention are those illustrated in Figures 8 (SEQ ID NO : 42) and 9 (SEQ ID NO :

43).

It will be appreciated that the polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention.

Due to the degeneracy of nucleotide coding sequences, other polynucleotide sequences which encode for substantially the same polypeptides of the present invention may be used in the practice of the present invention. These include but are not limited to nucleotide sequences which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change.

15

10

Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described (or the complement sequences thereof) having 50% and preferably at least 70% identity between sequences. More preferably polynucleotides are hybridizable under stringent conditions i.e. having at least 95% identity and most preferably more than 97% identity.

By capable of hybridizing under stringent conditions is meant annealing of a nucleic acid molecule to at least a region of a second nucleic acid sequence (whether as cDNA, mRNA, or genomic DNA) or to its complementary strand under standard conditions, e.g. high temperature and/or low salt content, which tend to disfavor hybridization of noncomplementary nucleotide sequences. A suitable protocol is described in Maniatis T. et al., Molecular cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, 1982, which is herein incorporated by reference.

35

In a further aspect, polynucleotides encoding polypeptides

of the invention, or fragments, analogs or derivatives thereof, may be used in a DNA immunization method.

That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

10

According to another aspect, there is provided a process for producing polypeptides of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product. Alternatively, the polypeptides can be produced according to established synthetic chemical techniques i.e. solution phase or solid phase synthesis of oligopeptides which are ligated to produce the full polypeptide (block ligation).

20

For recombinant production, host cells are transfected with vectors which encode the polypeptide, and then cultured in a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable in 25 the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the 30 appropriate site using restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and optionally an operator (control element). One can select individual components of the 35 expression control region that are appropriate for a given

host and vector according to established molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor, N.Y., 1989 incorporated herein by reference). Suitable promoters include but are not limited to LTR or SV40 promoter, E.coli lac, tac or trp 5 promoters and the phage lambda $P_{\scriptscriptstyle L}$ promoter. Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicillin resistance gene. bacterial vectors include pET, pQE70, pQE60, pQE-9, pbs, pD10 phagescript, psiX174, pbluescript SK, pbsks, pNH8A, 10 pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. E.coli, Bacillus subtilis,

15 Streptomyces; fungal i.e. Aspergillus niger, Aspergillus nidulins; yeast i.e. Saccharomyces or eukaryotic i.e. CHO, COS.

Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by 20 physical or chemical means (if the expressed polypeptide is not secreted into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the 25 properties of the polypeptide i.e. using ammonium sulfate or ethanol precipitation , acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final 30 purification may be achieved using HPLC.

The polypeptide may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US

4,431,739; 4,425,437; and 4,338,397 incorporated herein by reference) or be chemically removed subsequent to purifying the expressed polypeptide.

- 5 According to a further aspect, the GBS polypeptides of the invention may be used in a diagnostic test for streptococcus infection in particular GBS infection. Several diagnostic methods are possible, for example detecting streptococcus organism in a biological sample, the following procedure may be followed:
 - a) obtaining a biological sample from a patient;
 - b) incubating an antibody or fragment thereof reactive with a GBS polypeptide of the invention with the biological sample to form a mixture; and
- 15 c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of streptococcus.

Alternatively, a method for the detection of antibody
20 specific to a streptococcus antigen in a biological sample containing or suspected of containing said antibody may be performed as follows:

- a) isolating a biological sample from a patient;
- b) incubating one or more GBS polypeptides of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to streptococcus.

30

35

25

One of skill in the art will recognize that this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the protein are present in an organism.

The DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of streptococcus in a biological sample suspected of containing such bacteria. The detection method of this invention comprises:

- a) isolating the biological sample from a patient;
- b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound DNA probe in the mixture which indicates the presence of streptococcus bacteria.
- The DNA probes of this invention may also be used for detecting circulating streptococcus i.e. GBS nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing streptococcus infections. The probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labeled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the GBS polypeptides of the invention.

25

10

Another diagnostic method for the detection of streptococcus in a patient comprises:

- a) labeling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;
- 30 b) administering the labeled antibody or labeled fragment to the patient; and
 - c) detecting specifically bound labeled antibody or labeled fragment in the patient which indicates the presence of streptococcus.

35

A further aspect of the invention is the use of the GBS

polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of streptococcus infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against streptococcus infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigenbinding fragment thereof and may in general belong to any immunoglobulin class. The antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term 15 recombinant antibody or antibody fragment means antibody or antibody fragment which were produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the GBS 20 polypeptides but is preferably specific for one.

EXAMPLE 1 Murine model of lethal Group B Streptococcus (GBS)
25 infection

The mouse model of GBS infection is described in detail in Lancefield et al (J Exp Med 142:165-179,1975). GBS strain C388/90 (Clinical isolate obtained in 1990 from the cephalorachidian fluid of a patient suffering from meningitis, Children's Hospital of Eastern Ontario, Ottawa, Canada) and NCS246 (National Center for Streptococcus, Provincial Laboratory of Public Health for Northern Alberta, Edmonton, Canada) were respectively serotyped as type Ia/c and type II/R.

30

To increase their virulence, the GBS strains C388/90 (serotype Ia/c) and NCS 246 (serotype II/R) were serially passaged through mice as described previously (Lancefield et al. J Exp Med 142:165-179, 1975). Briefly, the increase of virulence was monitored using intraperitoneal inoculations of serial dilutions of a subculture in Todd-Hewitt broth obtained from either the blood or spleen of infected mice. After the last passage, infected blood samples were used to inoculate Todd-Hewitt broth. After an incubation of 2 hours at 37°C with 7% CO₂, glycerol at a final concentration of 10 10% (v/v) was added to the culture. The culture was then aliquoted and stored at -80° C for use in GBS challenge experiments. The number of cfu of GBS present in these frozen samples was determined. The bacterial concentration necessary to kill 100% (LD100) of the 18 weeks old mice were 15 determined to be 3.5X10⁵ and 1.1X10⁵ respectively for GBS strain C388/90 and NCS246, which corresponded to a significant increase in virulence for both strains. the LD100 recorded before the passages for these two strains 20 was higher than 10° cfu.

In a bacterial challenge, a freshly thawed aliquot of a virulent GBS strain was adjusted to the appropriate bacterial concentration using Todd-Hewitt broth and 1ml was 25 injected intraperitoneally to each female CD-1 mouse. mice used for the passive protection experiments were 6 to 8 weeks old, while the ones used for the active protection experiments were approximately 18 weeks old at the time of the challenge. All inocula were verified by colony counts. 30 Animals were observed for any sign of infection four times daily for the first 48 h after challenge and then daily for the next 12 days. At the end of that period, blood samples were obtained from the survivors and frozen at -20°C. spleen obtained from each mouse that survived the challenge was cultured in order to identify any remaining GBS. 35

EXAMPLE 2 Immunization and protection in mice with formaldehyde killed whole GBS cells

- Formaldehyde killed GBS whole cells were prepared according to the procedures described in Lancefield et al (J Exp Med 142:165-179,1975). Briefly, an overnight culture on sheep blood agar plates (Quelab Laboratories, Montreal, Canada) of a GBS strain was washed twice in PBS buffer (phosphate buffered-saline, pH7.2), adjusted to approximately 3X10° cfu/mL and incubated overnight in PBS containing 0.3% (v/v) formaldehyde. The killed GBS suspension was washed with PBS and kept frozen at -80°C.
- 15 Female CD-1 mice, 6 to 8 weeks old (Charles River, St-Constant, Québec, Canada), were injected subcutaneously three times at two weeks interval with 0.1 ml of formaldehyde killed cells of GBS strain C388/90 (~6X10⁷ GBS), or 0.1 ml of PBS for the control group. On the day before content immunization, AlhydrogelTM (Superfos Biosector, Frederikssund, Denmark) at a final concentration of 0.14 mg or 0.21 mg of Al, was added to these preparations and incubated overnight at 4°C with agitation. Serum samples were obtained from each mouse before the beginning of the immunization protocol and two weeks after the last injection. The sera were frozen at -20°C.

Eight mice in each control group injected with PBS and the group immunized with formaldehyde killed whole cells GBS strain C388/90 (Ia/c) were challenged with 1.5X104 cfu of GBS strain C388/90 (Ia/c) one week after the third injection. All mice immunized with the formaldehyde killed GBS whole cells survived the homologous challenge while, within 5 days after the challenge, only 4 out of the 8 mice injected with PBS survived from the infection. In order to increase the mortality rate in the control groups, the

bacterial suspension had to be adjusted according to the age of the mice at the time of the bacterial challenge. In subsequent challenge experiments, when mice were older than 15 weeks, the bacterial inoculum was increased to concentrations between 3.0X10⁵ and 2.5X10⁶ cfu.

Table 1 Immunization of CD1 mice with formaldehyde killed whole cells of GBS and subsequent homologous challenge [strain C388/90 (Ia/c)] and heterologous challenge [strain NCS246 (II/R)].

antigenic preparations used for immunization ¹	number of living mice 14 days after the bacterial challenge (% Survival)			
	homologous challenge: strain C388/90 (la/c)	heterologous challenge: strain NCS246 (II/R)		
1st infection				
formaldehyde killed cells of GBS strain C388/90 (la/c) ²	8/8 (100) ³	n.d. ⁵		
control PBS	4/8 (50)	n.d.		
2nd infection				
formaldehyde killed cells of GBS strain C388/90 (la/c)	6/6 (100)⁴	0/6 (0) ⁶		
control PBS	2/6 (33)	0/6 (0)		

¹ alhydrogel™ at a final concentration of 0.14 mg or 0.21mg of Al was used;

10

15

20

25

5

In another experiment, one group of 12 mice corresponding to a control group was injected with PBS, while a second group of 12 mice was immunized with formaldehyde killed whole cells of GBS strain C388/90 (Ia/c). Six mice from each of these two groups were challenged with 2.1X10⁶ cfu of the GBS strain C388/90 (Ia/c) (Table I). As the first challenge experiment, all mice immunized with the GBS strain C388/90 (Ia/c) survived the homologous challenge. Only two out of the 6 mice injected with PBS survived the infection.

² approximately 6X10⁷ cfu;

intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS C388/90 (la/c) suspension adjusted to 1.5X10⁴ cfu;

⁴ intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS C388/90 (la/c) suspension adjusted to 2.1X10⁶ cfu;

⁵ not done;

⁶ intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS NCS246 (II/R) suspension adjusted to 1.2X10⁵ cfu.

The remaining 6 mice in both groups were then used one week later to verify whether this antigenic preparation could confer cross protection against strain NCS246 (II/R) which produce a serologically distinct capsule. None of the mice infected with this second GBS strain survived the infection. The later result suggested that most of the protective immune response induced by formaldehyde killed strain C388/90 is directed against the capsular polysaccharide and that it could be restricted to strains of that particular serotype. These results clearly indicated that this particular model of infection can be efficiently used to study the protection conferred by vaccination.

15

30

EXAMPLE 3 Immunization of rabbit with formaldehyde killed whole GBS cells and passive protection in mice

A New Zealand rabbit (2.5 kg, Charles River, St-Constant,

Québec, Canada) was immunized with formaldehyde killed
cells of GBS strain C388/90 (Ia/c) to obtain hyperimmune
serum. This rabbit was injected subcutaneously three
times at three weeks interval with approximately 1.5X10°
cfu of formaldehyde killed whole cells of GBS strain

C388/90 (Ia/c). Freund's complete adjuvant (Gibco BRL
Life Technologies, Grand Island, New York) was used as the
adjuvant for the first immunization, while Freund's
incomplete adjuvant (Gibco BRL) was used for the following
two injections. Serum samples were obtained before the

The ability of this particular rabbit hyperimmune serum to passively protect mice against a lethal infection with GBS

beginning of the immunization protocol and two weeks after

the last injection. The sera were frozen at -20°C.

was also evaluated. Intraperitoneal injection of mice with either 15 or 25 μ L of hyperimmune rabbit serum 18 hours before the challenge protected 4 out of 5 mice (80%) against the infection. Comparatively, survival rates lower than 20% were recorded for mice in the control group injected with PBS or serum obtained from a rabbit immunized with meningococcal outer membrane preparation. This result clearly indicates that the immunization of another animal species with killed GBS cells can induce the production of antibodies that can passively protect mice. This reagent will also be used to characterize clones.

Table 2 Passive protection of CD-1 mice conferred by rabbit serum obtained after immunization with formaldehyde killed group B whole streptococci (strain C388/90 (Ia/c)) antigenic preparation

groups	number of living mice 14 days after the bacterial challenge with GBS strain C388/90 (Ia/c) ²	% survival
rabbit hyperimmune serum² - 25 μl	4/5	80
rabbit hyperimmune serum¹ - 15 μl	4/5	80
control rabbit serum - 25 μl	1/5	20
control PBS	1/10	10

Freund's complete adjuvant was used for first immunization, and Freund's incomplete adjuvant for the following two injections;

25

20

10

² intraperitoneal challenge with 1 ml Todd-Hewitt culture medium containing GBS C388/90 (Ia/c) suspension adjusted to 2X10⁴ cfu.

Recombinant production of His. Tag-GBS fusion EXAMPLE 4 protein

The coding region of a GBS gene was amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, San Jose, CA) from the genomic DNA of GBS strain C388/90 (Ia/c) using the oligos that contained base extensions for the addition of the restriction sites BglII (AGATCT) and HindIII (AAGCTT), respectively. The PCR product was purified from agarose gel using a Qiaex II gel extraction kit from Qiagen 10 (Chatsworth, CA), digested with the restriction enzymes BglII and HindIII (Pharmacia Canada Inc Baie d'Urfe, Canada), and extracted with phenol:chloroform before ethanol precipitation. The pET-32b(+) vector (Novagen, Madison, WI) containing the thioredoxin-His. Tag sequence was digested 15 with the restriction enzymes BglII and HindIII, extracted with phenol:chloroform, and then ethanol precipitated. BglII-HindIII genomic DNA fragment was ligated to the BglII-HindIII pET-32b(+) vector to create the coding sequence for thioredoxin-His. Tag-GBS fusion protein whose gene was under 20 control of the T7 promoter. The ligated products were transformed into E.~coli strain XLI Blue MRF' $(\Delta(\textit{mcr}A)$ 183 Δ (mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F'proAB lacIqZΔM15Tn10 (Tetr)]c) (Stratagene, La Jolla, CA) according to the method of Simanis (Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed.), pp. 109-135). The recombinant pET plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing (Taq Dye Deoxy Terminator Cycle Sequencing kit, ABI, Foster City, CA). 30 recombinant pET plasmid was transformed by electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Canada) into $E.\ coli$ strain AD494 (DE3) ($\Delta ara^{-}leu7697$ Δ lacX74 Δ phoA PvuII phoR Δ malF3 F'[lac*(lacIq) pro] trxB::Kan (DE3)) (Novagen, Madison, WI). In this strain of

E. coli, the T7 promoter controlling expression of the fusion protein, is specifically recognized by the T7 RNA polymerase (present on the $\lambda DE3$ prophage) whose gene is under the control of the lac promoter which is inducible by isopropyl- β -D-thio-galactopyranoside (IPTG).

The transformant AD494(DE3)/rpET was grown at 37°C with agitation at 250 rpm in LB broth (peptone 10g/L, Yeast extract 5g/L, NaCl 10g/L) containing 100µg of ampicillin (Sigma-Aldrich Canada Ltd., Oakville, Canada) per mL until the A₆₀₀ reached a value of 0.6. In order to induce the production of the thioredoxin-His.Tag-GBS fusion protein, the cells were incubated for 2 additional hours in the presence of IPTG at a final concentration of 1mM. The bacterial cells were harvested by centrifugation.

The recombinant fusion protein produced by AD494 (DE3) /rpET32 upon IPTG induction for 2h was partially obtained as insoluble inclusion bodies which were purified from 20 endogenous E. coli proteins by the isolation of insoluble aggregates (Gerlach, G.F. et al 1992, Infect. Immun. 60:892). Induced cells from a 500 mL culture were resuspended in 20 mL of 25% sucrose-50mM Tris-HCl buffer (pH8.0) and frozen at -70°C. Lysis of cells in thawed 25 suspension was achieved by the addition of 5mL of a solution of lysozyme (10mg/mL) in 250mM Tris-HCl buffer (pH8.0) followed by an incubation of 10 to 15 min on ice, and the addition of 150mL of detergent mix (5 parts of 20mM Tris-HCl buffer [pH7.4]-300mM NaCl-2% deoxycholic acid-2% Nonidet P-40 and 4 parts of 100mM Tris-HCl buffer [pH8]-50mM EDTA-2% Triton X-100) followed by 5 min incubation on ice. sonication, protein aggregates were harvested by centrifugation for 30 min at 35,000 X g and a sample of the soluble cellular fraction was kept. The aggregated proteins 35 were solubilized in 6M guanidine hydrochloride. The

presence of the fusion protein in both the soluble and insoluble fractions was shown by Western Blot analysis using the serum of a mouse injected with formaldehyde killed cells of GBS strain C388/90 (Ia/c) that survived a bacterial challenge with the corresponding GBS strain.

The purification of the fusion protein from the soluble fraction of IPTG-induced AD494(DE3)/rpET was done by affinity chromatography based on the properties of the 10 His. Tag sequence (6 consecutive histidine residues) to bind to divalent cations (Ni2+) immobilized on the His.Bind metal chelation resin (Novagen, Madison, WI). The purification method used are those described in the pET system Manual, 6th Edition (Novagen, Madison, WI). Briefly, the pelleted cells obtained from a 100mL culture induced with IPTG was 15 resuspended in 4mL of Binding buffer (5mM imidazole-500mM NaCl-20mM Tris-HCl pH7.9), sonicated, and spun at 39,000 $\rm X$ g for 20 min to remove debris. The supernatant was filtered $(0.45\mu\text{m}\text{ pore size membrane})$ and deposited on a column of 20 His.Bind resin equilibrated in Binding buffer. was then washed with 10 column volumes of Binding buffer followed by 6 column volumes of Wash buffer (20mM imidazole-500mM NaCl-20mM Tris-HCl pH7.9). The thioredoxin-His.Tag-GBS fusion protein was eluted with Elute buffer (1M 25 imidazole-500mM NaCl-20mM Tris-HCl pH7.9). The removal of the salt and imidazole from the sample was done by dialysis against 3 X 1 liter PBS at 4°C.

The quantities of fusion protein obtained from either the soluble or insoluble cytoplasmic fractions of *E. coli* were estimated by Coomassie staining of a sodium dodecyl sulfate (SDS)-polyacrylamide gel with serial dilutions of these proteins and a bovine serum albumin standard (Pierce Chemical Co. Rockford, Ill.).

35

EXAMPLE 5 Recombinant production of GBS protein under control of lambda P_L promoter

The DNA coding region of a GBS protein was inserted downstream of the promoter λP , into the translation vector pURV22. This plasmid was derived from p629 (George et al, 1987, Bio/Technology 5:600) from which the coding region for a portion of the herpes simplex virus type I (HSV-I) glycoprotein (gD-1) was removed and the ampicillin resistance gene replaced by a kanamycin cassette obtained from the plasmid vector pUC4K (Pharmacia Biotech Canada Inc., Baie D'Urfe, Canada). The vector contained a cassette of the bacteriophage λ cI857 temperature sensitive repressor gene from which the functional P, promoter had been deleted. 15 The inactivation of the cI857 repressor by temperature increase from the ranges of 30-37°C to 37-42°C resulted in the induction of the gene under the control of λ P₁. The translation of the gene was controlled by the ribosome binding site cro followed downstream by a BqlII restriction 20 site (AGATCT) and the ATG: ACTAAGGAGGTTAGATCTATG.

Restriction enzymes and T4 DNA ligase were used according to suppliers (Pharmacia Biotech Canada Inc., Baie D'Urfe, Canada; and New England Biolabs Ltd., Mississauga, Canada). 25 Agarose gel electrophoresis of DNA fragments was performed as described by Sambrook et al. (Molecular cloning : A laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, N.Y). Chromosomal DNA of the GBS bacteria was prepared according to procedures described in Jayarao et al 30 (J. Clin. Microbiol., 1991, 29:2774). DNA amplification reactions by polymerase chain reaction (PCR) were made using DNA Thermal Cycler GeneAmp PCR system 2400 (Perkin Elmer, San Jose, CA). Plasmids used for DNA sequencing were purified using plasmid kits from Qiagen (Chatsworth, CA). 35 DNA fragments were purified from agarose gels using Qiaex II

gel extraction kits from Qiagen (Chatsworth, CA). Plasmid transformations were carried out by the method described by Hanahan (DNA Cloning, Glover (ed.) pp, 109-135, 1985). The sequencing of genomic DNA inserts in plasmids was done using synthetic oligonucleotides which were synthesized by oligonucleotide synthesizer model 394 (the Perkin-Elmer Corp., Applied Biosystems Div. (ABI), Foster City, CA). The sequencing reactions were carried out by PCR using the Taq Dye Deoxy Terminator Cycle Sequencing kit (ABI, Foster City, CA) and DNA electrophoresis was performed on automated DNA 10 sequencer 373A (ABI, Foster City, CA). The assembly of the DNA sequence was performed using the program Sequencer 3.0 (Gene Codes Corporation, Ann Arbor, MI). Analysis of the DNA sequences and their predicted polypeptides was performed 15 with the program Gene Works version 2.45 (Intelligenetics, Inc., Mountain View CA).

The coding region of the GBS gene was amplified by PCR from GBS strain C388/90 (Ia/c) genomic DNA using oligos that contained base extensions for the addition of restriction 20 sites BglII (AGATCT) and XbaI(TCTAGA), respectively. The PCR product was purified from agarose gel using a Qiaex II gel extraction kit from Qiagen (Chatsworth, CA), digested with the restriction enzymes BglII and XbaI, and extracted with phenol:chloroform before ethanol precipitation. The pURV22 25 vector was digested with the restriction enzymes BglII and XbaI, extracted with phenol:chloroform, and ethanol precipitated. The BglII-XbaI genomic DNA fragment was ligated to the BglII-XbaI pURV22 vector in which the GBS gene was under the control of the λPL promoter. The ligated 30 products were transformed into $E.\ coli$ strain XLI Blue MRF' $(\Delta (mcrA)183\Delta (mcrCB-hsdSMR-mrr)173 endAl supE44 thi-l recAl$ gyrA96 relA1 lac[F' proAB lac1qZAM15 Tn10(Tetr)]c) (Stratagene, La Jolla CA) according to the methods described in Hanahan, supra. Transformants harboring plasmids with the 35

insert were identified by analysis of lysed cells submitted to electrophoresis on agarose gel (Sambrook et al, <u>supra</u>). The recombinant pURV22 plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing.

The transformant XLI Blue MRF'/rpURV22 was grown at 34°C with agitation at 250 rpm in LB broth containing $50\mu g$ of kanamycin per mL until the A_{600} reached a value of 0.6. In order to induce the production of the fusion protein, the cells were incubated for 4 additional hours at 39°C. The bacterial cells were harvested by centrifugation , resuspended in sample buffer, boiled for 10 min and kept at -20°C.

15

30

35

EXAMPLE 6 Subcloning GBS protein gene in CMV plasmid pCMV-GH

The DNA coding region of a GBS protein was inserted in phase downstream of the human growth hormone (hGH) gene which was under the transcriptional control of the cytomegalovirus (CMV) promoter in the plasmid vector pCMV-GH (Tang et al, Nature, 1992, 356:152). The CMV promoter is non functional in E. coli cells but active upon administration of the plasmid in eukaryotic cells. The vector also incorporated the ampicillin resistance gene.

The coding region of the gene was amplified by PCR from genomic DNA of GBS strain C388/90 (Ia/c) using the oligos that contained base extensions for the addition of the restriction sites BglII (AGATCT) and HindIII (AAGCTT). The PCR product was purified from agarose gel using a Qiaex II gel extraction kit from Qiagen (Chatsworth, CA), digested with the restriction enzymes BglII and HindIII, and extracted with phenol:chloroform before ethanol precipitation. The pCMV-GH vector (Laboratory of Dr. Stephen

A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas) containing the human growth hormone to create fusion proteins was digested with the restriction enzymes BamHI and HindIII, extracted with phenol:chloroform, and ethanol precipitated. The 1.3-kb BglII-HindIII genomic DNA fragment was ligated to the BamHI -HindIII pCMV-GH vector to create the hGH-GBS fusion protein under the control of the CMV promoter. The ligated products were transformed into E. coli strain DH5 α [ϕ 80 lacZ Δ M15 endA1 recAl hsdR17 ($^{r}K^{-m}K^{+}$) supE44 thi-1 λ^{-} gyrA96 relA1 Δ (lacZYA-10 argF)U169] (Gibco BRL, Gaithersburg, MD) according to the methods described by Hanahan, supra. Transformants harboring plasmids with the insert were identified by analysis of lysed cells submitted to electrophoresis on agarose gel (Sambrook, J. et al , supra). The recombinant 15 pCMV plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing.

20

EXAMPLE 7 Immunological activity of GBS protein to GBS challenge

Four groups of 12 female CD-1 mice (Charles River, St
Constant, Quebec, Canada) of 6 to 8 weeks were injected subcutaneously three times at three week intervals with 0.1mL of the following antigenic preparations: formaldehyde killed cells of GBS strain C388/90 (~6X107 cfu), 20µg of thioredoxin-His.Tag-GBS fusion protein obtained from the insoluble (inclusion bodies) or 20µg of the fusion protein, affinity purified (nickel column), from the soluble cytoplasmic fraction in E.coli, or 20µg of affinity purified (nickel column) thioredoxin-His.Tag control polypeptide.

20µg of QuilATM (Cedarlane Laboratories Ltd, Hornby, Canada)

was added to each antigenic preparation as the adjuvant. Serum samples were obtained from each mouse before immunization (PB) and on days 20 (TB1), 41 (TB2) and 54 (TB3) during the immunization protocols. Sera were frozen at -20°C.

An increase of the ELISA titers was recorded after each injection of the fusion protein indicating a good primary response and a boost of the specific humoral immune response 10 after each of the second and third administration. end of the immunization period, the means of reciprocal ELISA titers was 456,145 for the group immunized with 20µg of fusion protein obtained from inclusion bodies compared to 290,133 for the group of mice immunized with the protein from soluble fraction in E.coli. The latter result suggests 15 that the protein obtained from inclusion bodies could be more immunogenic than the soluble protein. Analysis of mice sera in ELISA using the affinity purified thioredoxin-His. Tag to coat plates showed that negligible antibody 20 titers are made against the thioredoxin-His. Tag portion of the fusion protein. The reactivity of the sera from mice injected with the recombinant fusion protein was also tested by ELISA against formaldehyde killed whole cells of GBS strain C388/90. The antibodies induced by immunization with 25 recombinant fusion protein also recognized their specific epitopes on GBS cells indicating that their conformation is close enough to the native streptococcal protein to induce cross-reactive antibodies.

30 To verify whether the immune response induced by immunization could protect against GBS infection, mice were challenged with 3.5X10⁵ cfu of GBS strains C338/90(Ia/c) and 1.2X10⁵ cfu of strain NCS246(II/R) the results of which are illustrated in tables 3 and 4 respectively. Mice immunized with control thioredoxin-His.Tag peptide were not protected against challenge with either GBS strain while those

immunized with formaldehyde killed C388/90 whole cells only provided protection against homologous challenge. The thioredoxin-His.Tag-GBS fusion protein of the invention protected mice from challenge with both GBS strains. Blood and spleen culture of these mice did not reveal the presence of any GBS.

PCT/CA99/00114 WO 99/42588

Table 3 Survival from GBS strain C388/90 (Ia/c) challenge¹

immunizing agent	no. mice surviving challenge	% survival
thioredoxin-His.Tag²	1 / 6	17
formaldehyde killed C388/90 cells ³	6 / 6	100
thioredoxin-His.Tag-GBS fusion (inclusion body preparation)4	6 / 6	100
thioredoxin-His.Tag-GBS fusion (cytoplasmic fraction)	6 / 6	100

intraperitoneal administration with 1 ml Todd-Hewitt culture medium adjusted to 3.5X10⁵ cfu;

 ^{2 20}μg administered; posterior legs paralyzed in surviving mouse; GBS detected in blood and spleen;
 3 6X10⁷ cfu administered;

^{4 20}µg administered.

Table 4 Survival from GBS strain NCS246 (II/R) challenge¹

immunizing agent	no. mice surviving challenge	% survival
thioredoxin-His.Tag²	0 / 6	0
formaldehyde killed C388/90 cells ³	2 / 6	34
thioredoxin-His.Tag-GBS fusion (inclusion body preparation) ²	5 / 54	100
thioredoxin-His.Tag-GBS fusion (cytoplasmic fraction) ²	6 / 6	100

intraperitoneal administration with 1 ml Todd-Hewitt culture medium containing GBS NCS246(II/R) suspension adjusted to 1.2X10⁵ cfu.

EXAMPLE 8 Immunization with recombinant GBS protein confers protection against experimental GBS infection

This example illustrates the protection of mice against fatal GBS infection by immunization with the recombinant protein corresponding to the SEQ ID NO:39.

- Groups of 10 female CD-1 mice (Charles River) were immunized subcutaneously three times at three-week intervals with 20 µg of recombinant protein purified from E.coli strain BLR (Novagen) harboring the recombinant pURV22 plasmid vector containing the GBS gene corresponding to SEQ ID NO:42 in
- 25 presence of 20 μg of QuilATM adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada) or, as control, with

² 20µg administered;

^{3 6}X107 cfu administered;

^{10 4} one mouse died during immunization.

QuilATM adjuvant alone in PBS. Blood samples were collected from the orbital sinus on day 1, 22 and 43 prior to each immunization and fourteen days (day 57) following the third injection. One week later the mice were challenged with approximately 10⁴ to 10⁶ CFU of various virulent GBS strains. Samples of the GBS challenge inoculum were plated on TSA/5% sheep blood agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded for a period of 14 days and on day 14 post-challenge, the surviving mice were sacrificed and blood and spleen were tested for the presence of GBS organisms. The survival data are shown in table 5.

Prechallenge sera were analyzed for the presence of antibodies reactive with GBS by standard immunoassays. Elisa and immunoblot analyses indicated that immunization with recombinant GBS protein produced in *E. coli* elicited antibodies reactive with both, recombinant and native GBS protein. Antibody responses to GBS are described in Example 9.

20

10

Table 5. Ability of recombinant GBS protein corresponding to SEQ ID NO: 39 to elicit protection against 8 diverse GBS challenge strains

10

	Challenge	strain		
Immunogen	Designation	Type	No. alive:	No. dead 1
rGBS protein	C388/90	Ia/c	8 : 2	(P<0.0001)
none			0:10	·
rGBS protein	NCS 246	II/R	10:0	(P=0.0012)
none			3:7_	
rGBS protein	ATCC12401	Ib	10 : 0	(P=0.001)
none			3:7	
rGBS protein	NCS 535	V	10 : 0	(P=0.01)
none			5:5	
rGBS protein	NCS 9842	VI	10 : 0	(P<0.0001)
none			0:10	
rGBS protein	NCS 915	III	7 : 3	$(P=0.0007)^2$
NCS 915-F ³			1:9	, , ,
none			4:6	
rGBS protein	NCS 954	III/R	7:3	(P=0.002)
NCS 954-F			4:6	
none			1:9	
rGBS protein	COH1	III	4:6	(P=0.0004)
COH1-F			3:7	
none			0:10	

Groups of 10 mice per group were used, the number of mice surviving to infection and the number of dead mice are indicated. The survival curves corresponding to recombinant GBS protein-immunized animals were compared to the survival curves corresponding to mock-immunized animals using the log-rank test for nonparametric analysis.

All hemocultures from surviving mice were negative at day 14 20 post-challenge. Spleen cultures from surviving mice were negative except for few mice from experiment MB-11.

² Comparison analysis to NCS915-F-immunized animals.

¹⁵ 3 Animals were immunized with formaldehyde-killed GBS in presence of QuilATM adjuvant.

EXAMPLE 9 Vaccination with the recombinant GBS protein elicits an immune response to GBS

Groups of 10 female CD-1 mice were immunized subcutaneously 5 with recombinant GBS protein corresponding to SEQ ID NO:39 as described in Example 8. In order to assess the antibody response to native GBS protein, sera from blood samples collected prior each immunization and fourteen days after the third immunization were tested for antibody reactive 10 with GBS cells by ELISA using plates coated with formaldehyde-killed GBS cells from type III strain NCS 954, type Ib strain ATCC12401, type V strain NCS 535 or type VI strain NCS 9842. The specificity of the raised antibodies for GBS protein was confirmed by Western blot analyses to 15 GBS cell extracts and purified recombinant antigens. The results shown in Figure 10 clearly demonstrate that animals respond strongly to recombinant GBS protein used as immunogens with median reciprocal antibody titers varying between 12000 and 128000, for sera collected after the third immunization, depending of the coating antigen. All 20 preimmune sera were negative when tested at a dilution of 1 :100. GBS-reactive antibodies were detectable in the sera of each animal after a single injection of recombinant GBS protein.

Example 10 Antigenic conservation of the GBS protein of the present invention

Monoclonal antibodies (MAbs) specific to the GBS protein of the present invention were used to demonstrate that this surface antigen is produced by all GBS and that it is also antigenically highly conserved.

A collection of 68 GBS isolates was used to evaluate the
reactivity of the GBS-specific MAbs. These strains were
obtained from the National Center for Streptococcus,
Provincial Laboratory of Public Health for Northern Alberta,
Canada; Centre Hospitalier Universitaire de Quebec, Pavillon
CHUL, Quebec, Canada; American Type Culture Collection, USA;
Laboratoire de Sante Publique du Quebec, Canada; and Dept.

of Infectious Disease, Children's Hospital and Medical Center, Seattle, USA. All eight Mabs were tested against the following panel of strains: 6 isolates of serotype Ia or Ia/c, 3 isolates of serotype Ib, 4 isolates of serotype II,

20 14 isolates of serotype III, 2 isolates of serotype IV, 2 isolates of serotype V, 2 isolates of serotype VI, 2 isolates of serotype VII, 1 isolate of serotype VIII, 10 isolates that were not serotyped and 3 bovine S. agalactiae strains. MAb 3A2 was also reacted with additional GBS: 9

isolates of serotype Ia/c and 10 isolates of serotype V. The strains were grown overnight on blood agar plates at 37°C in an atmosphere of 5% CO_2 . Cultures were stored at -70°C in heart infusion broth with 20% (v/v) glycerol.

To obtain the GBS protein-specific MAbs, mice were immunized three times at three-week intervals with 20 μ g of purified recombinant GBS protein (SEQ ID NO :44) in the presence of 20% QuilATM adjuvant. Hybridoma cell lines were generated by fusion of spleen cells recovered from immunized mice with the nonsecreting SP2/O myeloma cell line as described

previously (Hamel, J. et al. 1987. J. Med. Microbiol. 23:163-170). Hybrid clone supernatants were tested for specific antibody production by ELISA using formaldehyde inactivated GBS and purified recombinant GBS protein (SEQ ID NO :39 or 44) as coating antigen, as previously described (Hamel, J. et al. 1987. J. Med. Microbiol. 23:163-170). Specific hybrid were cloned by limiting dilutions, expanded, and frozen in liquid nitrogen. Production of recombinant GBS protein was presented in Examples 4 & 5. Purified recombinant GBS protein or formaldehyde inactivated GBS were 10 resolved by electrophoresis by using the discontinuous buffer system of Laemmli as recommended by the manufacturer and then transfer onto nitrocellulose membrane for Western immunoblotting as described previously (Martin et al. 1992. 15 Infect. Immun. 60:2718-2725).

Western immunoblotting experiments clearly indicated that all eight MAbs recognized a protein band that corresponded to the purified recombinant GBS protein (SEQ ID NO :39). These MAbs also reacted with a protein band present in every GBS isolates tested so far. The reactivity of these GBS-specific MAbs are presented in Table 6. Each MAb reacted well with all 46 GBS. In addition, these MAbs also recognized the 3 S. agalactiae strains of bovine origin that were tested. MAb 3A2 also recognized nineteen GBS; 9 isolates of serotype Ia/c and 10 of serotype V. The other

These results demonstrated that the GBS protein (SEQ ID NO:39) was produced by all the 65 GBS and the three 3 S. agalactiae strains of bovine origin that were tested so far. More importantly, these results clearly demonstrated that the epitopes recognized by these eight GBS-specific MAbs were widely distributed and conserved among GBS. These results also indicated that these epitopes were not

MAbs were not tested against these additional strains.

20

restricted to serologically related isolates since representatives of all known GBS serotypes including the major disease causing groups were tested.

In conclusion, the data presented in this example clearly demonstrated that the GBS protein of the present invention is produced by all GBS and that it is antigenically highly conserved.

Reactivity of eight GBS protein-specific MAbs with different S. agalactiae strains as evaluated by Western immunoblots. Table 6.

	و							T	٦				_
MAbs.	Rovine	(3)	٣	3	2	3	-	,\ \ -	~	3	3		•
by the	πOπΔI.	(26)	46	46	46	46	71	4.0	46	46	46		
agalactiae strains recognized		NT(10) 2	10	10	10	10	21.	10	10	10	10	,	
trains r		(1)	1		-	-	4	-		-	-	7	
tiae s		VII (2)	2	, ,	7 0	7 (7	7	2	1	3 6	7	
agalac		IA (C)	+	4 6	7	7	7	2	C	3 0	7	7	
of s.			(2)			2 2	2 2	2	1	7 7	1	2	
serotype of			(4)	4	4	4	4		4	4	4	4	
each se		-	(4)	4	4	4	4	.	4	4	4	4	
Number of		l Ib	(3)	٣	3	3	-	7	3	m	3	7	,
Numh		Ia or	Ia/c (6)	9	9	e		٥	9	9	9		٥
Mabs				3421	5012	2577	7700	8B9	8E11	12R12	18611	77107	2002
L				<u> </u>			_i		<u></u>	_1_		_1.	

1 Nine additional strains of serotype Ia/c and 10 strains of serotype V were recognized by MAb 3A2.

10 2 These strains were not serotyped

15

Ś

WE CLAIM:

1. An isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

- 2. A polynucleotide according to claim 1, wherein said polynucleotide encodes a polypeptide having at least 95% identity to the second polypeptide.
- An isolated polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence selected from the group consisting of:

 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

4. An isolated polynucleotide that is complementary to the polynucleotide of claim 1.

- 5. An isolated polynucleotide that is complementary to the polynucleotide of claim 3.
- 6. The polynucleotide of claim 1, wherein said polynucleotide is DNA.
- The polynucleotide of claim 3, wherein said polynucleotide is DNA.
- 8. The polynucleotide of claim 1, wherein said polynucleotide is RNA.
- The polynucleotide of claim 3, wherein said polynucleotide is RNA.
- 10. A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of:

 SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 22, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 42 and SEQ ID NO: 43 or fragments, analogues or derivatives thereof.
- 11. A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of :

 SEQ ID NO : 37, SEQ ID NO : 42 and SEQ ID NO : 43.
- 12. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 37.

13. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 42.

- 14. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 43.
- 15. A polynucleotide according to claim 10 wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.
- 16. A polynucleotide according to claim 11 wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.
- 17. A vector comprising the polynucleotide of claim 1, wherein said polynucleotide is operably linked to an expression control region.
- 18. A vector comprising the polynucleotide of claim 3, wherein said polynucleotide is operably linked to an expression control region.
- 19. A host cell transfected with the vector of claim 17.
- 20. A host cell transfected with the vector of claim 18.
- 21. A process for producing a polypeptide comprising culturing a host cell according to claim 19 under conditions suitable for expression of said polypeptide.
- 22. A process for producing a polypeptide comprising culturing a host cell according to claim 20 under condition suitable for expression of said polypeptide.

23. An isolated polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

- 24. The isolated polypeptide of claim 23 having a sequence according to SEQ ID NO : 39.
- 25. The isolated polypeptide of claim 23 having a sequence according to SEQ ID NO : 44.
- 26. An isolated polypeptide capable of generating antibodies having binding specificity for a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

27. The isolated polypeptide of claim 26 having a sequence according to SEQ ID NO : 39.

28. The isolated polypeptide of claim 26 having a sequence according to SEQ ID NO : 44.

29. An isolated polypeptide having an amino acid sequence

- selected from the group consisting of:

 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,

 SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,

 SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,

 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,

 SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24,

 SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,
 - SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,
 - SEQ ID NO:40 and SEQ ID NO:41 or fragments, analogs or derivatives thereof.
- 30. The isolated polypeptide of claim 29 having an amino acid sequence according to SEQ ID NO : 39.
- 31. An isolated polypeptide having an amino acid sequence according to SEQ ID NO : 44.
- 32. An isolated polypeptide according to any one of claims 29 to 31, wherein the N-terminal Met residue is deleted.
- 33. An isolated polypeptide according to any one of claims 29 to 30, wherein the secretory amino acid sequence is deleted.
- 34. A vaccine composition comprising a polypeptide according to any one of claims 23 to 31 and a pharmaceutically acceptable carrier, diluent or adjuvant.

35. A vaccine composition comprising a polypeptide according to claim 32 and a pharmaceutically acceptable carrier, diluent or adjuvant.

- 36. A vaccine composition comprising a polypeptide according to claim 33 and a pharmaceutically acceptable carrier, diluent or adjuvant.
- 37. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 34.
- 38. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 35.
- 39. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 36.
- 40. A method according to any one of claims 37 to 39, wherein said animal is a bovine.
- 41. A method according to any one of claims 37 to 39, wherein said animal is a human.

42. A method according to any one of claims 37 to 39, wherein said bacterial infection is selected from the group consisting of group A streptococcus and group B streptococcus.

- 43. A method according to claim 42, wherein said bacterial infection is group B streptococcus.
- 44. Use of a vaccine composition according to claim 34 for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 45. Use of a vaccine composition according to any one of claims 35 to 36 for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 46. Use of a vaccine composition according to any one claims 23 to 31 for the manufacture of a vaccine for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 47. Use of a vaccine composition according to claim 32 for the manufacture of a vaccine for the therapeutic or

prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.

48. Use of a vaccine composition according to claim 33 for the manufacture of a vaccine for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.

-	3 1					AA1 N	rcg1 R	rtt: F	ra S	GTTG W	GGC' A	TAA K	AAA' N	TAAJ K	ATTA L	TT2 L	AAT(CAA N	TG G	60
GATTCA F				CTA L			AAC: T			TATT F			AGT V			AT.			TA K	120
AACCA(P I	GAT'		CCCI P				CTA Y			TTAT I			GAC T		ATGG W	AC' T		GAT M	GG A	180
CATTAC L '	GTA V									ATAG R			TTC S			TC: S			'AA I	240
TATTA'			CCA(Q				AAG S					CCC P				AG S	TCC P		GT F	300
TCTTT			AAT' I				TTT L				TTA Y		TGT V		AGGA G	TT. L	AAG R	AGA E	GA T	360
CCATC I	TCG S		GAC				TAA N							AGT V		TT F	TTT L	AG1 V	TAT S	420
CATCG S		AT I	ACT L			CT L		TTA Y				AAGA E	AGA D	ATTA	ATAG	AA	AGT	'ATC	CTA	480
GTGAT	'AGA	.CT	AAC	AGT	ATGA	TA	TGG	TAT	GT	CAAA	AGTA	ATTT	AGG	SAGG	AGAA	GA	M	GTO	T	540
CTTTA L	ACA T	AT I	AAT I	TAT I	TGCA A	AC T				CTT				TTTA Y		AT M	GTF	ATT!	-	600
AGACO T		GC A	CAC T		GTCA S					GGAZ K					GTCT S		AAGA E	AAG: E		660
TGTCA S	ATAT Y			CGI V						AGA.				TAT Y		G G			TTG G	720
GCCT/	ATT(F			TTT? Y		TT L			TTT S				AG E		TTGTA V	G(A	CTG: V	TTT F	TTT L	780
TAAT	CAA' N		ATT L		ragti V					GTG A				TTG.		A K				840
TAAA K	ACA Q			GTT: L		'A 1		TAG A						TAT F		A T	ACT.	ACT	TAG	900
CCGT	TCG.	TTA	AT	GTT(GAAC	G G	CTT	TTA	GTA	ATC	TTA	TTT	TC	TCA	TAAT	A C	AGG	TAG	TTT	960
AAGT	AAT	TTG	TC'	TTT	AAAA	A T	AGT	ATA	ATA	A TAA	CTA	CGA	TT A	CAA	AGAG	A G	GTG	ACI	TTG	1020
М	Т	E	AG	AAC' N	TGGT' W L	T A	CAT H	ACT T	'AA <i>I</i> K	A GAI D	GGT G	TTCA S	G AT	TTA' I	TATT:	A T	CGT R			1080
		GTC	AA	CCG. P	ATTG I V	т т	TTT F	TTA L	CAT H	r GGC G	CAAT N	ragc s	T T <i>F</i> L	AGT S	AGTC	G C	TAT Y	TTT F	rgat D	1140
AAGC K Q	AAA: I (DAT.	CA	TAT Y	TTTT F S	СТ	'AAG K	TAT Y	TAC Y	C CAF	AGT: V	TATT I	G TI V	TATO M	GATA D S	G I	'AGA R	G G	SCAT H	1200
															AGCAG					

GATA	ATC I	TT. L	AG V	TTC.	ATI I	CTA L	GA E	G?	TTA I	GAT D	K K) A	GTI V	'ATA I	ATT L	GG V)AT	GGC G	CA:	rag S	CG?	ATG G	GT	GC(A	3	1320	
AAT' N	TTA L	GC A	TT L	TAG V	TT:	rti F	CA Q	A	ACG T	ATC M	F F	T (CC <i>P</i> P	G G	TAT M	GG V	TT	AGA R	G G	GCT L	TT:	rgc 1	TT.	AA: N	Γ	1380	
TCA S				TGA T	CT	TTA I	CA H	T	GGT G	CA(Q	GCG R	A	TGC W	TG W	GGA D	AT. I	TT(CTI L	TT. L	AGT V	AA(R	GGA I	TT:	GC(A	С	1440	
TAT Y	AAA K	TT! F	CC	TTC H	AC'	TAT Y	TT L	A	GGG G	AA K	ACI L	`C	TTI F	rcc P	GTA Y	ATA M	TG.	AGC R	ÇA. Q	AAA K	AG A	OTC Q	CAA 2	GT V	Т	1500	
TTA I				TGT L	TG	GA(E	GGA D	T	TTG L	AA(K	GAT I	T	AG: S	rcc P	AGC A	TG D	TA	TT <i>F</i> L	ACA Q	GCA H	TG' V	TG1	rca S	AC T	Т	1560	
CCT P	GTZ V	LAAI M	GG V	TTT I	TG	GT: V	rgg G	Α	laa N	raa K	GG <i>I</i> D	4C	AT.	AAT I	TA! K	AGT L	TA	AA: N	rca H	TTC S	TA K	AG <i>I</i>	AAA K	CT L	T	1620	
GCI A	TC' S	TT <i>F</i> Y	TTA F	TTC	CA	AG R	GGG G	G	GA(STT F	TT? Y	T	TC' S	TTT L	'AG' V	TTG G	GC	TT'	rgg G	GCA H	TC H	AC	ATI I	TAT I	T	1680	
AAC K				CCC	CAI H	GT V	TTI F	1	'AA' N	TAT I	TA!	гт	GC. A	AAA K	AA) K	AGT F	TT	'AT	CAA N	CGA D	TA T	.CG	TTC L	SAA K	IA.	1740	
				TT					'AA' N	TTG	AA	AA	AG	TCF	AA,	rca	CI	'GA	CTI	CTG	TG	AT'	TA	AAA	T	1800	
TG.	TAT	TT.	TTT	AT	ATC	CTG	TT:	r :	rag'	TGC	TT.	AT	TA	TT.	STT	GAA	M	GA I	I	CATI H I	TO	K K	AC(R	GA <i>I</i>	r AC	1860	
TA'		CT		GA E	GC2 Q	AAC I	TA	A A	AGA S	GTC.	STT /	TT F	TG	GG(CAA Q	TTA L	T	CTC	CA	ATG <i>I</i> M N	A AT	rct L	TT' F	TC:	rt L	1920	
AA I		ATC		GT V	GG(GGG V	STT. I	A '	TCG A	CTC	STC V	TT L	AC I	CG	ACA T	ACC T	G G	GAT Y	TA	GAC:	r Ti	rgi V	'AC L	TG	A.A N	1980	í
			TT <i>I</i> L	A CG R	AT: T	CAC	GAT O	A K	AAA S	AGC2	AAA K	AG R	G: Y	TAT.	TTA I	TTA L	Q Q	AG <i>P</i>	CT.	AGT' S	r G	GT0 C	ATS I	TC.	A.A N	2040	,
CA T	CT:	rTI F	'AA' N	r a <i>p</i> N	CT L	TG:	rca s	.G G	GA1 F	TC	GG1 G	rgg G	L C	ATI	ATC I	GAT D	: A	TTC	GG G	TTG L	C G R	CAI M	r G G A	CT	TT F	2100)
TI Y	AT(GGI G	'AAI K	A AA K	A A G	GT	CAA Q	G E	AG <i>I</i> K	AAG	AGT S	rga D	C L	CTA	AGA R	AGA <i>I</i> E	A G V	TG	ACT T	CGT R	T T F	TT: L	PAT E	CC	TA Y	2160)
TC	CTT.	ATI I	TTC' S	T GO	GTC L	TG	TCA S	YT F	TT?	TTA	AG' S	rgi V	G I	ATI	GC(A	CTT/ L	A A I	TC:	ATG M	AGC S	C A H	'AT I	TTT H	TT F	'CA H	2220	3
T(GCC A	AAI K	AGC A	T A	GTC /	TT /	GAT D	TT Y	AC' Y	TAT	TA Y	TTI L	r G V	GTA	ATT. L	TAA I	r G	GT	GC1 A	ragt S	r A' M	GT. Y	AT:	rt1 F	P P	228	0
T	GTT V	'AT'	TTA Y	T T W	GG?	ATT I	TC: S	TG G	GT H	CAI	'AA K	AG(G	3 A S	AG(CCA H	TTA Y	T T	CTC	GG# G	AGAI D	r Ar M	rgc P	CA'	rc'i s	rag S	234	0
T	ACI T	CG R	TAT I	'A A K	AA'	TTA L	G /GG	TG V	TT V	GT1	rtc S	TT' F	r r H	TT'	TGA E	ATG W	G (GGA	TG' C	TGC(A	GG (A	CCG A	CA	GCI A	ATT F	240	O
Ť	ATA	TAL	TAT	c G	GT'	TAT	TT.	AA M	TG	GGG	CAT	TC	A :	CT.	ACC	AGT	T'	TAT	'AA K	AAT:	rt 1 L	TAC P	CA	CT.	ATT F	246	i C

TTGTATTGGT TGTGCCGTCG GGATTGTATC CCTTATTCCC GGTGGATTAG GAAGTTTTGA C I G C A V G I V S L I P G G L G S F E	2520
ATTAGTTCTA TTTACAGGGT TTGCTGCCGA GGGACTACCT AAAGAAACTG TGGTTGCATG L V L F T G F A A E G L P K E T V V A W	2580
GTTATTACTT TATCGTTTAG CCTACTATAT TATTCCATTC TTTGCAGGTA TCTATTTCTT L L L Y R L A Y Y I I P F F A G I Y F F	2640
TATCCATTAT TTAGGTAGTC AAATAAATCA ACGTTATGAA AATGTCCCGA AAGAGTTAGT I H Y L G S Q I N Q R Y E N V P K E L V	2700
ATCAACTGTT CTACAAACCA TGGTGAGCCA TTTGATGCGT ATTTTAGGTG CATTCTTAAT S T V L Q T M V S H L M R I L G A F L I	2760
ATTTTCAACA GCATTTTTTG AAAATATTAC TTATATTATG TGGTTGCAGA AGCTAGGCTT F S T A F F E N I T Y I M W L Q K L G L	2820
GGACCCATTA CAAGAACAAA TGTTATGGCA GTTTCCAGGT TTATTGCTGG GGGTTTGTTT D P L Q E Q M L W Q F P G L L L G V C F	2880
TATTCTCTTA GCTAGAACTA TTGATCAAAA AGTGAAAAAT GCTTTTCCAA TTGCTATTAT I L L A R T I D Q K V K N A F P I A I I	2940
CTGGATTACT TTGACATTGT TTTATCTTAA TTTAGGTCAT ATTAGTTGGC GACTATCTTT W I T L F Y L N L G H I S W R L S F	3000
CTGGTTTATT TTACTATTGT TAGGCTTATT AGTCATTAAG CCAACTCTCT ATAAAAAACA W F I L L L G L L V I K P T L Y K K Q ATTTATTTAT AGCTGGGAAG AGCGTATTAA GGATGGAATC ATTATCGTTA GTTTAATGGG	3060
F I Y S W E E R I K D G I I I V S L M G AGTTCTATT TATATTGCAG GACTACTATT CCCTATCAGG GCTCATATTA CAGGTGGTAG V L F Y I A G I	3120
V L F Y I A G L L F P I R A H I T G G S TATTGAACGC CTGCATTATA TCATAGCATG GGAGCCGATA GCATTGGCTA CGTTGATTCT I E R L H Y I L	3180
TACTCTCGTT TATTTATGTT TGGTTAAGAT TTT1C11GG1 AAATCTTCTC ACATTCCTC	3240
TGTGTTCAAT GTGGATCGTT ATAAAAAACT ACTTCAAGCT TACCCTCCTT CTTGCGATAG	3300
CGGTTTAGCC TTTTTAAATG ATAAAAGGCT CTACTGGTAC CAAAAAAATG CAGAAAAAGGCT CTACTGGTAC CAAAAAAATG CAGAAAAAAGGCT CTACTGGTAC CAAAAAAAATG CAGAAAAAAAGGCT CTACTGGTAC CAAAAAAAAAGGCT CTACTGGTAC CAAAAAAAAAA	3360 3420
CGTTGCGTTC CAATTTGTAA TTGTCAATAA TAAATGTCTT ATTAAATGTCTT	3420
TGATGACACT TATATTCGTG AAGCTATTGA ATGCTTTATT CATTGATT	3540
D D T Y I R E A I E S F I D D A D K L D CTATGACCTT GTTTTTTACA GTATTGGACA GAAGTTGACA CTACTTTTAC ATGAGTATGG Y D L V F Y S I G Q K L T L L H E Y G	3600

AGGGAATAAG TACAAACCTT G N K Y K P F	TCAGAAATGC R N A	CCTAAATAGA GTTGAAAAGG L N R V E K D	ATGGTTTCTA 3720 G F Y
TTTCGAAGTT GTACAATCGC F E V V Q S P	CACATAGTCA H S Q	AGAGCTACTA AATAGTTTGG E L L N S L E	AAGAGATTTC 3780 E I S
		AGGTTTCTCA CTAGGATATT G F S L G Y F	
	TAGCTTTGGT A L V	AAAAAATGCT GAACACGAAG K N A E H E V	
TGCTAATATT ATGCCAAACT A N I M P N Y	ATGAAAAGAG E K S	TATTATCTCT ATTGATTTAA I I S I D L M	TGCGTCACGA 3960 R H D
TAAACAGAAA ATTCCGAATG K Q K I P N G	GCGTTATGGA V M D	TTTCCTCTTT TTATCATTAT F L F L S L F	TCTCTTATTA 4020 S Y Y
		GGGGATGGCA CCTTTATCAG G M A P L S G	
	AAGAGAGAAT E R M	GGCGTATCTT GTCTATCATT A Y L V Y H F	
TTTCTACTCA TTTAATGGTT		TAAGAAGAAG TTTACACCAT K K K F T P L	
ACGTTATATT TCTTGTTCTC		GTTAATTTGT GCTATTTGTG L I C A I C A	
GGAAGATAGT AAAATTAAGA E D S K I K :		AGCTTTATTT GGCAATTAAA	AAGAGCATGT 4320
CATGCGACAT GCTCTTTTT	AATCATTTAA	TACCATTGAT TGCTTGAATC	TACTTTATAA 4380
TATGATGTGC TTTTAAATA	TGTTTAGCTA	CTGTAGCTGC TGATTTATGC	TTTACAGCTA 4440
CTTGGTAGTT CATTTCTTG	ATTTCTTTT	CAGTGATATG ACCAGCAAGT	TTATTGAGAG 4500
CTTTTTTTAC TTGA (SE	Q ID NO:1)	•	4514

FIG. la [clonel-dna/aa]

		ETC 1	•		
575 (250	10 NO:2)				154
KQED (SEQ	TD NO.21	~		OUTDALLIK	120
FQTIQPFLPM	TYSVSGLRET	ISLTGDVNHQ	WRMLVIFLVS	SMILALLIYR	1 5 0
	HAIVEAGMON	RIGSELSLLI	LLFQLGSSAG	TYPIELSPKF	100
ILLTAWTT.MA	T.VTAT.VCWDN	DVCCET GT T T			
SGKEPANRFS	WAKNKLLING	FIATLAATIL	FFAVQFIGLK	PDYPGKTYFI	50

FIG. 1b

MSTLTIIIAT	LTALEHFYIM	YLETLATQSN	MTGKIFSMSK	EELSYLPVIK	50
LFKNQGVYNG	LIGLFLLYGL	YISQNQEIVA	VFLINVLLVA	IYGALTVDKK	100
ILLKQGGLPI	LALLTFLF	(SEQ ID NO:3	3)		118

FIG. 1c

MTENWLHTKD	GSDIYYRVVG	QGQPIVFLHG	NSLSSRYFDK	QIAYFSKYYQ	50
VIVMDSRGHG	KSHAKLNTIS	FRQIAVDLKD	ILVHLEIDKV	ILVGHSDGAN	100
LALVFQTMFP	GMVRGLLLNS	GNLTIHGQRW	WDILLVRIAY	KFLHYLGKLF	150
PYMRQKAQVI	SLMLEDLKIS	PADLQHVSTP	VMVLVGNKDI	IKLNHSKKLA	200
SYFPRGEFYS	LVGFGHHIIK	QDSHVFNIIA	KKFINDTLKG	EIVEKAN	247
(SEQ ID NO:					411

FIG. 1d

MIHLKRTISV	EQLKSVFGQL	SPMNLFLIIL	VGVIAVLPTT	GYDFVLNGLL	50
RTDKSKRYIL	QTSWCINTFN	NLSGFGGLID	IGLRMAFYGK	KGQEKSDLRE	100
VTRFLPYLIS	GLSFISVIAL	IMSHIFHAKA	SVDYYYLVLI	GASMYFPVIY	150
WISGHKGSHY	FGDMPSSTRI	KLGVVSFFEW	GCAAAAFIII	GYLMGIHLPV	200
YKILPLFCIG	CAVGIVSLIP	GGLGSFELVL	FTGFAAEGLP	KETVVAWLLL	250
YRLAYYIIPF	FAGIYFFIHY	LGSQINQRYE	NVPKELVSTV	LQTMVSHLMR	300
ILGAFLIFST	AFFENITYIM	WLQKLGLDPL	QEQMLWQFPG	LLLGVCFILL	350
ARTIDQKVKN	AFPIAIIWIT	LTLFYLNLGH	ISWRLSFWFI	LLLLGLLVIK	400
PTLYKKQFIY	SWEERIKDGI	IIVSLMGVLF	YIAGLLFPIR	AHITGGSIER	450
LHYIIAWEPI	ALATLILTLV	YLCLVKILQG	KSCQIGDVFN	VDRYKKLLQA	500
YGGSSDSGLA	FLNDKRLYWY	QKNGEDCVAF	QFVIVNNKCL	IMGEPAGDDT	550
YIREAIESFI	DDADKLDYDL	VFYSIGQKLT	LLLHEYGFDF	MKVGEDALVN	600
LETFTLKGNE	YKPFRNALNR	VEKDGFYFEV	VQSPHSQELL	NSLEEISNTW	650
LEGRPEKGFS	LGYFNKDYFQ	QAPIALVKNA	EHEVVAFANI	MPNYEKSIIS	700
IDLMRHDKQ	(IPNGVMDFLF	LSLFSYYQEK	GYHYFDLGMA	PLSGVGRVET	750
SFAKERMAYI	. VYHFGSHFYS	FNGLHKYKKK	FTPLWSERYI	SCSRSSWLIC	800
AICALLMEDS	s KIKIVK (S	EQ ID NO:5)			816
		FIG	. 1e		
MRILGAFLI	F STAFFENITY	Y IMWLQKLGLI	PLQEQMLWQE	PGLLLGVCFI	50
LLARTIDQK	V KNAFPIAIIV	V ITLTLFYLNI	_ GHISWRLSFV		100
IKPTLYKKQ	F IYSWEERIKI	GIIIVSLMG	/ LFYIAGLLFE	PIRAHITGGSI	150
ERLHYIIAW	E PIALATLIL	L TAATCTAKI	C QGKSCQIGD	/ FNVDRYKKLL	200

LLARTIDQKV KNAFPIAIIW ITLTLFYLNL GHISWRLSFW FILLLGLLV 100
IKPTLYKKQF IYSWEERIKD GIIIVSLMGV LFYIAGLLFP IRAHITGGSI 150
ERLHYIIAWE PIALATLILT LVYLCLVKIL QGKSCQIGDV FNVDRYKKLL 200
QAYGGSSDSG LAFLNDKRLY WYQKNGEDCV AFQFVIVNNK CLIMGEPAGD 250
DTYIREAIES FIDDADKLDY DLVFYSIGQK LTLLLHEYGF DFMKVGEDAL 300
VNLETFTLKG NKYKPFRNAL NRVEKDGFYF EVVQSPHSQE LLNSLEEISN 350
TWLEGRPEKG FSLGYFNKDY FQQAPIALVK NAEHEVVAFA NIMPNYEKSI 400
ISIDLMRHDK QKIPNGVMDF LFLSLFSYYQ EKGYHYFDLG MAPLSGVGRV 450
ETSFAKERMA YLVYHFGSHF YSFNGLHKYK KKFTPLWSER YISCSRSSWL 500
ICAICALLME DSKIKIVK (SEQ ID NO:6)

FIG. 1f

>		I I E	A M K		LLE	60
		E	F D K		P Y W	120
	-	- <i>U</i> 3	пАЕ		$C \Gamma K$	180
	0		эбгі		LFE	240
_ •		2 1 1	r 2 W E	AAGTTGAACA VEH	T K T	300
		5 1 n	r Q K L		I V D	360
	v	., G L	AKEH	ATCTTTATCG L Y R	Y G K	420
	£ 5	0 1 K	r A R G		DFE	480
_		D D A	T H D R	- -	V V N	540
	_ •• ••	201	K P G P		DII	600
		· 11 G	O T I N		A I L	660
	~	5		ATGAGCGATT M S D F	r a d	720
		2 M 1	v r S	AATGTTTCAT N V S F	ΙΙΗ	780
		- G V	N G T	GGAAAGACAA (G K T T	LLD	840
	•	r D G	D R S	CCTTTTTCAT (PFSS	A N D	900
	- • • • • • • • • • • • • • • • • • • •	2 - 1	D F D	GATTCTCAGA (I L D	960
		2 11	W T I	AAAGAATATG A K E Y E	LLL	1020
	- •	2 0 1	L E K	GTAATGGCAG A	M D S	1080
		·	K I V	TTATCCAAAT 1 L S K L	GIT	1140
TGATTTGCAG	TTGTCGGTTG	GTGAATTATC	1.661.65	CGAAGACGTG T R R R V		1200

GCAAGTATTA	TTAAATGA	ATG CAGAT	TTATT	GCTCTTA	GAC G	AACCTACTA	ACCACTTA	GA 1260
Q V L	L N D	A D	L L	L L		P T N	H L	D
TATTGACACT	ATTGCATO	GGT TAACO L T	AATTT N F	TTTGAAA L K	AAT A N S	AGTAAAAAGA S K K 1	CAGTGCTT	TT 1320 F
TATAACTCAT	GATCGTTA D R Y	ATT TTCT/ F L	AGACAA D N	TGTTGCA V A	ACA C	CGTATTTTTC R I F I	AATTAGAT L D	
GGCACAGAT:	T ACAGAATA	ATC AAGGO	CAATTA	TCAGGAT	TAT (STCCGACTTO	GTGCAGAA	ACA 1440
A Q I	T E Y	Q G	N Y	Q D		/ R L I	R A E	Q
AGACGAGCG' D E R	GATGCTGO D A A	CTA GTTT	ACATAA H K	AAAGAAA K K	ACAG (CTTTATAAA L Y K (C AGGAACTA D E L	
TTGGATGCG W M R	T ACTCAGC	CAC AAGC	rcgtgc R A	AACGAAA T K	ACAA (CAGGCTCGT O A R	A TTAATCGT I N R	TTT 1560 F
TCAAAATCT	A AAAAACG	ATT TACA	CCAAAC	AAGCGAT	TACA I	AGCGATTTG	S AAATGACA	ATT 1620
Q N L	K N D	L H	Q T	S D		S D L	E M T	F
TGAAACAAG	T CGAATTG	GGA AAAA	GGTTAT	TAATTT:	IGAA .	AATGTCTCT	TTTCTTA	DCC 1680
E T S	R I G	K K	V I	N F	E	N V S		P
AGATAAATC D K S	T ATCTTGA I L K	AAG ACTT	TAATTT N L	GTTAAT'	TCAA . Q	AATAAAGAC N K D	C GTATTGG R I G	
CGTTGGAGA	T AATGGTG	TTG GAAA	GTCAAC	CTTACT	TAAT	TTAATTGTT	C AAGATTT	ACA 1800
V G D	N G V	'G K	S T		N	L I V	Q D L	Q
GCCGGATTC	G GGTAATO		TGGTGA	AACGAT	ACGT	GTAGGTTAC	T TTTCACA	ACA 1860
P D S	G N V		G E	T I	R	V G Y	F S Q	Q
ACTTCATAA	T ATGGATO	GCT CAAF	ACGTGT	TATTAA	TATT.	TTGCAAGAG	G TTGCAGA	TGA 1920
L H N	M D O	S S K	R V	I N	Y	L Q E	V A D	E
GGTTAAAAC V K T	S V C		CAAGTGT S V	GACAGA T E	ACTA L	TTGGAACAA L E Q	T TTCTCTT F L F	TCC 1980 P
ACGTTCGAC	CA CATGGAM	ACAC AAA:	TTGCAAA	ATTATO	AGGT	GGTGAGAAA	AA AAAGACT	TTTA 2040
	H G T	r Q I	A K	L S	G	G E K	K R L	Y
CCTTTTAA	AA ATCCTG	ATTG AAA I E K	AGCCTAA P N	TG T GTI V L	PACTA L	CTTGATGAC L D E	C CGACAAA P T N	ATGA 2100 D
CTTAGATA'	T GCTACA	TTAA CTG	ITCTTGA	AAATTI	TTTTA	CAAGGCTT'	rg GTGGTC0	CTGT 2160
L D I		L T V	L E	N F	L	Q G F	G G P	V
GATTACAG	TT AGTCAC	GATC GTT.	ACTTTTT	r agatai	AAGTG	GCTAATAA	AA TTATTGO	CGTT 2220
I T V	S H	D R Y	F L	D K	V	A N K	I I A	F
TGAAGATA	AC GATATC	CGTG AAT	TTTTTG(TAATT	ATACT	GATTATTT	AG ATGAAA	AAGC 2280
E D N	D I	R E F	F G	N Y	T	D Y L	D E K	A
ATTTAATG F N E	AG CAAAAT Q N	AATG AAG N E V	TTATCA	g taaaa K K	AAGAG E	AGTACCAA S T K	GA CAAGTC T S R	
AAAGCAAA	GT CGTAAA	AAGAA TGI	CTTACT	T TGAAA	AACAA	. GAATGGGC	GA CAATTG	AAGA 2400
K Q S	R K	R M S		E K	Q	E W A	T I E	D
CGATATTA	TG ATATTO	GAAA ATA	CTATCA	C TCGTA	TAGAA	AATGATAI	GC AAACAT	GTGG 2460

	C G
TAGTGATTTT ACAAGGTTAT CTGATTTACA AAAGGAATTA GATGCAAAAA ATGAF S D F T R L S D L Q K E L D A K N E	AGCACT 2520 A L
TCTAGAAAAG TATGACCGTT ATGAGTACCT TAGTGAGTTA GACACATGAT TATCCLL E K Y D R Y E Y L S E L D T M I I R	
ATTATTAAAA ATGATGACCA AGCAGTTGCA CAATTAATTC GACAAAGTTT ACGCG I I K N D D Q A V A Q L I R Q S L R A	
GATTTAGATA AACCTGATAC AGCATATTCA GACCCTCACT TAGATCATTT GACCT D L D K P D T A Y S D P H L D H L T S	CCATAC 2700
TACGAAAAA TAGAGAAGTC AGGATTCTTT GTCATTGAGG AGAGAGATGA GATTA Y E K I E K S G F F V I E E R D E I I	ATTGGC 2760
TGTGGCGGCT TTGGTCCGCT GAAAAATCTA ATTGCAGAGA TGCAGAAGGT GTACA C G G F G P L K N L I A E M $\mathbb Q$ K V Y I	
GAACGTTTCC GTGGTAAGGG GCTTGCTACT GATTTAGTGA AAATGATTGA AGTAG E R F R G K G L A T D L V K M I E V E	A
CGAAAAATTG GGTATAGACA ACTTTATTTA GAGACAGCCA GTACTTTGAG TAGGGG R K I G Y R Q L Y L E T A S T L S R A	T
GCGGTTTATA AGCATATGGG ATATTGTGCC TTATCGCAAC CAATAGCAAA TGATCAAR V Y K H M G Y C A L S Q P I A N D Q	G
CATACAGCTA TGGATATTIG GATGATTAAA GATTTATAAG TTGAAAGTGG ATTAGT H T A M D I W M I K D L	
ATGGATTAAT TATTTTGAGA TAAGAGGAAA GAAAAGGAGA CATATATGGC ATATAT $m{ t M}$ A Y I	
TCTTATTTGA AAAGGTACCC CAATTGGTTA TGGCTTGATT TACTAGGAGC TATGCTS Y L K R Y P N W L W L D L L G A M L	FTTTT 3180
GTGACGGTTA TCCTAGGAAT GCCCACAGCC TTAGCGGGTA TGATTGATAA TGGCGT V T V I L G M P T A L A G M I D N G V	TTACA 3240
AAAGGTGATC GGACTGGAGT TTATCTGTGG ACGTTCATCA TGTTTATATT TGTTGT K G D R T G V Y L W T F I M F I F V V	TACTA 3300 L
GGTATTATTG GGCGTATTAC GATGGCTTAC GCATCTAGTC GCTTAACGAC AACAATG I I G R I T M A Y A S S R L T T T M	I
AGAGATATGC GTAATGATAT GTATGCTAAG CTTCAAGAAT ACTCCCATCA TGAATA R D M R N D M Y A K L Q E Y S H H E Y	E
CAGATAGGTG TATCTTCACT AGTGACACGT ATGACAAGCG ATACTTTTGT TTTGAT Q I G V S S L V T R M T S D T F V L M	Q
TTTGCTGAAA TGTCTTTACG TTTAGGCCTA GTAACTCCTA TGGTAATGAT TTTTAG ${ m F}$ A E M S L R L G L V T P M V M I F S	V
GTTATGATAC TAATTACGAG TCCATCTTTG GCTTGGCTTG	L
TTGGTAGGAG TCGTTTTATA TGTAGCTATA AAAACAAAAC	

AC: T	TATO M		rg D			CAA N	TCAA Q	Y Y	CGTT V		rga. E			TAAC! T		GTT L	ACG R	CGT: V	rgtt V	3720
		CTT'		CAAG R	AGA E	AGAA N	TTTT	rcaj Q	ATCA S	CAJ Q	AAA K	ATT F	TC Q	AAGT(V	CGC' A	raa N	CCA. Q	ACGʻ R	TTAC Y	3780
	AGA! D		rT S	_			TTTT							CAGA E			TTT F			3840
		TAT' I					GGC:							TGGA' D				AAG R		3900
							AGT'							GCTT F			TCT L		TTCA S	3960
		GCT.				ATCT L	TTT'				TCC P			TGGT V	GGT. V		AAG S			4020
		AGA E												ATGC A			TGT V		GGAT D	4080
AC T		ACT L					AGA E							TCGC A					AACA T	4140
				TT T			TAT							CTGG G	AGA E			TGC A		4200
		TTC S					AAA K							TGAT I	TCC P			TTA Y		4260
		ACT L				TCTT L					TGA D				TTA Y		CCI		ATCA S	4320
CI L	TCG R	CC <i>P</i> Q	AA K	AGA I	TTG G	GAT1	TAT I	CCC P	CCAA Q	AA K	AGC A	L L	r T T L	TATI F	TAC T	AGG G	GA(AGGA G	4380
														ATCI L				CGGI V	TGAT D	4440
				CTA K				TGA E						CCTT				ATTI L	AGCT A	4500
		GTG(TGG G									TTGC A		GGG(A	V V	4560
G: V	TAZ K	AAGZ D	OTA E	CAG	ATI I	TATI Y	A TAT	TTT1 F	TGAI D	G G? D	ATT S	CAT F	TTT S	CTG(A	CTC: L	rcga D	Y TT	ATA <i>I</i> K	AGACA T	4620
D	A	T	I	L F	R 1	A R	L	K	E	V	T	G	D	S	T	V	L	I	V	4680
G A	CTC. Q	AAA R	GG(TG(GGTZ G	ACGA T I	AT T M	r G G? D	ATGC: A	r G	ATC. Q	AGA I	ATT. I	TTG'	TCC'	TTGA D	TG. E	AAG G	GCGAA E	4740
I	V	G	1	R (G '	т н	A	Q	L	I	E	. N	1 1	1 A	I	Y	R	E		
							A CC. Q								GAT				AAAAA K K	4860

10/40

ATCTGTTTTT S V F	TTGAGATTAT GGTCTT	TACCT A	AACTCGCTAC T R Y	AAAGCTACTC K A T L	TTTTCTTAGC F L A	4920
GATTTTTTG I F L	AAAGTTTTAT CTAGTT	TTTAT (GAGTGTTCTG S V L	GAGCCTTTTA E P F I	TTTTAGGGTT L G L	4980
AGCGATAACA A I T	GAGTTGACTG CTAACC	CTTGT T	GATATGGCT D M A	AAGGGAGTTT K G V S	CTGGGGCAGA G A E	5040
ATTGAACGTT L N V	CCTTATATTG CTGGTA P Y I A G I	ATTTT G	SATTATTTAT I I Y	TTTTTCAGAG F F R G	GTGTTTTCTA V F Y	5100
TGAATTAGGT E L G	TCTTATGGCT CAAATT S Y G S N	` (SEQ) ID NO:7)			5126

FIG. 2a

NFDIETTTFE	AMKKHASLLE	KISVERSFIE	FDKLLLAPYW	RKGMLALIDS	50
HAFNYLPCLK	NRELQLSAFL	SQLDKDFLFE	TSEQAWASLI	LSMEVEHTKT	100
FLKKWKTSTH	FQKDVEHIVD	VYRIREQMGL	AKEHLYRYGK	TIIKQAEGIR	150
KARGLMVDFE	KIEQLDSELA	IHDRHEIVVN	GGTLIKKLGI	KPGPQMGDII	200
SQIELAIVLG	QLINEEEAIL	HFVKQYLMD	(SEQ ID NO	:8)	229

FIG. 2b

MSDFLVDGLT	KSVGDKTVFS	NVSFIIHSLD	RIGIIGVNGT	GKTTLLDVIS	50
GELGFDGDRS	PFSSANDYKI	AYLKQEPDFD	DSQTILDTVL	SSDLREMALI	100
KEYELLLNHY	EESKQSRLEK	VMAEMDSLDA	WSIESEVKTV	LSKLGITDLQ	150
LSVGELSGGL	RRRVQLAQVL	LNDADLLLLD	EPTNHLDIDT	IAWLTNFLKN	200
SKKTVLFITH	DRYFLDNVAT	RIFELDKAQI	TEYQGNYQDY	VRLRAEQDER	250
DAASLHKKKQ	LYKQELAWMR	TQPQARATKQ	QARINRFQNL	KNDLHQTSDT	300
SDLEMTFETS	RIGKKVINFE	NVSFSYPDKS	ILKDFNLLIQ	NKDRIGIVGD	350
NGVGKSTLLN	LIVQDLQPDS	GNVSIGETIR	VGYFSQQLHN	MDGSKRVINY	400
LQEVADEVKT	SVGTTSVTEL	LEQFLFPRST	HGTQIAKLSG	GEKKRLYLLK	450
ILIEKPNVLL	LDEPTNDLDI	ATLTVLENFL	QGFGGPVITV	SHDRYFLDKV	500
ANKIIAFEDN	DIREFFGNYT	DYLDEKAFNE	QNNEVISKKE	STKTSREKQS	5 50
RKRMSYFEKQ	EWATIEDDIM	ILENTITRIE	NDMQTCGSDF	TRLSDLQKEL	600
DAKNEALLEK	YDRYEYLSEL	DT (SEO I	D NO:9)		622

FIG. 2c

MIIRPIIKND	DQAVAQLIRQ	SLRAYDLDKP	DTAYSDPHLD	HLTSYYEKIE	50
KSGFFVIEER	DEIIGCGGFG	PLKNLIAEMQ	KVYIAERFRG	KGLATDLVKM	100
IEVEARKIGY	RQLYLETAST	LSRATAVYKH	MGYCALSQPI	ANDQGHTAMD	150
IWMIKDL (S	SEQ ID NO:10	O)			157

FIG. 2d

MAYIWSYLKR	YPNWLWLDLL	GAMLFVTVIL	GMPTALAGMI	DNGVTKGDRT	50
GVYLWTFIMF	IFVVLGIIGR	ITMAYASSRL	TTTMIRDMRN	DMYAKLQEYS	100
		FVLMQFAEMS			150
TSPSLAWLVA	VAMPLLVGVV	LYVAIKTKPL	SEROOTMLDK	INOVVENIT	
GLRVVRAFAR	ENFQSQKFOV	ANQRYTDTST	GLEKITGITE	DIEVOTATA	200
TIINTIIINT		2	CHIMPIGHIE	PPI AOTITAM	250
IVAIVWEALD	PLQRGAIKIG	DLVAFIEYSF	HALFSFLLFA	NLFTMYPRMV	300
VSSHRIREVM	DMPISINPNA	EGVTDTKLKG	HLEFDNVTFA	YPGETESPVL	350
HDISFKAKPG	ETIAFIGSTG	SGKSSLVNLI	PRFYDVTLGK	ILVDGVDVRD	400
YNLKSLRQKI	GFIPQKALLF	TGTIGENLKY	GKADATIDDL	ROAVDISOAK	450
EFIESHOEAF	ETHLAEGGSN	LSGGQKQRLS	TADAIIII	***********	
		PPOGÓVÓVES	TARAVVKDPD	LYIFDDSFSA	500
LDYKTDATLR	ARLKEVTGDS	TVLIVAQRVG	TIMDADQIIV	LDEGEIVGRG	550
THAQLIENNA	IYREIAESQL	KNQNLSEGE	(SEQ ID NO:	11)	579
		-			_

FIG. 2e

MRKKSVFLRL	WSYLTRYKAT	LFLAIFLKVL	SSFMSVLEPF	ILGLAITELT	50
		AGILIIYFFR			92
(SEQ ID NO:	:12)				22

FIG. 2f

F	G	S		TGCT A			A 1	ACAG V	TTC	AAG V	TAA	AG(GAG E	AT I	TATI	NAG! S	rgaa E	GAA E	AAA N	I	TA: W	60
GGTT		YTC(R		GCTC L	AG1 S	rTG(C	C :	rgcc C H	ATI	ATTT T	CTA S	GC.	TAC Y	TC S	ATA Y	rtg(W	GAAG K		ACC <i>I</i> P	AAC T	TT W	120
GGTA	AGO	CAT	c i	M		L				AAAG K							TATA I	TG# D			AGC S	180
AAAG K G				CAAA	AG	ccc				AAAC N					ATC <i>I</i> Q		TCAG S	TGC A	TG/ E	AAC E		240
GGC# G I	TC	rct s	G A	CTGA E	AC Q	AGA I	T	CGT <i>I</i> V	AGT(V	CAAA K					AAG(G		ATGT V	GA(CCT(S	CAC i		300
				ATCA H				CAAT N			GTT V				ATG(TATT I	TAC S	STG.		SAG E	360
TTGT L I	ا ر		T	D		CTA N	A	ATT Y	CCG' R	TTTT F	AA/ K	ACA Q	ATC S	CAG D	ACG'		TCAA N	TG2 E	'AAA' I			420
GAC(GT	TAC	G	TTAT		AAG V			rgg G	CAAC N	TA: Y	TTA Y	TGT V	TTT Y	ACC'	TCA K	AGCC P	AG(G	GTA S	GT:	A AG K	480
CGCI R I			A			CCA K			ACA. Q		GC:						AAGG G	AA T		AA		540
GCTA				AAG(G													AAGT V		CGG A			600
				AAA R							AC. T						TTTT	TA S			ACA T	660
GAT.		ATI I				TAC		AGA D			TT. L						ATCA I H	. CT			TAT Y	720
ATT						TG		TCC P							CAC		SCCTA Y	CT W			CAA Q	780
AAA K				GAG G	GT0	CTA	AG R	ACC P	GTC S	TGAT D	TA Y	.CCC	GCC P	CGA T	CAC F	CAC	CCCC	AG G		GT		840
AAA K										TAAC N							CAGCO P		ATA 1			900
																	AAACA K H				GAT D	960
																	CGTC:					1020
TAC Y	CG: R	rca' H	TG V	TGG E	AA(GAA E	GA D	TGC G	GTT L	rgati I	r TI F	TG: E	AAC P	CGA	CTC	AAC '	GTGA:	C C F	AA!	rc <i>i</i> s	N N	1080
																	CCAA(P R				STTA L	1140
TCA S	ACC'	TCT L	TG E	AAA 1	ATG 1	GAA E	TT L	AG(A	CAG D	ATCG/ R	A TA	ACT L	TAC	ECTO	G GCG	CAA Q	ACTG. T E	A GO	GAC.	AA' N	rgac D	1200
тCI	200	ጥጥር	AC	: AGC	-מכ	ጥሮል	AA	AC	CAT	CAGA	מ יד	AAG	ממ	TC	A CA	CAT	ACCT	тт	тт	GG'	TCAT	1260

S G S E H S K P S D K E V T H T F CGCATCAAAG CTTACGGAAA AGGCTTAGAT GGTAAACCAT ATGATACGAG TGATGCTTAT 1320 RIKA Y G K G L D G K P Y D T S GTTTTTAGTA AAGAATCCAT TCATTCAGTG GATAAATCAG GAGTTACAGC TAAACACGGA 1380 V F S K E S I H S V D K S G V T A GATCATTTCC ACTATATAGG ATTTGGAGAA CTTGAACAAT ATGAGTTGGA TGAGGTCGCT 1440 D H F H Y I G F G E L E Q Y E L D E V A AACTGGGTGA AAGCAAAAGG TCAAGCTGAT GAGCTTGCTG CTGCTTTGGA TCAGGAACAA N W V K A K G Q A D E L A A A L D GGCAAAGAAA AACCACTCTT TGACACTAAA AAAGTGAGTC GCAAAGTAAC AAAAGATGGT G K E K P L F D T K K V S R K V T K D G AAAGTGGGCT ATATGATGCC AAAAGATGGT AAGGACTATT TCTATGCTCG TGATCAACTT K V G Y M M P K D G K D Y F Y A R DOI. GATTTGACTC AGATTGCCTT TGCCGAACAA GAACTAATGC TTAAAGATAA GAAGCATTAC D L T Q I A F A E Q E L M L K D K K H Y CGTTATGACA TTGTTGACAC AGGTATTGAG CCACGACTTG CTGTAGATGT GTCAAGTCTG 1740 V D T G I E P R L A V D V S S L CCGATGCATG CTGGTAATGC TACTTACGAT ACTGGAAGTT CGTTTGTTAT CCCACATATT 1800 PMHAGNATYD TGSSFVIPHI GATCATATCC ATGTCGTTCC GTATTCATGG TTGACGCGCG ATCAGATTGC AACAGTCAAG 1860 D H I H V V P Y S W L T R D Q I A TATGTGATGC AACACCCCGA AGTTCGTCCG GATGTATGGT CTAAGCCAGG GCATGAAGAG 1920 Y V M Q H P E V R P D V W S K P G H E E TCAGGTTCGG TCATTCCAAA TGTTACGCCT CTTGATAAAC GTGCTGGTAT GCCAAACTGG 1980 S G S V I P N V T P L D K R A G M P N W CAAATTATCC ATTCTGCTGA AGAAGTTCAA AAAGCCCTAG CAGAAGGTCG TTTTGCAACA 2040 Q I I H S A E E V Q K A L A E G R F A T CCAGACGGCT ATATTTCGA TCCACGAGAT GTTTTGGCCA AAGAAACTTT TGTATGGAAA 2100 PDGY I FD PRD V L A K E T F V W K GATGGCTCCT TTAGCATCCC AAGAGCAGAT GGCAGTTCAT TGAGAACCAT TAATAAATCT D G S F S I P R A D G S S L R T I NKS GATCTATCCC AAGCTGAGTG GCAACAAGCT CAAGAGTTAT TGGCAAAGAA AAATACTGGT 2220 D L S Q A E W QQAQELL AKK NTG GATGCTACTG ATACGGATAA ACCCAAAGAA AAGCAACAGG CAGATAAGAG CAATGAAAAC 2280 DAT D T D K P K E K Q Q A D K S N E N CAACAGCCAA GTGAAGCCAG TAAAGAAGAA AAAGAATCAG ATGACTTTAT AGACAGTTTA 2340 Q Q P S E A S K E E K E S D D F I D S L CCAGACTATG GTCTAGATAG AGCAACCCTA GAAGATCATA TCAATCAATT AGCACAAAAA 2400 PDYG LDR ATL EDHI NQL AQK GCTAATATCG ATCCTAAGTA TCTCATTTTC CAACCAGAAG GTGTCCAATT TTATAATAAA 2460 ANIDPKY LIFQPEG VQF YN K

AATGGTGAAT N G E L	TGGTAACTTA V T Y	TGATATCAAG D I K	ACACTTCAAC T L Q Q	AAATAAACCC I N P	TTAACCAAAA	2520
GAAGATCTCA	TTGTTAAAGC	ACTGCTTTGT	CAAAGCAAGT	TACGGTGATT	TTGAAGTCAT	2580
TCTATGTAAC	GAGTAGTGAT	AAAAGTTGGA	TAATAGCGGT	TTTCTTTTGC	AAAGAAATGG	2640
TATCCATGTT	AGAATAGTAA	AAAAAGAGGA	GGATTCTTGG	ACTAATGTCA	AATAAGTAGA	2700
CAGAAAACTG	TGTTATTTTA	TTGCGTTAAA I A N F		TCTTTCTGAT E K Q	TAGGGGTTAG N P T L	2760
TCCTAGATTA G L N	GCCGTATGTG A T H	GGTTGTAATT P N Y N		TTCTCAATGT N E I	ATTCAAAGCA Y E F C	2820
GTCTAATTGA D L Q	ACCTGTTTGA V Q K	TATTTTGATA I N Q Y		TTGATTTGTC N I Q	TATGCTTTAA R H K L	2880
ATACTTGAAA Y K F	AATGCTTCAG F A E	TTACGGCATT T V A N		TATCCAGGAT Y G P	TAGAAAAAGA N S F S	2940
ATGCATGATA H M <	TTGGCACTGC	ACCCTAATAG	TGAGACGCAA	GAAAAACACT	TTTAGGCAAT A I	3000
		GCGACTGGTC PSQD			TAGTTTCATT R T E N	3060
ATAAAATGTA Y F T	ATGTAATTTI I Y N	TAACAATATT K V I N		TCTTTGTTGT D K N	ATTTTCTCCT Y K R R	3120
ATTATGGAAA N H F	TAAAAGGTTT Y F T	CAGTCTTTAG E T K L		AACCATTCAA F W E	TACAGGCATT I C A N	3180
ATCTGCAGGT D A P	GTTCCTTTTC T G K	GAGACATTGA R S M S		TCTTTTTCCG D K E	TGCAAGCCTG T C A Q	3240
Y Y A	ATAGAAGTA M {	r ACACTGAGCC	TTGGTCACTG	: TGTAAGATTG	CTCCTTTATT	3300
	TAACTGATT		A GTACAAAATO L V F D		CAATCTGAGA C D S	3360
TAGTGTAAGO		r cggttatag <i>i</i> R N Y	A GATTCATAAT L N M I		TACAATTTAC Y L K	3420
		G GTAATATCTO T I D			TTATCGGCAT K D A	3480
GGAAATCCCC H G D I	G ACTCAATTT R S L K	A TTATCTGTT N D T	A AATAATAAG L Y Y X	TTTACCCAAA A K G L	A TTGGGAACTT N P V	3540
TCTTGGTACO		A AGCCAGCCA L W G			ACTTTCTTTG V K K	3600
TATTAACAG T N V	T CAATCCGTG T L G H	G ATTTTTTG. I K K	A GCAATCGTG	T AATGGTACGA T I T R	A TAGCCATAAA Y G Y	3660
TAAAGTGAT I F H		G AGCTGTTCA	A TTAATTCAA	T AAGGTCATC	T TTTTTTGCGG	3720

CTTCTCATA	C TCCTT	TTTCC	AACG	GTAAT.	A GGT	CGACC	GC TT	GACCTTA	A AACACI	ירייי א	3700
AATGAAAACI	T ATCGG	STAGT	TGTT	TTTAT	A GTC	TTCCA	CA AGO	CTTGATA	A GACTT	CTAC	3780
ATCGATTTCC I S K	TTATCA	AAGCC	TCGA'	TACTT'	ייייי יי	ስ እ C እ C c	·		ar GACTIF	· K	3840
				- 10	11	r r	D	V Q	Loi		
			_		G	1 I	ĭ	QK	G V G	\circ	
TGAAAACGAT H F R			_		**	L/ [A]	w	T Y	I OS	N	
TTTTTGATGC N K I					11	14 2	ĸ	G A 1	KKM	D	4080
ATGCAAGCCA I C A				•	Α.	v v	V	M			4140
TTCTAGTTTA	CTAAAT'	TTCA A	ACAGG	AGTGT	TTTT	CTTTT	< 5 TCT	CATTTT <i>I</i>	GGGATTO	CAGT	4200
GCCTATTGTT	GTCATC	AATT A	ATTTT'	TCTAA	ATTC	CCCGG	A CTT	AAATTGI	GACCCTT	GGT	4260
CGGAATGAAA	GAGAAG:	IGTT C	CTTC	AATCT	TTCT	TTTATI	AAG	rgaaaac	GCAACAC	TTT	4320
TCTGTACAAC					• д	1 1	R	KT	мрт	. 0	4380
GTAGTTGAGA Y N L					14	MA NA	н	VY	Dкт	K	4440
AAGAGCTAGT L A L			-		E	Q I	V	FE	IKF	AGC	4500
ACGATACGTA R Y T				_	ATAA(Y	GGATAA P Y	CCAG G	CCTGAC A O	TAAGCGA	ACG	4560
TGTGATTCCA . T I G					_	ьΩ	N	υF	EKG	ACG	4620
ATCTGAATGG A D S H					-	1 P	i,	S O	$I A \cap$	ĸ	4680
AACGAGTTCA (V L E					5	<u> </u>	1.	ı E	RNY	'AG	4740
GTCAATGATG A					14	G V	K 1	√ Y	Tr I. D	.GT	4800
GACTAAGGCT I V L A		GTC TT	TCTT(GCTT :	AAATT F	GCCTG Q R	TCTAA	AGTGGT L H	TGGGAATA	.GG	4860
GGCTTCATTC I A E N	TGCCTCI K G F	rag aa R s	TGTG(GTTT (GAAGG F	TGGCT T A	TTCTC	SATAAA Y	CAGAAACC V S V	AA	4920
ATTGAGTCGC T N L R		GC GT	CGAA1	rccg <i>i</i> I R	ACGAC	GTGAA R S	AGTGT	GATAC	CTTCGTTA G E N	TT	4980
CAAGCATATT T L C I	ΊGAΤΤΤΤ	TC TG	CATC	~~~~ -			CTATC S D	GAGAA .	AAATTCTT F I R	TT	5040

AATAGTTTCT I T E	TCAAACTCCG TTTCAGA E F E T E S		GCTTGATAGT A Q Y	AATAACTTGA 5100 Y Y S S				
GTGTGGCATA H P M	TTCAGCCAGC GACACAT N L W R C M		TATTTATCCT Y K D	TATTAGCAGT 5160 K N A T				
GATTATTTCC I I E (SEQ ID N	CTTTTTGTGC CATAATC R K T G Y D IO:13)		K P Y	TAATT 5215 R I 				
FIG. 3a								
FGSALSTVE	EV KEIISEENIW LY	RLSCCHFT SYS	YWKLPTW	40				

FIG. 3b

(SEQ ID NO:14)

MGLATKDNQI AYIDDSKGKA KAPKTNKTMD QISAEEGISA EQIVVKITDQ 50 GYVTSHGDHY HFYNGKVPYD AIISEELLMT DPNYRFKQSD VINEILDGYV 100 IKVNGNYYVY LKPGSKRKNI RTKQQIAEQV AKGTKEAKEK GLAQVAHLSK 150 EEVAAVNEAK ROGRYTTDDG YIFSPTDIID DLGDAYLVPH GNHYHYIPKK 200 DLSPSELAAA QAYWSQKQGR GARPSDYRPT PAPGRRKAPI PDVTPNPGQG 250 HOPDNGGYHP APPRPNDASQ NKHQRDEFKG KTFKELLDQL HRLDLKYRHV 300 350 EEDGLIFEPT QVIKSNAFGY VVPHGDHYHI IPRSQLSPLE MELADRYLAG QTEDNDSGSE HSKPSDKEVT HTFLGHRIKA YGKGLDGKPY DTSDAYVFSK 400 450 ESIHSVDKSG VTAKHGDHFH YIGFGELEQY ELDEVANWVK AKGQADELAA ALDQEQGKEK PLFDTKKVSR KVTKDGKVGY MMPKDGKDYF YARDQLDLTQ 500 IAFAEQELML KDKKHYRYDI VDTGIEPRLA VDVSSLPMHA GNATYDTGSS 550 FVIPHIDHIH VVPYSWLTRD QIATVKYVMQ HPEVRPDVWS KPGHEESGSV 600 IPNVTPLDKR AGMPNWQIIH SAEEVQKALA EGRFATPDGY IFDPRDVLAK 650 ETFVWKDGSF SIPRADGSSL RTINKSDLSQ AEWQQAQELL AKKNTGDATD 700 TDKPKEKQQA DKSNENQQPS EASKEEKESD DFIDSLPDYG LDRATLEDHI 750 793 NOLAOKANID PKYLIFOPEG VQFYNKNGEL VTYDIKTLQQ INP (SEQ ID NO:15)

FIG. 3c

MTDPNVPERO	SDVINEILDG				
		YVIKVNGNYY	VYLKPGSKRK	NIRTKQQIAE	50
QVAKGTKEAK	EKGLAQVAHL	SKEEVAAVNE	AKRQGRYTTD	DGYIFSPTDI	100
IDDLGDAYLV	PHGNHYHYIP	KKDLSPSELA			
PTPAPGRRKA	PIPDVTPNPG		2		150
		QGHQPDNGGY		SQNKHQRDEF	200
	QLHRLDLKYR	HVEEDGLIFE	PTQVIKSNAF	GYVVPHGDHY	250
HIIPRSQLSP	LEMELADRYL	AGQTEDNDSG	SEHSKPSDKE		
KAYGKGLDGK	PYDTSDAYVF		SGVTAKHGDH		300
QYELDEVANW	VKAKGQADEL			FHYIGFGELE	350
		AAALDQEQGK	EKPLFDTKKV	SRKVTKDGKV	400
GYMMPKDGKD	YFYARDQLDL	TQIAFAEQEL	MLKDKKHYRY	DIVDTGIEPR	450
LAVDVSSLPM	HAGNATYDTG	SSFVIPHIDH	IHVVPYSWLT		
MQHPEVRPDV	*****			RDQIATVKYV	500
LAEGRFATPD		SVIPNVTPLD	KRAGMPNWQI	IHSAEEVQKA	550
	GYIFDPRDVL	AKETFVWKDG	SFSIPRADGS	SLRTINKSDL	600
SQAEWQQAQE	LLAKKNTGDA	TDTDKPKEKO	QADKSNENQQ		
SDDFIDSLPD					650
ELVTYDIKTL			IDPKYLIFQP	EGVQFYNKNG	700
D I KI L	QQINP (SEQ	TD NO:16)			715

FIG. 3d

MHSFSNPGYP	YDNAVTEAFF	KYI.KHROTI	NR KHYQNIKQVQ		
YNNYNPHTAN	IGITONOVED	MI BIGINGI	AK KHIQNIKQVQ	LDCFEYIENF	50
- THE THE HIN	TGTIPNOKEE	NYFNAIK	(SEQ ID NO:17	7)	77

FIG. 3e

MAYYQACTEK	DIIRSMSRKG	TPADNACTEW	FUTUT MEET	F YFHNRRKYNK	
DSTTNTUKNY	TTEVATERNA	W	THIVEKIET	F YEHNRRKYNK	50
DDT1141 A1(141	TILINETRIO	QRLNDQSPVQ	YRKLIA (SEQ ID NO:18)	26

FIG. 3f

MENHFIYGYR	TTTDIIVVTU	CT MILLIAM			
2112	TINDDUNTH	GTIANIKKAA	RIMKNNGWL	RTRTKKVPNL	5.0
GKAYYLTDNK	LSRDFHADKP	KEKLVTDITY	LYFGNCKIV	SSIMNLYNRE	
IIAYTISDCO	חיים זעז חייים אז	OT WE DE	TIT ONCKET	POSTMULINKE	100
	PIDIVIDILIN	QLKLPK (SE	EQ ID NO:19	9)	126

FIG. 3g

19/40

MVKKAYSWET	KLACIDMKKA	GKSNRVIMET	LGIKNNSQIY	TWMKWYENEE	50
LYRFHQGVGK	QYTYGKGLEH	LSEVEQLQLQ	VDLLKKYRGL	IRKSIK	96
(SEQ ID NO	:20)				

FIG. 3h

IRYPKASSGD YGTKREIITA NKDKYSISKM CRWLNMPHSS YYYQAVESVS 50
ETEFEETIKR IFLDSESRYG SRKIKICLNN EGITLSRRRI RRIMKRLNLV 100
SVYQKATFKP HSRGKNEAPI PNHLDRQFKQ ERPLQALVTD LTYVRVGNRW 150
AYVCLIIDLY NREIIGLSLG WHKTAELVKQ AIQSIPYALT KVKMFHSDRG 200
KEFDNQLIDE ILEAFGITRS LSQAGYPYDN AVAESTYRAF KIEFVYQETF 250
QLLEELALKT KDYVHWWNYH RIHGSLNYQT PMTKRLIA (SEQ ID NO:21) 288

FIG. 3i

AATTTGAAA N L K				GAGCAATAT	CAGCAACAGT A T V	TTATGGTAAA Y G K	60
					G CGACTTATTT	AGCTCTTTAT A L Y	120
					TAGATGTTAC D V T	AGCCAACATT A N I	180
ATTCACGAA					r atgaagatga y e d d	CTGTATGGGA C M G	240
CCATTGAGG P L S				TTTGATGAA F D E	A CTAATGATGA I N D D	TAATACTATC N T I	300
				GATGCTAAA D A K	CTATCCAAAC I Q T	TAAGCTTGAG .K L E	360
				TCTGACCAT S D H	G AACACACACC E H T P	ACACTATGTA H Y V	420
CCTATGGA					T ATGAAAAGCA Y E K Q	AACTGGTCTT T G L	480
					C GCTTACTTGA R L L E	ACGGGGTGTT R G V	540
					C ATCAAGCTAA H Q A N	TGAGTACATG E Y M	600
CCTTTAGA	TTATA AA	TTCCG TT	CGGCTGCT	ATCTACGC	G AAGCTATCTA	TGAATTAATC	660

20/40

P	L	E	N	I	F	R	S	I	A A]	I y	Y	А	Ε	A	I	Y		E	L	I	
A.A K	ATA •	AAA	TA	ATC	CTT	AAA	TA.	AAI	TATGI	rg A	ATCA	TAF	GAI	'A A	AAGO	GT	GGT	G 1		ACA	TGA	A 720
AG	TGT	CTT	rg	CCT	CTT	rtc <i>i</i>	A TA	AGG	TTAG	A T	TTG	GA	GAC	T T	TAT	GA(CTG.	A C	TT	GGA E	AAA	A 780
TA I	TAT I	TAA. K	AG A	CAAT	r Laal	AAA	TG	TTA	CACA	G A	ATC	:AA	AAT	T A	-		->					3 940
CC	TTT	STTT	rG	СТСС	-יייר	ממידי	<u> አ</u> ክር	- - תר	~ ~ ~			, I	N	I	T	Ε	N		G	I	D	
									- •	_	14	-	L	V	G	Q	Α		Ρ	G	Τ.	
									GGAA K	D	11	-	, ,	_	D	R	L		R	0	W	
							_	-	ACCA'	5	G	L	. 1	:	Α	V	L		Ρ	L	D	
								_	CAGG? G	ט	-	F	1	-	ĸ	ĸ	G	Ī	-	Α	F	1080
								_	AAATO M	-	14	v	Ų	?	L	T	L	I		V	G	1140
	Y Y	GCT A	C 2 Q	AGAA. K	ATA: Y	TTA Y	TCT L	TGG G	SAAGO S	TC S	CGC A	CAC. H	ATA K	A.A	LAAI N	CT <i>I</i> L	AAC T	AG	AA	ACA T	GTT	1200
									TATT. Y	~	-	т	V		н	Р	S	P	, ;	R	N	1260
									GTTT F	_	1	D	L		1	V	D	L	. (O .	K	1320
ATA	GTA	GCA(3 A	I I	בדדב	AA	ACAT	א ידיי	n c c n	TA	GGA	GTI	rgg	TA	TGA R	GAG	AT	AA	TC	- ATC' L	TAC	1380
							_	•	ACGG T A			<u>r</u>	D	CT.	1	TTA N		G	F	Т	G	1440
GTG. E	AAT: F	TAT I	' C	ACGA	CAG	AA	CATI	ттс	GATT D L	יאיד	י איז	7 7 m									_	1500
				AGTG S A	CTT.	TA	TGTC C Q	AA. H	AAAA I >	AT I	GAT1	TAT Y	CT L	TAI N	ATC <i>I</i> Q	AGA. K	AA	TA: Y	rge G	AA. N	ATC	1560
GAT!	TA <i>F</i> K	AAA K	A	GGAA	ምም ር:	ממ	7	~~~	TATT								AT	ATI	rtt	'AGA D	TT	1620
ATT1	TAAA K	AAA N	T	AAAG.	AAT:	TT (SATT	TAZ	AAAC L	יי עיד	· · · · · ·		ΑT	CCF	ATCA H	LATA	AT .	GG1	ľAG	GTA	ጥር	1680
ATTA Y	ATCT L	GCA Q	AC	GAAG	AAG	CT C	TGA	AAC		C D D												1740
AATO	GTA	TGG	AA	TTT	GCCA	A TA	GGC	CGT	GTG	GAA	GCG	CA	CG	TTI	'TAG	CTC	CA (CTI	TG.	АТТ	ΔT	1800
GGTT	TTC	GTA	AG	TTA	AACI	T A	GAT	GTA	.GA.A	GAT	'TTA	AA	AC	CGI	TTG	AAA	AC (GCA	AT'	TGA	AG	1860
CGCA	TTT	TCA	TA	AAG	ATGI	TA	TCT	A AG	GGG	TTA	GCT	TT:	rg .	AAC	TAA	AT <i>P</i>	C C	ממר	ል ጥ		d) d)	1020

TATCTATATG	GGAATGAAAA	ACTTTATCGC	TATGCTTTAG	AGATACTCAA	ACAGCTTGGT	1980
TGTAAACAAT	ACTCTATAGG	CTCTGACGGT	CATATTCCTG	AACATTTTTG	TTATGAATTT	2040
GATAGACTTC	AAGGTCTGCT	AAAGGACTAT	CAAATTGATG	AAAATCATTT	GATATGAGGA	2100
AATTTTTGAT	AAAAAAGCTA	GGCAATATTG	CTTAGCTTTT	TTGTAATGCT	ATTGATAGTT	2160
TTAGTGAAAA	TTTCAAAAAA	ATAAAGAAAT	CATTTACTTG	TTGCAAGCGC	TTGCGTAAAT	2220
TGTTATGATT	TTATTGGTAA	CAATTCATTA	AAAAAGGAGA	ATGATATGAA M K	R K D	2280
LFGD	K Q T		I R K L	S V G	V A S	2340
VTTG	V C I	TTTTCTTCAT F L H	S P Q V	F A E	E V S	2400
GTTTCTCCTG	CAACTACAGC	GATTGCAGAG	TCGAATATTA	ATCAGGTTGA	CAACCAACAA	2460
V S P A	T T A	I A E	S N I N	Q V D	N Q Q	
TCTACTAATT	TAAAAGATGA	CATAAACTCA	AACTCTGAGA	CGGTTGTGAC	ACCCTCAGAT	2520
S T N L	K D D	I N S	N S E T	V V T	P S D	
ATGCCGGATA	CCAAGCAATT	AGTATCAGAT	GAAACTGACA	CTCAAAAGGG	AGTGACAGAG	2580
M P D T	K Q L	V S D	E T D T	Q K G	V T E	
CCGGATAAGG	CGACAAGCCT	GCTTGAAGAA	AATAAAGGTC	CTGTTTCAGA	TAAAAATACC	2640
P D K A	T S L	L E E	N K G P	V S D	K N T	
TTAGATTTAA	AAGTAGCACC	ATCTACATTG	CAAAATACTC	CCGACAAAAC	TTCTCAAGCT	2700
L D L K	V A P	S T L	Q N T P	D K T	S Q A	
ATAGGTGCTC I G A P	CAAGCCCTAC S P T	CTTGAAAGTA L K V	GCTAATCAAG A N Q A		TGAAAATGGT E N G	2760
TACTTTAGGC	TACATCTTAA	AGAATTGCCT	CAAGGTCATC	CTGTAGAAAG	CACTGGACTT	2820
Y F R L	H L K	E L P	Q G H P	V E S	T G L	
TGGATATGGG	GAGATGTTGA	TCAACCGTCT	AGTAATTGGC	CAAATGGTGC	TATCCCTATG	2880
W I W G	D V D	Q P S	S N W P	N G A	I P M	
ACTGATGCTA	AGAAAGATGA	TTACGGTTAT	TATGTTGATT	TTAAATTATC	TGAAAAACAA	2940
T D A K	K D D	Y G Y	Y V D F	K L S	E K Q	
CGAAAACAAA	TATCTTTTTT	AATTAATAAC	AAAGCAGGGA	CAAATTTAAG	CGGCGATCAT	3000
R K Q I	S F L	I N N	K A G T	N L S	G D H	
CATATTCCAT	TATTACGACC	TGAGATGAAC	CAAGTTTGGA	TTGATGAAAA	GTACGGTATA	3060
H I P L	L R P	E M N	Q V W I	D E K	Y G I	
CATACTTATC	AACCCCTCAA-	AGAAGGGTAT	GTCCGTATTA	ACTATTTGAG	TTCCTCTAGT	3120
H T Y Q	P L K	E G Y	V R I N	Y L S	S S S	
AACTATGACC	ACTTATCAGC	ATGGCTCTTT	AAAGATGTTG	CAACCCCYTC	AACAACTTGG	3180
N Y D H	L S A	W L F	K D V A	T P S	T T W	
CCAGATGGTA P D G S	GTAATTTTGT N F V	GAATCAAGGA N O G	CTATATGGAA	GGTATATTGA	TGTATCACTA	3240

AAAACTAACG CCAAAGAGAT TGGTTTTCTA ATCTTAGATG AAAGTAAGAC AGGAG K T N A K E I G F L I L D E S K T G D	D A
GTGAAAGTTC AACCCAACGA CTATGTTTTT AGAGATTTAG CTAACCATAA CCAAA $f V \ K \ V \ Q \ P \ N \ D \ V \ F \ R \ D \ L \ A \ N \ H \ N \ Q \ I$	F
GTAAAAGATA AGGATCCAAA GGTTTATAAT AATCCTTATT ACATTGATCA AGTGC. V K D K D P K V Y N N P Y Y I D Q V Q	L
AAGGATGCCC AACAAATTGA TTTAACAAGT ATTCAAGCAA GTTTTACAAC TCTAGA	G
GTAGATAAAA CTGAAATTTT AAAAGAATTG AAAGTGACTG ATAAAAATCA AAATGO V D K T E I L K E L K V T D K N Q N A	I
CAAATTTCTG ATATCACTCT CGATACTAGT AAATCTCTTT TAATAATCAA AGGCGA ${\sf Q}$ I S D I T L D T S K S L L I I K G D	F
AATCCTAAAC AAGGTCATTT CAACATATCT TATAATGGTA ACAATGTCAT GACAAGN PKQGHFNISYNGNNVMTR	Q
TCTTGGGAAT TTAAAGACCA ACTTTATGCT TATAGTGGAA ATTTAGGTGC AGTTCT S W E F K D Q L Y A Y S G N L G A V L	N
CAAGATGGTT CAAAAGTTGA AGCCAGCCTC TGGTCACCGA GTGCTGATAG TGTCAC $\mathbb Q$ $\mathbb D$ $\mathbb G$ $\mathbb S$ $\mathbb K$ $\mathbb V$ $\mathbb E$ $\mathbb A$ $\mathbb S$ $\mathbb L$ $\mathbb W$ $\mathbb S$ $\mathbb P$ $\mathbb S$ $\mathbb A$ $\mathbb D$ $\mathbb S$ $\mathbb V$ $\mathbb T$	M
ATTATTTATG ACAAAGATAA CCAAAACAGG GTTGTAGCGA CTACCCCCCT TGTGAA I I Y D K D N Q N R V V A T T P L V K	N
AATAAAGGTG TTTGGCAGAC GATACTTGAT ACTAAATTAG GTATTAAAAA CTATAC ${\sf N}$ K G V W Q T I L D T K L G I K N Y T	G
TACTATTATC TTTACGAAAT AAAAAGAGGT AAGGATAAGG TTAAGATTTT AGATCC' Y Y Y L Y E I K R G K D K V K I L D P	Y
GCAAAGTCAT TAGCAGAGTG GGATAGTAAT ACTGTTAATG ATGATATTAA AACGGCTA K S L A E W D S N T V N D D I K T A	K
GCAGCTTTTG TAAATCCAAG TCAACTTGGA CCTCAAAATT TAAGTTTTGC TAAAATT A A F V N P S Q L G P Q N L S F A K I	A
AATTTTAAAG GAAGACAAGA TGCTGTTATA TACGAAGCAC ATGTAAGAGA CTTCACTN F K G R Q D A V I Y E A H V R D F T	S
GATCGATCTT TGGATGGAAA ATTAAAAAAT CAATTTGGTA CCTTTGCAGC CTTTTCADD R S L D G K L K N Q F G T F A A F S	E
AAACTAGATT ATTTACAGAA ATTAGGAGTT ACACACATTC AGCTTTTACC GGTATTG K L D Y L Q K L G V T H I Q L L P V L	S
TATTTTTATG TTAATGAAAT GGATAAGTCA CGCTCAACAG CTTACACTTC CTCAGACY FYVNEM DKSRSTAYTSSD	N
AATTACAATT GGGGCTATGA CCCACAGAGC TATTTTGCTC TTTCTGGGAT GTATTCA N Y N W G Y D P Q S Y F A L S G M Y S	E
AAACCAAAAG ATCCATCAGC ACGTATCGCC GAATTAAAAC AATTAATACA TGATATTK PKD PSA RIA ELKQLIH DI	TCAT 4440 H

AAACGTGGCA	TGGGGGTTAT	ACTTGATGTC	GTCTATAATC	ACACTGCAAA	AACTTATCTC	4500
K R G M	G V I	L D V	V Y N H	T A K	T Y L	
TTTGAGGATA F E D I		TTATTATCAC Y Y H			ACCAAGAGAA P R E	4560
AGTTTTGGAG	GGGGACGTTT	AGGAACCACT	CATGCAATGA	GTCGTCGTGT	TTTGGTTGAT	4620
S F G G	G R L	G T T	H A M S	R R V	L V D	
TCCATTAAAT	ATCTTACAAG	TGAATTTAAA	GTTGATGGTT	TCCGTTTTGA	TATGATGGGA	4680
S I K Y	L T S	E F K	V D G F	R F D	M M G	
GATCATGATG	CGGCTGCGAT	TGAATTAGCT	TATAAAGAAG	CTAAAGCTAT	TAATCCTAAT	4740
D H D A	A A I	E L A	Y K E A	K A I	N P N	
ATGATTATGA	TTGGTGAGGG	CTGGAGAACA	TTCCAAGGCG	ATCAAGGTCA	GCCGGTTAAA	4800
M I M I	G E G	W R T	F Q G D	Q G Q	P V K	
CCAGCTGACC	AAGATTGGAT	GAAGTCAACC	GATACAGTTG	GCGTCTTTTC	AGATGATATT	4860
P A D Q	D W M	K S T	D T V G	V F S	D D I	
CGTAATAGCT	TGAAATCTGG	TTTTCCAAAT	GAAGGTACTC	CAGCTTTCAT	CACAGGTGGC	4920
R N S L	K S G	F P N	E G T P	A F I	T G G	
CCACAATCTT	TACAAGGTAT	TTTTAAAAAT	ATCAAAGCAC	AACCTGGGAA	TTTTGAAGCA	4980
P Q S L	Q G I	F K N	I K A Q	P G N	F E A	
GATTCGCCAG	GAGATGTGGT	GCAGTATATT	GCTGCACATG	ATAACCTTAC	CTTGCATGAT	5040
D S P G	D V V	Q Y I	A A H D	N L T	L H D	
GTGATTGCAA V I A K		(SEQ ID NO	0:22)			5058

FIG. 4a

NLKAELSVED	EQYTATVYGK	SAHGSTPQEG	VNGATYLALY	LSQFDFEGPA	50
RAFLDVTANI	IHEDFSGEKL	GVAYEDDCMG	PLSMNAGVFQ	FDETNDDNTI	100
ALNFRYPQGT	DAKTIQTKLE	${\tt KLNGVEKVTL}$	SDHEHTPHYV	PMDDELVSTL	150
LAVYEKQTGL	KGHEQVIGGG	TFGRLLERGV	AYGAMFPGDE	NTMHQANEYM	200
PLENIFRSAA	IYAEAIYELI	K (SEQ ID	NO:23)		221

FIG. 4b

MTDLEKIIKA	IKSDSQNQNY	TENGIDPLFA	APKTARINIV	GQAPGLKTQE	50
ARLYWKDKSG	DRLRQWLGVD	EETFYHSGKF	AVLPLDFYYP	GKGKSGDLPP	100
RKGFAEKWHP	LILKEMPNVQ	LTLLVGQYAQ	KYYLGSSAHK	NLTETVKAYK	150
DYLPDYLPLV	HPSPRNQIWL	KKNPWFEKDL	IVDLQKIVAD	ILKD	194
(SEQ ID NO:	:24)				

FIG. 4c

MRDNHLHTYF	SYDCQTAFED	YINGFTGEFI	TTEHFDLSNP	YTGQDDVPDY	50
SAYCQKIDYL	NQKYGNRFKK	GIEIGYFKDR	ESDILDYLKN	KEFDLKLLSI	100
HHNGRYDYLQ	EEALKVPTKG	AFSRLL (SE	EQ ID NO:25)		126

FIG. 4d

MYDYDT ECDY	OMOVERTOR		•		
MKRKDLFGDK		VGVASVTTGV	CIFLHSPQVF	AEEVSVSPAT	50
TAIAESNINQ	VDNQQSTNLK	DDINSNSETV	VTPSDMPDTK	QLVSDETDTQ	100
KGVTEPDKAT	SLLEENKGPV	SDKNTLDLKV	APSTLQNTPD	KTSQAIGAPS	150
PTLKVANQAP	RIENGYFRLH	LKELPQGHPV	ESTGLWIWGD	VDQPSSNWPN	200
GAIPMTDAKK	DDYGYYVDFK	LSEKQRKQIS	FLINNKAGTN	LSGDHHIPLL	250
RPEMNQVWID	EKYGIHTYQP	LKEGYVRINY	LSSSSNYDHL	SAWLFKDVAT	300
PSTTWPDGSN	FVNQGLYGRY	IDVSLKTNAK	EIGFLILDES	KTGDAVKVOP	350
NDYVFRDLAN	HNQIFVKDKD	PKVYNNPYYI	DQVQLKDAQQ	IDLTSIQASF	400
TTLDGVDKTE	ILKELKVTDK	NQNAIQISDI	TLDTSKSLLI	IKGDFNPKQG	450
HFNISYNGNN	VMTRQSWEFK	DQLYAYSGNL	GAVLNQDGSK	VEASLWSPSA	500
DSVTMIIYDK	DNQNRVVATT	PLVKNNKGVW	QTILDTKLGI	KNYTGYYYLY	550
EIKRGKDKVK	ILDPYAKSLA	EWDSNTVNDD	IKTAKAAFVN	PSQLGPQNLS	600
FAKIANFKGR	QDAVIYEAHV	RDFTSDRSLD	GKLKNQFGTF	AAFSEKLDYL	650
QKLGVTHIQL	LPVLSYFYVN	EMDKSRSTAY	TSSDNNYNWG	YDPQSYFALS	700
GMYSEKPKDP	SARIAELKQL	IHDIHKRGMG	VILDVVYNHT	AKTYLFEDIE	750
PNYYHFMNED	GSPRESFGGG	RLGTTHAMSR	RVLVDSIKYL	TSEFKVDGFR	800
FDMMGDHDAA	AIELAYKEAK	AINPNMIMIG	EGWRTFQGDQ		850
WMKSTDTVGV	FSDDIRNSLK	SGFPNEGTPA	FITGGPQSLQ	GIFKNIKAQP	900
GNFEADSPGD	VVQYIAAHDN	LTLHDVIAKS	I (SEQ ID		931
			. ~	-	J

FIG. 4e

AATTCAAAGT	TTGACAGAAG	GTCAACTTCG	TTCTGATATC	CCTGAGTTCC	GTGCTGGTGA	60
I Q S >	LTEG	.	S D I	PEFR	5 5	
TACTGTACGT T V R	GTTCACGCTA V H A K	AAGTTGTTGA V V E	AGGTACTCGC G T R	GAACGTATTC E R I Q		120
AGGTGTTGTT G V V	ATCTCACGTA I S R K	AAGGTCAAGG G Q G	AATCTCAGAA I S E	ATGTACACAG M Y T V	TACGTAAAAT R K I	180
TTCTGGTGGT S G G	ATCGGTGTAG I G V E	AGCGTACATT R T F	CCCAATTCAC P I H	ACTCCTCGTG T P R V	TTGATAAAAT D K I	240
CGAAGTTGTT E V V	CGTTATGGTA R Y G K	AAGTACGTCG V R R	TGCTAAACTT A K L	TACTACTTAC Y Y L R		300
AGGTAAAGCT	GCACGTATTA	AAGAAATCCG	TCGTTAATTT	TGATGATCAG	ATTTTAAAAA	360
TGCTTGGTTG	TTTGAGGATA	GTAACTATGT	TTTAAAACTG	GACAACCAAG	ACGTAAAAAA	420
TCTGCCTGTG	GGCAGTTTTT	TTACTAGGTC	CCCTTAGTTC	AATGGATATA . H I Y	ACAACTCCCT C S G	480
CCTAAGGAGT G L S	AATTGCTGGT Y N S T	TCGATTCCGG R N R	CAGGGGACAT C P V	ATTCATTGCA Y E N C	TGTAAATAGC T F L	540
GGTTTAGAGC P K S	TATTTTGCCC S N Q G	CAAATTTCTC L N R	TGATTAAGTT Q N L	TATCGTTCCT K D N R	ATCTTTTTGT D K Q	600
TCTTGTAATT E Q L	GATGTGCGTA Q H A Y	AACTTCTAAA V E L	GTGATATTTA T I N	AATTCTCGTG L N E H	ATCTAAAACT D L V	660
TGAGAGATGG Q S I	AAATTAGATA S I L Y	GCTTGCAAAT S A F	GTATGCCTGA T H R	GAGAGTGCAC L S H V	TCGTACCTCG R V E	720
CGACCAGTTA R G T	TTTTTCGGAT I K R I	AGTTTTATTG T K N	ACTGCATTAT V A N	TTGAAAGTTT N S L K	GTCGAATAAT D F L	780
CTGTCGTTTT R D N	TATTTTTTGT K N K T	AAATTCATGC F E H	AAAAAAAATA L F F	ATGTATCATT L .T D N	GTCAATTGGT D I P	840
ATATTTCTGA I N R	TACTACTTTT I S S K	GTTTTTTGTT N K T	GGCAGGTATC P L Y	TTTGGTTGAA R Q N F	ATGATAATCC H Y D	900
CAAGTTTTAT W T K	TAATTGATAA N I S L	ATATTTGTTA Y K N	GTGTAATCAA T Y D	TATCATTAAC I D N V	TGTTAAACCT T L G	960
AAACATTCAG L C E	CGAAGCGCAT A F R M	GCCAGTTTTA	GCGATGAGGT	ATAACGCTGC	ATACGATTGA	1020
TGTTGTGATT	- 1	AATTTTTATC	AAGCGTAAGT	ATTCATTGGT	TTCAAGAAAT	1080
TTTATCTCTA	TTTACGCCCC	TTATTTTTTG	CTTTAACCTT	AGTGAATAAA	CAAAAATTTT	1140
TTTCTATATA	TCCCTCGTGA	ACAGCCATGG	ATACGCAGGC	TTTTACATGT	ATGTTAAAAC	1200
GCTTTACTGT	ATCTTGCACA	TGCGTTTGAC	TATAATGATT	TATGACTTGT	TGATATTTAG	1260

TGGAAGTAA	r attgcaaagt	AATATATTTC	CTATTATATG	TTTATACGAT	ATTCGATATT	1320
CCCACCCGT	GTCGCGTTTA	CGGAAATACG	CCATTGATAT	ACTCCACATT	AGCTAAAGAA	1380
CAGGGTGTT	AAGGCTACCT	TGATGGAAAA	GGCTCTCTTA	GAGATATTTG	TAAATGGTAT	1440
GATATCTCA	GTCGCTCTGT	TCTCCAAAAG	TGGATAAAAC	GGTATACTAG	TGGTGAAGAC	1500
TTGAAAGCC	CTAGTAGAGG	ATATAGCCGT	ATGAAACAAG	GAAGGCAAGC	CACATTTGAA	1560
GAACGTGTAG	AGATTGTTAA	CTACACCATT	GCCCATGGGA	AAGACTATCA	AGCAGCTATT	1620
GAGAAGTTTC	GTGTTTCCTA	CCAACAAATT	TATTCTTGGG	TGCGTAAGCT	TGAGAAGAAT	1680
GGCTCACAAG	GTTTGGTTGA	TAGACGTGTG	AAAGGGTTGG	AGAGTAGGCC	TGATTTAACC	1740
GAGATTGAGO	AACTTTAACT	CAAGATTAAA	CAATTGGAGG	AACGTAATCG	TCTCTTAGAA	1800
ATCGAGGTTA	GTTTACTAAA	AAAGTTAGAA	GACATCAAAC	GAGGAAACAG	ACGGTAAGAC	1860
TAGGTAAGCA	TTTAGCGGAG	TTCCAAGTAA	TCAAGAATTA	TTACGATGAG	GAATCTAATG	1920
TGCCTATTCA	GGCCTTATGC	CAACTCTTGA	AGGGGTCTCG	TTCAGGCTAT	TACAAGTGGC	1980
TCAATCGTCA	AAAAACAGAT	TTTGAGACAA	AAAATACAAA	GCTAATGGCT	AAAATCAAGG	2040
AACTTCGTAG	ACTCTACAAT	GGTATCTTAG	GTTATCGCCG	TATGACAACA	TTTATTAATC	2100
GTCAACTTGG	GACAACTTAA	AACAAGAAAC	GGATTCGTTG	ATTGATGAAC	ATTCTGGGGA	2160
TTAGTTCAGT	CATTCGTCGT	GTTAGCCATG	CTTGTACAAA	AGCTGGTGAC	AGATTTTACG	2220
AAGAAAATAT	TCTTAATCGT	GAATTTACAG	CCACAGCTCA	TAACCAGAAA	TGGTGCACAG	2280
ATGTCACCTA	TCTTCAATAC	GGTCTGGGAG	CTAAAGCTTA	TCTCAGTGCG	ATTAAAGACC	2340
TGTATAACGG	TTCTATTATC	GCTTATGAGA	TTAGTCACAA	CAATGAAATC	CACTTGTTAT	2400
GAAGACCATT	AAAAAGGGGC	TAGAGCTCAA	TCCAGGAGCC	ACACCTATCA	TCCATAGCGA	2460
TTGAGGTAGT	CAATATACTT	CCAAAGAATA	CCGTTATATC	ATACAACAAG	CTGGTCTGAC	2520
CTTATCCATG	TCCCGGATTG	GCAAATGTAT	TGATAATGCA	CCAACTGAAA	GTTTCTTTGG	2580
	ACTGAGTCTT					2640
TGATGTGGCA	CGTTATATCG	AATTCTACAA	CACACAACGT	TATCAATCAA	AATTAAACAA	2700
CCTGACTCCT	CTAGAATTCA	GGAATCAGGT	TGCATAACTT	ATCTTTTATT	ATTTGACTGT	2760
CTACTTGACA	GGGAGCCGTT	CAGATTGCTT	AACCTTTCTA	AATTTGCTAA	AATAGCTACA	2820
AGAAAACGAG	CCATTTAATG	CTTATTTCTT	ATACTGTCTT	GCCTCACGCT	CTCCTCGACC	2880
	CGTGAGGCTT					2940
	GAGCCATCAA					3000
	TATATAAAA					3060
ATGCCGCCCA	AAAGAACGTT	AATAAAACAT .	AAACTACTAT	GTTAGCATAA	GACTTTATTT	3120

TTACAACTGA ATTTCATATA	AATGGATTAG	AGTAAGGGAT	AAAAGAAATT	AGCATAGCTC	3180
TTTTGAAAAT AAAAAAATTA	ATATAATATG	GAAAAAATTT	TATTTCATAA	ACGTTTCATA	3240
AAAGGTATGT AATCTAGTAT	TTAGGCAACA	CTATTTTGTC	ACTGGTGTCT	AGTAACTTAT	3300
AGATTGATAA TTTTACTAGT	AAACGTAATT	CTTCGCTTTA	AGAGTTAAAT	GTCTATTTAT	3360
TGTAAGCTAA ATTGGGAGGT	GAACTTATGT	AAAATTAGAT	AGGTACTGTC	AAGTACGGGA	3420
TGATTATTGA AACAGCCAGT	ATGCATCATA	AAATCTGTAT	TGCTTAATAA	CTATTTCCTT	3480
AACCAGACAT CAGTTCATTG	TTTATCATCG	CTACCCTAAG	TCTAGTTTTT	TCAATAGAGC	3540
ATTAGGTAGT TTTTGATAAT	AAAACTATAT	AAACATGAGA	ATTAGATTTC	GTATTGCATT	3600
CTTCATAATG AGTTATTTGA	GATTTTCCTT	TGAATAAATA	GATACGAAAT	TCAGTAACTT	3660
CATATATAAA CGGCTCTATC	ATTGAGATAG	TTTGTCAAAT	GAAGAAATTT	TTAATGGAAA	3720
TAGTTTTAAA AACATTAGTT	GTAGGCGATG	TAAAAATATT	AATCCAGTGG	ATGCAATAGT	3780
TGCGGAGTAA AAATAGAGAG	GAGTAATTAG	GAAGTGATAA	AAAATGCTAT	AGCATATATT	3840
ACCAGAAAAA AAAATAGAAC	ACTTATTATA	TTTGCTATTT	TAACAATTGT	TCTTTCTTGC	3900
TTGTATTCAT GTTTAACAAT	AATGAAATCA M K S l>	AGTAATGAAA S N E I	TAGAAAAGGC E K A	TTTATATGAA L Y E	3960
AGTTCTAATT CTTCAATATC S S N S S I S	AATTACAAAA I T K	AAAGATGGTA K D G K	AATATTTTAA Y F N	TATTAATCAA I N Q	4020
TTTAAGAATA TTGAAAAAAT F K N I E K I	AAAAGAGGTT K E V	GAAGAAAAA E E K I	TATTTCAATA F Q Y	TGATGGATTA D G L	4080
GCAAAATTGA AAGATCTTAA A K L K D L K	AGTAGTTAGT V V S	GGTGAGCAAA G E Q S	GTATAAATAG I N R	AGAAGATTTA E D L	4140
TCTGACGAAT TTAAAAATGT S D E F K N V	TGTTTCACTA V S L	GAAGCTACAA E A T S	GTAATACTAA N T K	AAGAAATCTT R N L	4200
TTATTTAGTA GTGGAGTATT L F S S G V F	TAGTTTTAAA S F K	GAAGGAAAAA E G K N	ATATAGAAGA I E E	AAATGATAAG N D K	4260
AATTCAATTC TTGTTCATGA N S I L V H E	AGAATTTGCT E F A	AAACAAAACA K Q N K		GGGTGATGAA G D E	4320
ATTGATCTTG AATTACTAGA I D L E L L D	TACGGAAAAA T E K	AGTGGAAAAA S G K I	TAAAAAGTCA K S H	TAAATTTAAA K F K	4380
ATTATAGGAA TCTTTTCTGG I I G I F S G	TAAAAAACAG K K Q	GAAACATATA E T Y T	CAGGATTATC G L S	ATCTGATTTT S D F	4440
AGCGAAAATA TGGTTTTTGT S E N M V F V	AGATTATTCA D Y S	ACTAGCCAAG T S Q E	AAATATTAAA I L N	TAAATCAGAG K S E	4500
AATAATAGAA TTGCAAATAA N N R I A N K	AATTTTAATG I L M	TATTCTGGTA Y S G S	GTTTAGAATC L E S	TACAGAGCTT T E L	4560
GCCTTAAACA AATTGAAAGA	CTTTAAAATT	GATAAGTCAA	AGTATTCTAT	TAAGAAAGAT	4620

A	L	N	K	L	K	D	F	K	I	D	K	S	K	Y	s	I	К	K	D	
	11	^	r		£	٥	L	£	S	V	S	G	I	K	Н	Ι	I	K	I	4680
••	•	•	٠		1.1	ш	G	G	1	V	V	L	S	L	Ι	L	I	L	W	4740
TI L	AAC R	GAG? E	AAA R	GAAT I	TT <i>P</i> Y	ATGA E	TAA I	'AGG G	TATA I	TT F	TTT L	ATC S	TA I	TTGG G	AAC T	AAC T	TAA K	GAT I	ACAA Q	4800
I I	TAT I	AA1 R	GC Q	AATI F	TAT I	TATT F	TGA E	GTT L	AATA I	TT F	CAT. I	ATC S	AA I	TACC P	AAG S	TAT I	AAT I	ATC S	CTCC	4860
TT L	'AT' F	TTT L	PAT G	GGAA N	TCI L	ACT L	ATT L	AAA K	AGTA V	AT I	TGT. V	AGA E	AG G	GATT F		TAA N	CTC S	AGA E	GAAC N	4920
TC S	AA: M	GAT I	TT F	TCGG G	TGG G	AAG S	TTT. L	AAT I	AAAT N	AA K	AAG S	CAG S	TT F	TTAT	GTT. L	AAA N	CAT	AAC T	AACA T	4980
CT L	TGC A	AGA E	AA S	GTTA Y	TTT L	'AAT I	ATT.	AAT. I	AAGT S	AT' I	TAT'	TGT V	TT L	TATC:	AGT V	TGT V		GGC A		5040
TC S	ATI L	IAA'	'AT L	TATT F	TAA K	GAA K	ACC:	ACA. Q	AGAA E	AT.	ATT! L	ATC S	AA K	AAAT I	AAG' S		GGA	GCA	ATA	5100
.,	GGA D	+	'AT L	TAGA E	AAT I	AAA K	GAA: N	TGT: V	AAAT N	TA(Y	CAG:	rta Y	CG A	CAAA? N	TC' S	TAA K	AGA E	AAA K		5160
TT L	GTC S	AGG G	AG V	TAAA N	TCA Q	AAA K	ATT:	IGA E	ACTT L	GG2 G	AAA(K	GTT' F	TT Y	ATGC(SAT I	AGT V	AGG G		GTCA S	5220
GG. G	AAC T	AGG G	AA K	AATC S	CAC T	ACT L	TCT:	rtc S	CTTA L	CT: L	rgc <i>i</i> A	AGG2 G	AC L	TTGAT D	raaz K	AGT V	TCA.			5280
AA. K	AAT I	CTT L	GT F	TTAA K	GAA N	TGA E	AGA:	TATA I	AGAA E	AA(K	Saaa K	AGG <i>I</i> G	T. Y		'AA' N		CAG R	AAA) K		5340
AA'	TAT I	ATC S	TT L	TGGT: V	ATT F	TCA Q	AAA: N	TAT Y	TAAT N	TTA L	ATA I	AGAT D	TT Y	ATTTA L	TC(S		GAT:	rga <i>i</i> E		5400
•	1		٧	TAAA' N	r	5	V	ט	£	S	I	L	F	E	L	G	L	D	K	5460
•	¥	_	10		14	٧	[4]	r	Ļ	S	G	G	Q	Q	Q	R	V	A	I	5520
SC:	rag R	GGC. A	AC L	TGGT? V	ATC: S	AGA D	TGCC A	CCC <i>F</i> P	ATA I	ATA I	L L	AGCI A	G D	ATGAG E	CCI P	TAC	CGG1 G	raac N	CTA L	5580
A(CAG	TGT	TA	CTGC	rggz	AGA	AATA	ATI	. (SEC) IC) NC	:2	7						5607

FIG. 5a

IQSLTEGQLR	SDIPEFRAGD	TVRVHAKVVE	GTRERIQIFE	GVVISRKGQG	50					
ISEMYTVRKI	SGGIGVERTF	PIHTPRVDKI	EVVRYGKVRR	AKLYYLRALQ	100					
GKAARIKEIR	R (SEQ ID	NO:28)			111					
		_								
		FIG. 5	b							
			FNQRYLPTKN		50					
			IRKITGREVR		100					
YLISISQVLD	HENLNITLEV	YAHQLQEQKD	RNDKLNQRNL	GQNSSKPLFT	150					
CNEYVPCRNR	TSNYSLGGSC	YIH (SEQ	ID NO:29)	•	173					
D-0 5										
FIG. 5c										
	*	T million City Thi		ADDEDICT DOV	50					
			INQFKNIEKI							
			VSLEATSNTK		100					
		•	GDEIDLELLD		150					
KFKIIGIFSG	KKQETYTGLS	SDFSENMVFV	DYSTSQEILN	KSENNRIANK	200					
ILMYSGSLES	TELALNKLKD	FKIDKSKYSI	KKDNKAFEES	LESVSGIKHI	250					
IKIMTYSIML	GGIVVLSLIL	I:LWLRERIYE	IGIFLSIGTT	KIQIIRQFIF	300					
ELIFISIPSI	ISSLFLGNLL	LKVIVEGFIN	SENSMIFGGS	LINKSSFMLN	350					
ITTLAESYLI	LISIIVLSVV	MASSLILFKK	PQEILSKIS		389					
(SEQ ID NO	:30)									
		FIG. 5	5d							
				GTGKSTLLSL	50					
LAGLDKVQTG	KILFKNEDIE	KKGYSNHRKN	NISLVFQNYN	LIDYLSPIEN	100					
IRLVNKSVDE	SILFELGLDK	KQIKRNVMKL	SGGQQQRVAI	ARALVSDAPI	150					
ILADEPTGNL	DSVTAGEII	(SEQ ID NO	:31)		169					

FIG. 5e

CATATGACAA TATTTTTCAA AGTCTACATC ACTTACTCGC CTGTCGTGGA AAATCTGGCA	60
ATACATTAAT CGACCAATTA GTTGCTGATG GTTTACTTCA TGCAGATAAT CACTACCATT	
TITICAATGG GAAGTCTCTG GCCACTTTCA ATACTAACCA ATTGATTCGC CAACTTCTCT	120
AIGIIGAAAT ATCCTTAGAT ACTATGTCTA GTGGTGAACA TGATTTAGTA AAACTTAAGA	
TATCAGACC CACTACCGAG CATACTATCC CCACGATGAT GACAGCTAGG CCCTAGGAG	240
AAGGIAICAA TGATCCTGCC GCAGACCAAA AAACATACCA AATGGAGGGT GGGTTAGAA	300
THAACAGCC TAAACACATA CAAGTTGACA CAAAACCATT TAAACAACAA CTAAAAACATA	360
CITCAAAAII ACCCATCAGC CCTGCAACTG AAAGCTTCAC ACACATTCAC ACTTATTA CTC	420
TCAATGACTA TITTCTTTCT CGTGGTTTTG CTAATATATA CGTTTCACCT CTCCCTACTC	480
CIGGCICIAC GGGTTTCATG ACCAGTGGGG ATTACCAACA AATACAAGC TTTAAAGCAC	540
TCATTGATTG GTTAAATGGT AAGGTTACTG CATTCACAAG TCATAAACCA CATAAACAAC	600
TCAAGGCTGA TTGGTCAAAC GGCCTTGTAG CAACCACAGG TAAATCTTAT CTCCCTACCA	660
IGICAACTGG TTTAGCAACA ACTGGCGTTG AGGGGCTGAA AGTCATTATC CCTCAACGG	720
CAATCTCCAC ATGGTATGAT TATTATCGAG AAAATGGGCT TGTGTGTAGT CCACGGGGGT	780
ACCCCGGTGA AGATTTAGAC GTTTTTAACAG AATTAACATA CTCACGAAAC CTCTTTACCTC	840
GIGATTACAT CAAAAACAAC GATTGCTATC AAGCATTGTT AAATGAACAA TGAAAACCAA	900 960
IIGACCGICA AAGIGGGGAT TACAACCAAT ACIGGCATGA CCGIDATIAC CORRESON	1020
ICAAIAATGI CAAAAGTCGA GTAGTTTACA CTCATGGACT ACAGGATTGG AATGTTA	1020
CAAGACATGI CTACAAAGTT TTCAATGCAT TGCCTCAAAC CATCAAAAA GAGGTTTTTT	1140
TACATCAAGG TCAACATGTG TATATGCATA ATTGGCAGTC GATTCATTTT CCTCARA	1200
IGAAIGCCII ACIAAGCCAA GAACTACTIG GCATTGACAA TCATTTCCAA TTAGAACAA	1260
TCATTIGGCA AGATAATACT ACTGAGCAAA CTTGGCAAGT TTTAGATCCT TTGGCAGCAA	1320
ACCAICAGA GCAAATTGGT TTAGGTGATA GTAAAAAACT TATTGATAAC CATTATGAGA	1380
AAGAAGCCII IGATACTTAT TGTAAAGACT TCAATGTGTT CAAAAATCAT CTTTTCAAGG	1440
GAAATAATAA AACCAATCAA ATCACTATTA ATCTTCCTCT AAAGAAAAT TATCTCCTCA	1500
AIGGACAGIG CAAACTCCAT CTACGTGTTA AAACTAGTGA CAAAAAGGCC ATTTTATCAG	1560
CCCAAATCII AGACTATGGT CCTAAAAAAC GATTCAAAGA TACACCAACC ATCAAATTGT	1620
TAAACAGCCI TGATAATGGT AAAAATTTTG CCAGAGAAGC TTTACGTGAA CTCCCCTTTTA	1680
CIAAAGAICA TTATCGTGTC ATCAGTAAAG GTGTCTTGAA CCTTCAAAT CCTAGAGAG	1740
TACTIACAAT TGAGGCTATC GAGCCAGAAC AATGGTTTGA TATCGAGTTT ACCCTGAAC	1800
CAAGIAIAIA ICAATTGAGT AAAGGTGATA ATCTAAGGAT TATCCTTTAT ACAAGGAT	1860
IIGAACAIAC CATICGAGAT AATGCTAGTT ACTCTATAAC AGTAGATTTC ACTCAATGTT	1920
ATTIAACTAT CCCAACTAAT CAAGGAAATT AACTTATGAA ACTTCTTACT AAACAACTA	1980
IIGAIGAILE TCAACACTTT TGGTACCAGA TCAATTTATT ACAAGACACT AACTTGGGAG	2040
CAGITITICA CCATGATAAT AAAAACATTC CACAGGTTGT TGCAACTATT CTTCATGATT	2100
TACAAGGIIC CGGAAGTTCG AATCATTTCT GGTATTTTGG CAATACTACT CATACTTCT	2160
TOCTIAIGAT TGCTCATTTA AATCGAAAAT TCTATATTCA GGTTAATTTA AAGCAGTTA	2220
ACTITICACT CAATTTAATA GCTATAAATA ATTGGAAGAG TCTCCTCCAA ACTGAACTTC	2280
AAGCTCTAAA CGATACCCTA GCAATATTC AATAAATAAG GTAGAATGGA GTGACAAAGC 2	2340
AACGCGAGGG AGACTGATTA ATGTCATCTT ATTGGAATAA CTATCCTGAA CTTAAAAAAA 2	2400

ATATTGATGA	AACCAATCAA	CTAATTCAAG	AAAGAATACA	GGTCAGAAAT	AAAGATATTG	2460
AAGCGGCGCT	AAGCCAACTC	ACAGCTGCGG	GAGGAAAACA	GCTCAGACCA	GCATTCTTTT	2520
ACCTTTTTTC	TCAACTTGGT	AATAAGGAGA	ATCAAGATAC	TCAGCAACTA	AAGAAAATCG	2580
				TGATGATGTC		2640
				TGGCAAAGAC		2700
				TTTAGAATCT		2760
CACCATTTAT	GAGGATTAAT	GCAAAATCTA	TGCGTAAAAT	TCTCATGGGA	GAATTGGACC	2820
AGATGCACCT				CTATTTACGT		2880
GTAAGACAGC	CGAACTCTTT	AAATTAGCTA	GCAAAGAAGG	AGCTTACTTT	GGTGGTGCAG	2940
AGAAGGAGGT				CATTGGTATG		3000
				ATTTAATAAG		3060
				TGCCATTGAA		3120
				TACTGAAGAC		3180
				TCGCCATCTA		3240
				GAACTCTGCA		3300
					AAACATTCCA	3360
CAATGCTAGA	AAAGCAGTTA	GGGAATGTTT	TTTTATTATC	ATTTATTTAT	CGCACCTATC	3420
				•	ACTACTTTGA	3480
GACAATTCTT					TAAGATACGA	3540
TCAGCATGTT	CAATACCTTT	TAAGTGATGI	GTAATCCAA	CTAAGGTCTT	ACCTTCCAAT	3600
		TAAGGCTTGT			AACAGTTGGC	3660
					AATTCTATGC	3720
					ACCATCTGAT	3780
					ATCTTCTTCA	3840
					AAGGTAGGGC	3900
GCTTGTTGT					A AACATCAGCA	3960
CCGCCTAGG					ACTAGCTAAG	4020
GTACTCTTG					TTTAATATCC	4080
AAATCTAAA'	T GATGCAAAA	C CCATTTCTC	T TGTGGCTTA	T ACTGGAAAC'	r TAAATTCTTG	4140
ACGGAAAAA	T CATATGGCT	T ATTAGGCAA	T T (SEQ I	D NO:32)		4171

FIG. 6a

YDNIFQSLHH	LLACRGKSGN	TLIDOLVADO	: II UA DAIME	FNGKSLATFN	
TNQLIREVVY	VEISLDTMSS	GFHDI WYWAT			
GINDPAADOK	TYOMEGALAV	ACUAL AVAIL	IRPTTEHTIP KPFKEEVKHP	TMMTASPYHQ	100
SETHIDSVSI	NDVEL CDCD	KÖNKHIÖADT	KPFKEEVKHP	SKLPISPATE	150
TOWI NOVIMA	NDIFLSRGFA	NIYVSGVGTA	GSTGFMTSGD	YQQIQSFKAV	200
IDWLNGKVTA	FTSHKRDKQV	KADWSNGLVA	TTGKSYLGTM	STGLATTGVE	250
GLKVIIAEAA	ISTWYDYYRE	NGLVCSPGGY	PGEDLDVLTE	I.TVCDNT T NO	300
DYIKNNDCYQ .	ALLNEQSKAI	DRQSGDYNQY	WHDRNYLTHV	NNVKSRVVYT	
HGLQDWNVKP	T		HQGQHVYMHN		350
NALLSQELLG :		IWQDNTTEQT	WQVLDAFGGN		400
KKLIDNHYDK I					450
GQCKLHLRVK T	TSDKKAILSA	OTINVERVE	NNKTNQITIN	LPLKKNYLLN	500
REALRELPFT F	KDHYRVISKC	VINI ONDER!	FKDTPTIKFL	NSLDNGKNFA	550
REALRELPFT F		ATMT DAKI DL	LTIEAIEPEQ	WFDIEFSLQP	600
SIYQLSKGDN I	SECTION 1	EHTIRDNASY	SITVDLSQSY	LTIPTNQGN	649
(SEQ 15 NO:3)3)	FIG. 6	_		
		116. 6	5		
MKLLTKERFD D	SQHFWYQIN I	LLOESNEGAV	FDHDNKNIPQ '		
GSGSSNHFWY F	GNTTDTSII. N	TAHI NDVEV	TOWN	VVATIVDDLQ	50
KSLLQTQLEA L	NDTLATEO	/SEO IS TO	TQVNLKDFDF 1	ALNLIAINNW	100
		(SEC ID NO	:34)		119
		FIG. 6c			
		- 10. 00	•		

MSSYWNNYPE LKKNIDETNQ LIQERIQVRN KDIEAALSQL TAAGGKQLRP 50
AFFYLFSQLG NKENQDTQQL KKIAASLEIL HVATLIHDDV IDDSPLRRGN 100
MTIQSKFGKD IAVYTGDLLF TVFFDLILES MTDTPFMRIN AKSMRKILMG 150
ELDQMHLRYN QQQGIHHYLR AISGKTAELF KLASKEGAYF GGAEKEVVRL 200
AGHIGFNIGM TFQILDDILD YTADKKTFNK PVLEDLTQGV YSLPLLLAIE 250
ENPDIFKPIL DKKTDMATED MEKIAYLVVS HRGVDKARHL ARKFTEKAIS 300
DINKLPQNSA KKQLLQLTNY LLKRKI (SEQ ID NO:35) 326

FIG. 6d

LPNKPYDFSV	KNLSFQYKPQ	EKWVLHHLDL	DIKEGEKIAI	LGRSGSGKST	50	
LASLLRGDLK	ASQGKITLGG	ADVSIVGDCI	SNYIGVIQQA	PYLFNTTLLN	100	
NIRIGNQDAS	EEDVWKVLER	VGLKEMVTDL	SDGLYTMVDE	AGLRFSGGER	150	
HRIALARILL	KDVPIVILDE	PTVGLDPITE	QALLRVFMKE	LEGKTLVWIT	200	
HHLKGIEHAD	RILFIENGQL	ELEGSPQELS	QSSQRYRQLK	AADDGDL	247	
(SEQ ID NO:36)						

FIG. 6e

AATTCTATTT GGAGGTTTTT CTTGAATAAA TGGTTAGTTA AGGCAAGTTC CTTAGTT	CTT CO
TIAGGIGGTA TGGTTTTATC TGCGGGTTCC CGAGTTTTAG CGGATACTTA TCTCCC	
ATTGATAATG GTAGAATTAC AACAGGTTTC AATGGTTATC CTGGACATTC TCCCCTC	~~ ·
TAIGCIGITE CGACTGGAAC GATTATTAGG GCAGTGGCAG ATGGTACTCT CARACTER	
GGAGCIGGAG CCAACTTTC TTGGATGACA GACTTAGCAG GAAATTGTCT CATGATT	
CAIGCGGAIG GAAIGCAIAG IGGITACGCI CAIAIGICAC GIGIGGIGGC TACCACH	222
GAAAAAGICA AACAAGGAGA TATCATCGGT TACGTAGGAG CAACTGGTAT CCCCACC	202
CCICACCTIC ATTITGAATT TITACCAGCT AACCCTAATT TICAAAATGG TITCGATT	202
CGIATCAATC CAACGTCACT AATTGCTAAC GTTGCGACCT TTAGTGCAAA AACGCAAC	707 540
TCAGCTCCAA GCATTAAGCC ATTACAATCA GCTCCTGTAC AGAATCAATC TACTAAA	100 m
AAAGTGTATC GAGTAGATGA ATTACAAAAG GTTAATGGTG TTTGGTTACT CAAAAAAG	
ACCUTAACGC CGACTGGGTT TGATTGGAAC GATAATGGTA TACCAGCATC ACADAMAG	
GAGGITGATG CTAATGGTAA TTTGACAGCT GACCAGGTTC TTCAAAAACC TCCTTACA	,
ATCTTAATC CTAAAACTCT TAAGACTGTA GAAAAACCCA TCCAACCAAC ACCTGCTT	
ACTIGGGCIA AGACACGCII IGCIAAIGGI AGIICAGIII GGCIICCGI TCLOLO	
CAAGAACIGC ITTACAAATA GTTTGAGGTA TTGATTCATT GTTTTAAATC ACACTTTT	
TACTAACTAA GTACAATTTC TTTAAACCGT CTGAAAATAA TTTTATAGTC CACTAAAC	mc
IGAIAIIAIA GICTCGGACT AATAAAAAGG AAATAGGAAT IGAAGCAATG AAAAAGA	ma
AAAAGGIACI AIIGACATCG ACAATGGCAG CTTCGCTATT ATCAGTCGCA ACTCTTCG	30 1110
CACAAGAAAC AGATACGACG TGGACAGCAC GTACTGTTTC AGAGGTAAAC CCTCATTTT	CC 1000
TAMAGCAAGA CAATAAATCA TCATATACTG TGAAATATGG TGATACACTA ACCCTTAM	mm 1000
CAGAAGCAAI GICAATTGAT ATGAATGTCT TAGCAAAAAT TAATAACATT CCACATA	a
AICTIATITA TOOTGAGACA ACACTGACAG TAACTTACGA TOAGAGAGT CATACTCC	CN 1300
CIICAATGAA AATAGAAACA CCAGCAACAA ATGCTGCTGG TCAAACAACA CCTACTGCT	70 1440
ATTIGAAAAC CAATCAAGTT TCTGTTGCAG ACCAAAAAGT TTCTCTCAAT ACAATTTTC	20 1500
AAGGIATGAC ACCAGAAGCA GCAACAACGA TTGTTTCGCC AATGAAGACA TATTCTTCT	PC 1560
CGCCAGCTTT GAAATCAAAA GAAGTATTAG CACAAGAGCA AGCTGTTAGT CAAGGAGC	1.00
CIAATGAACA GGTATCAACA GCTCCTGTGA AGTCGATTAC TTCAGAAGTT CCACGAGG	7. 7.000
AAGAGGAAGT TAAACCAACT CAGACGTCAG TCAGTCAGTC AACAACAGTA TCAGGGGGG	
CIGITGOCGC TGAAACACCA GCTCCAGTAG CTAAAGTAGC ACCGCTAACA ACTGTAGG	
CCCCIAGAGT GGCAAGTGTT AAAGTAGTCA CTCCTAAAGT AGAAACTCCT CCAMGAGC	
AGCAIGIAIC AGCICCAGCA GTTCCTGTGA CTACGACTTC AACAGCTACA CAGACTACA	
TACAAGCGAC TGAAGTTAAG AGCGTTCCGG TAGCACAAAA AGCTCCAAGA GGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	
TAGCACAACC AGCTTCAACA ACAAATGCAG TAGCTGCACA TCCTGAAAAT CCAGGGGGGG	
AACCICATGT TGCAGCTTAT AAAGAAAAAG TAGCGTCAAC TTATGGAGTT AATGAATTG	
GIACAIACCG TGCAGGTGAT CCAGGTGATC ATGGTAAAGG TTTAGCACTC CAGTTTA	
TAGGIAAAA CCAAGCACTT GGTAATGAAG TTGCACAGTA CTCTACAGA AATTAGGGA	
CARACAT TICATATGTT ATCTGGCAAC AAAAGTTTTA CTCAAATACA AAAAGTTTTA	
AIGGACCIGC TAATACTIGG AATGCAATGC CAGATCGTGG TGGCGTTACT CGGAAGG	
ATGACCATGT TCACGTATCA TTTAACAAAT AATATAAAAA AGGAAGCTAT TTGGCTTCT	T 2400

TTTTATATGC	CTTGAATAGA	CTTTCAAGGT	TCTTATCTAA	AATTATTTTT	ATTGAGGAGA	2460
TTAAGCTATA	AGTCTGAAAC	TACTTTCACG	TTAACCGTGA	CTAAATCAAA	ACGTTAAAAC	2520
TAAAATCTAA	GTCTGTAAAG	ATTATTGAAA	ACGCTTTAAA	AACAGATATA	ATAAGGTTTG	2580
TAGATATCTA	AAATTAAAA	AGATAAGGAA	GTGAGAATAT	GCCACATCTA	AGTAAAGAAG	2640
CTTTTAAAAA	GCAAATAAAA	AATGGCATTA	TTGTGTCATG	TCAAGCTTTG	CCTGGGGAGC	2700
CTCTTTATAC	TGAAAGTGGA	GGTGTTATGC	CTCTTTTAGC	TTTGGCAGCT	CAAGAAGCAG	2760
GAGCGGTTGG	TATAAGAGCC	AATAGTGTCC	GCGACATTAA	GGAAATTCAA	GAAGTTACTA	2820
ATTTACCTAT	CATCGGCATT	ATTAAACGTG	AATATCCTCC	ACAAGAACCA	TTTATCACTG	2880
CTACGATGAC	AGAGGTGGAT	CAATTAGCTA	GTTTAGATAT	TGCAGTAATA	GCCTTAGATT	2940
GTACACTTAG	AGAGCGTCAT	GATGGTTTGA	GTGTAGCTGA	GTTTATTCAA	AAGATAAAAG	3000
GGAAATATCC	TGAACAGTTG	CTAATGGCTG	ATATAAGTAC	TTTTGAAGAA	GGTAAAAATG	3060
CTTTTGAAGC	AGGAGTTGAT	TTTGTGGGTA	CAACTCTATC	TGGATACACA	GATTACAGCC	3120
GCCAAGAAGA	AGGACCGGAT	ATAGAACTCC	TTAATAAGCT	TTGTCAAGCC	GGTATAGATG	3180
TGATTGCGGA	AGGTAAAATT	CATACTCCTA	AGCAAGCTAA	TGAAATTAAT	CATATAGGTG	3240
TTGCAGGAAT	TGTAGTTGGT	GGTGCTATCA	CTAGACCAAA	AGAAATAGCG	GAGCGTTTCA	3300
TCTCAGGACT	TAGTTAAAAG	TGTTACTCAA	AAATCAAAAT	CAAAATAAAA	AAGGGGAATA	3360
GTTATGAGTA	TCAAAAAAAG	TGTGATTGGT	TTTTGCCTCG	GAGCTGCAGC	ATTATCAATG	3420
TTTGCTTGTG	TAGACAGTAG	TCAATCTGTT	ATGGCTGCCG	AGAAGGATAA	AGTCGAAATT	3480
(SEQ ID N	10:37)					

FIG. 7a

NSIWRFFLNK	WLVKASSLVV	LGGMVLSAGS	RVLADTYVRP	IDNGRITTGF	50
NGYPGHCGVD	YAVPTGTIIR	AVADGTVKFA	GAGANFSWMT	DLAGNCVMIQ	100
HADGMHSGYA	HMSRVVARTG	EKVKQGDIIG	YVGATGMATG	PHLHFEFLPA	150
npnfqngfhg	RINPTSLIAN	VATFSGKTQA	SAPSIKPLQS	APVQNQSSKL	200
KVYRVDELQK	VNGVWLVKNN	TLTPTGFDWN	DNGIPASEID	EVDANGNLTA	250
DQVLQKGGYF	IFNPKTLKTV	EKPIQGTAGL	TWAKTRFANG	SSVWLRVDNS	300
OELLYK (SEO ID NO:3	8)			306

FIG. 7b

MKMNKKVLLT	STMAASLLSV	ASVQAQETDT	TWTARTVSEV	KADLVKQDNK	50
SSYTVKYGDT	LSVISEAMSI	DMNVLAKINN	IADINLIYPE	TTLTVTYDQK	100
SHTATSMKIE	TPATNAAGQT	TATVDLKTNQ	VSVADQKVSL	NTISEGMTPE	150
AATTIVSPMK	TYSSAPALKS	KEVLAQEQAV	SQAAANEQVS	TAPVKSITSE	200
VPAAKEEVKP	TQTSVSQSTT	VSPASVAAET	PAPVAKVAPV	RTVAAPRVAS	250
VKVVTPKVET	GASPEHVSAP	AVPVTTTSTA	TDSKLQATEV	KSVPVAOKAP	300
			YKEKVASTYG		350
DPGDHGKGLA	VDFIVGKNQA	LGNEVAQYST	QNMAANNISY	VIWOOKFYSN	400
	WNAMPDRGGV			ID NO:39)	434
			• -		204

FIG. 7c

MPHLSKEAFK	KQIKNGIIVS	CQALPGEPLY	TESGGVMPLL	ALAAQEAGAV	50
GIRANSVRDI	KEIQEVTNLP	IIGIIKREYP	PQEPFITATM	TEVDQLASLD	100
IAVIALDCTL	RERHDGLSVA	EFIQKIKGKY	PEQLLMADIS	TFEEGKNAFE	150
				EGKIHTPKQA	200
NEINHIGVAG	IVVGGAITRP	KEIAERFISG	LS (SEQ II	NO:40)	232

FIG. 7d

MSIKKSVIGF CLGAAALSMF ACVDSSQSVM AAEKDKVEI 39
(SEQ ID NO:41)

FIG. 7e

ATGAAAATGA	ATAAAAAGGT	ACTATTGACA	TCGACAATGG	CAGCTTCGCT	50
ATTATCAGTC	GCAAGTGTTC	AAGCACAAGA	AACAGATACG	ACGTGGACAG	100
CACGTACTGT	TTCAGAGGTA	AAGGCTGATT	TGGTAAAGCA	AGACAATAAA	150
TCATCATATA	CTGTGAAATA	TGGTGATACA	CTAAGCGTTA	TTTCAGAAGC	200
AATGTCAATT	GATATGAATG	TCTTAGCAAA	AATTAATAAC	ATTGCAGATA	250
TCAATCTTAT	TTATCCTGAG	ACAACACTGA	CAGTAACTTA	CGATCAGAAG	300
AGTCATACTG	CCACTTCAAT	GAAAATAGAA	ACACCAGCAA	CAAATGCTGC	350
TGGTCAAACA	ACAGCTACTG	TGGATTTGAA	AACCAATCAA	GTTTCTGTTG	400
CAGACCAAAA	AGTTTCTCTC	AATACAATTT	CGGAAGGTAT	GACACCAGAA	450
GCAGCAACAA	CGATTGTTTC	GCCAATGAAG	ACATATTCTT	CTGCGCCAGC	500
TTTGAAATCA	AAAGAAGTAT	TÁGCACAAGA	GCAAGCTGTT	AGTCAAGCAG	550
CAGCTAATGA	ACAGGTATCA	ACAGCTCCTG	TGAAGTCGAT	TACTTCAGAA	600
GTTCCAGCAG	CTAAAGAGGA	AGTTAAACCA	ACTCAGACGT	CAGTCAGTCA	650
GTCAACAACA	GTATCACCAG	CTTCTGTTGC	CGCTGAAACA	CCAGCTCCAG	700
TAGCTAAAGT	AGCACCGGTA	AGAACTGTAG	CAGCCCCTAG	AGTGGCAAGT	750
GTTAAAGTAG	TCACTCCTAA	AGTAGAAACT	GGTGCATCAC	CAGAGCATGT	800
ATCAGCTCCA	GCAGTTCCTG	TGACTACGAC	TTCAACAGCT	ACAGACAGTA	850
AGTTACAAGC	GACTGAAGTT	AAGAGCGTTC	CGGTAGCACA	AAAAGCTCCA	900
ACAGCAACAC	CGGTAGCACA	ACCAGCTTCA	ACAACAAATG	CAGTAGCTGC	950
ACATCCTGAA	AATGCAGGGC	TCCAACCTCA	TGTTGCAGCT	TATAAAGAAA	1000
AAGTAGCGTC	AACTTATGGA	GTTAATGAAT	TCAGTACATA	CCGTGCAGGT	1050
GATCCAGGTG	ATCATGGTAA	AGGTTTAGCA	GTCGACTTTA	TTGTAGGTAA	1100
AAACCAAGCA	CTTGGTAATG	AAGTTGCACA	GTACTCTACA	CAAAATATGG	1150
CAGCAAATAA	CATTTCATAT	GTTATCTGGC	AACAAAAGTT	TTACTCAAAT	1200
ACAAATAGTA	TTTATGGACC	TGCTAATACT	TGGAATGCAA	TGCCAGATCG	1250
TGGTGGCGTT	ACTGCCAACC	ATTATGACCA	TGTTCACGTA	TCATTTAACA	1300
AATAA					1305

(SEQ ID NO:42)

FIG. 8


	ATACGACGTG		` ACTGTTTCAG	AGGTAAAGGC	
TGATTTGGTA	AAGCAAGACA	ATAAATCATC			50
ATACACTAAG	CGTTATTTCA				100
GCAAAAATTA	ATAACATTGC				150
ACTGACAGTA					200
TAGAAACACC					250
TTGAAAACCA				TACTGTGGAT	300
AATTTCGGAA				CTCTCAATAC	350
TGAAGACATA				GTTTCGCCAA	400
CAAGAGCAAG	CTGTTAGTCA			AGTATTAGCA	450
TCCTGTGAAG		AGCAGCAGCT	AATGAACAGG	TATCAACAGC	500
AACCAACTCA		CAGAAGTTCC	AGCAGCTAAA	GAGGAAGTTA	550
GTTGCCGCTG	AAACACCAGC	AGTCAGTCAA	CAACAGTATC	ACCAGCTTCT	600
TGTAGCAGCC		TCCAGTAGCT	AAAGTAGCAC	CGGTAAGAAC	650
AAACTGGTGC	CCTAGAGTGG	CAAGTGTTAA	AGTAGTCACT	CCTAAAGTAG	700
ACGACTTCAA	ATCACCAGAG	CATGTATCAG	CTCCAGCAGT	TCCTGTGACT	750
		CAGTAAGTTA	CAAGCGACTG	AAGTTAAGAG	800
CGTTCCGGTA	GCACAAAAAG	CTCCAACAGC	AACACCGGTA	GCACAACCAG	850
CTTCAACAAC	AAATGCAGTA	GCTGCACATC	CTGAAAATGC	AGGGCTCCAA	900
CCTCATGTTG	CAGCTTATAA	AGAAAAAGTA	GCGTCAACTT	ATGGAGTTAA	950
TGAATTCAGT	ACATACCGTG	CAGGTGATCC	AGGTGATCAT	GGTAAAGGTT	1000
TAGCAGTCGA	CTTTATTGTA	GGTAAAAACC	AAGCACTTGG	TAATGAAGTT	1050
GCACAGTACT	CTACACAAAA	TATGGCAGCA	AATAACATTT	CATATGTTAT	
CTGGCAACAA	AAGTTTTACT	CAAATACAAA	TAGTATTTAT	GGACCTGCTA	1100
ATACTTGGAA	TGCAATGCCA	GATCGTGGTG	GCGTTACTGC	CAACCATTAT	1150
GACCATGTTC	ACGTATCATT	TAACAAATAA	(SEQ ID	NO: 43)	1200
			(DDG ID	140.40)	1230

FIG. 9

QETDTTWTAR	TVSEVKADLV	KQDNKSSYTV	KYGDTLSVIS	EAMSIDMNVL	50
AKINNIADIN	LIYPETTLTV			AAGQTTATVD	100
LKTNQVSVAD	QKVSLNTISE	GMTPEAATTI	VSPMKTYSSA	PALKSKEVLA	150
QEQAVSQAAA	NEQVSTAPVK	SITSEVPAAK	EEVKPTQTSV	SQSTTVSPAS	200
VAAETPAPVA	KVAPVRTVAA	PRVASVKVVT	PKVETGASPE	HVSAPAVPVT	250
TTSTATDSKL	QATEVKSVPV	AQKAPTATPV	AQPASTTNAV	AAHPENAGLO	300
PHVAAYKEKV	ASTYGVNEFS	TYRAGDPGDH	GKGLAVDFIV	GKNOALGNEV	350
AQYSTQNMAA	NNISYVIWQQ	KFYSNTNSIY	GPANTWNAMP	DRGGVTANHY	400
DHVHVSFNK	(SEQ ID NO:				409

FIG. 9a

Fig. 10



1 / 63

SEQUENCE LISTING

```
<110> BioChem Vaccins
            RIOUX, Clément
            DENIS, Martin
            BRODEUR, Bernard R.
            HAMEL, Josée
            CHARLEBOIS, Isabelle
            BOYER, Martine
      <120> NOVEL GROUP B STREPTOCOCCUS ANTIGENS
      <130> 12806-9PCT
      <150> 60/075,425
      <151> 1998-02-20
      <160> 44
      <170> FastSEQ for Windows Version 3.0
      <210> 1
      <211> 4514
      <212> DNA
      <213> Streptococcus
      <220>
      <221> CDS
      <222> (3)...(464)
      <221> CDS
      <222> (534)...(887)
      <223>
      <221> CDS
      <222> (1024)...(1767)
      <221> CDS
      <222> (1841)...(4288)
      <221> CDS
      <222> (2735)...(4288)
     <400> 1
ta tot ggc aaa gag cca gct aat cgt ttt agt tgg gct aaa aat aaa
                                                                     47
  Ser Gly Lys Glu Pro Ala Asn Arg Phe Ser Trp Ala Lys Asn Lys
```

10

tta Leu	tta Leu	atc Ile	aat Asn	gga Gly 20	ttc Phe	att Ile	gca Ala	act Thr	cta Leu 25	gca Ala	g A	ca la	act Thr	atc Ile	tta Leu 30		it ne	95
ttt Phe	gca Ala	gtt Val	caa Gln 35	ttc Phe	ata Ile	ggt Gly	ctt Leu	aaa Lys 40	cca Pro	gat As <u>ı</u>	t to	ac yr	cct Pro	gga Gly 45	aaa Lys	ac Th	nr	143
tac .Tyr	ttt Phe	att Ile 50	atc Ile	cta Leu	ttg Leu	aca Thr	gca Ala 55	tgg Trp	act	tt:	g a ı M	tg let	gca Ala 60	tta Leu	gta Val	a ad	ct hr	191
gct Ala	tta Leu 65	gtg Val	gga Gly	tgg Trp	gat Asp	aat Asn 70	agg Arg	tat Tyr	ggt	tc Se	c t r P	tc he 75	ttg Leu	tcg Ser	tt: Le	a t ı L	ta eu	239
ata Ile 80	tta Leu	tta Leu	ttc Phe	cag Gln	ctt Leu 85	ggt Gly	tca Ser	agc Ser	gca	ع ب	а а у Т О	act Thr	tac Tyr	cca Pro	at Il	ag eG	aa lu 95	287
ttg Leu	agt Ser	cct Pro	aag Lys	ttc Phe 100	Phe	caa Gln	aca Thr	att Ile	caa Gl: 10	n Pi	a t	ttt Phe	tta Leu	ccç Pro	at Me	-	ict Thr	335
tac Tyr	tct Ser	gtt Val	tca Ser	Gly	tta Leu	aga Arg	gag Glu	acc Thr 120	- 11	c to e Se	g t	ttg Leu	acg Thr	gga Gl; 12	y As	c ç p V	gtt /al	383
aac Asn	cat His	caa Glr 130	1 Trp	g aga Arg	atç Met	cta Lei	a gta ı Val	a ato l Ile	c tt e Ph	t tt	a e	gta Val	tca Ser 140		g at r Me	g a	ata Ile	431
ctt Leu	gct Ala 145	a Le	t ctt u Lei	t ati	tate Ty:	cgt r Arg	3 PA	a ca s Gl:	a ga n Gl	ia g .u A	at sp	taa	taga	aaag	tat	ct	agtga	484
tag	gact	aaca	gta	tgat	atg +	gtat	gtca	aa g	tatt	tag	ga	gga	agaa	gat	atg Met 155	tc Se	t act r Thr	542
tt: Le	a ac u Th	a at r Il 16	e Il	t at e Il	t gc e Al	a ac a Th	a tt r Le 16	a ac u Th	r A	ct t la I	tg	gaa Gli	a ca u Hi 17	5 F1	t t ne T	at yr	att Ile	590
at Me	g ta t Ty 17	r Le	g ga eu Gl	ig ac .u Th	g tt ır Le	a go u Al 18	a Tr	ec ca ir Gl	ig t In S	ca a er A	at Asn	ate Me 18	L 11.	t gg	gg a ly L	ag ys	att Ile	638
tt Ph 19	e Se	jt at er Me	ig to et Se	et aa er Ly	ia ga /s Gl	u G	ig ti lu Le	ig to eu Se	ca t er T	λr 1	ta Leu 200	. PI	c gt	t a	tt a le I	ıaa .ys	ctt Leu 205	686
t t Pł	t aa ne Ly	ag a	at ca sn G	ln G	gt g† ly Va	ta ta	ac a yr A	ac go sn G	TÀ T	tg Leu 215	att Ile	gg Gl	jc ct	ta t eu P	11- 1	ctc Leu 220	ctt Leu	734

. 3/63

	225	e ser gr	n Asn G	In Glu	Ile Val	l Ala Va 23	_	782
atc aat gt Ile Asn Va 24	a ttg ct al Leu Le a0	a gtt gci u Val Ala	t att t a Ile T 245	at ggt yr Gly	gct tto Ala Lei	g aca gt 1 Thr Va 250	t gat aaa l Asp Lys	830
aaa atc tt Lys Ile Le 255	a tta aa u Leu Ly	a cag ggt s Gln Gl _y 260	CIA P	ta cct eu Pro	ata tta Ile Leu 265	Ala Le	t tta aca u Leu Thr	878
ttc tta tt Phe Leu Ph 270	t taatac e	tact tago	egtteg	atttaç	gttga ac	ggctttt	a	927
gtaatcattt atataactac	ttttctca gaattcaa	ata ataca aag agagg	ggtag t tgact t	tgatt	atg act	gag aac	aaatagtata tgg tta Trp Leu	987 1041
cat act aa. His Thr Ly: 280	a gat ggt s Asp Gly	tca gat Ser Asp 285	att ta Ile Ty	t tat r Tyr	cgt gtc Arg Val 290	gtt ggt Val Gly	caa ggt Gln Gly	1089
caa ccg att Gln Pro Ile 295	- var rne	300	GIY AS	n Ser	Leu Ser 305	Ser Arg	Tyr Phe 310	1137
gat aag caa Asp Lys Glr	315	TYL PHE	Ser Ly	320	Tyr Gln	Val Ile	Val Met 325	1185
gat agt aga Asp Ser Arg	ggg cat Gly His 330	ggc aaa Gly Lys	agt cat Ser His	s Ala I	aag cta Lys Leu	aat acc Asn Thr 340	att agt Ile Ser	1233
ttc agg caa Phe Arg Gln 345	ata gca Ile Ala	gtt gac Val Asp	tta aaq Leu Lys 350	gat a S Asp I	lle Leu	gtt cat Val His 355	tta gag Leu Glu	1281
att gat aaa Ile Asp Lys 360	gtt ata Val Ile	ttg gta Leu Val 365	ggc cat Gly His	agc g Ser A	gat ggt (Asp Gly) 370	gcc aat Ala Asn	tta gct Leu Ala	1329
tta gtt ttt Leu Val Phe 375	caa acg Gln Thr	atg ttt Met Phe 380	cca ggt Pro Gly	Met V	tt aga g al Arg (85	ggg ctt Gly Leu	ttg ctt Leu Leu 390	1377
aat tca ggg Asn Ser Gly	aac ctg Asn Leu 395	act att Thr Ile :	cat ggt His Gly	cag c Gln A 400	ga tgg t rg Trp 1	gg gat Trp Asp	att ctt Ile Leu 405	1425
tta gta agg Leu Val Arg	att gcc Ile Ala 410	tat aaa 1 Tyr Lys 1	ttc ctt Phe Leu 415	cac to	at tta <u>c</u> yr Leu G	gg aaa Sly Lys 420	ctc ttt Leu Phe	1473

ccg tat Pro Tyr	atg a Met <i>P</i> 425	igg c	aa a ln L	aa g ys <i>P</i>	Ala (caa Gln 430	gtt Val	att t Ile S	cg (Ser)	Leu	atg Met 435	ttg Leu	gag Glu	gat Asp	1521
ttg aag Leu Lys 440	att a Ile S	agt c Ser F	cca g Pro A	la A	gat Asp :	tta Leu	cag Gln	cat (/al :	tca Ser 450	act Thr	cct Pro	gta Val	atg Met	1569
gtt ttg Val Leu 455	gtt g Val (gga a Gly <i>P</i>	Asn I	aag g Lys 1	gac Asp	ata Ile	att Ile	Lys .	tta Leu 465	aat Asn	cat His	tct Ser	aag Lys	aaa Lys 470	1617
ctt gct Leu Ala	tct ! Ser '	Tyr I	ttt o Phe I 475	cca (Pro	agg Arg	ggg ggg	gag Glu	ttt Phe 480	tat Tyr	tct Ser	tta Leu	gtt Val	ggc Gly 485	ttt Phe	1665
ggg cat Gly His	His	att i Ile : 490	att a Ile :	aag Lys	caa Gln	gat Asp	tcc Ser 495	cat His	gtt Val	ttt Phe	aat Asn	att Ile 500	att Ile	gca Ala	1713
aaa aag Lys Lys	ttt Phe 505	atc Ile	aac Asn	gat Asp	acg Thr	ttg Leu 510	aaa Lys	gga Gly	gaa Glu	att Ile	gtt Val 515	gaa Glu	aaa Lys	gct Ala	1761
aat tga Asn *	aaaa	gtca	aa t	cact	gact	t c	tgtga	attaa	aat	tgta	attt	ttt	atat	ctg	1817
ttttagt	get t	atta	ittgt	t ga	Me	ig a et I 20	tt c le H	at tt is Le	g aa eu Ly	ys A	ga a rg T 25	ct a hr I	tt t le S	ct gtt Ser Val	1870
ttttagt gag caa Glu Glr 530	cta	aad	agt	att	Me 5: ttt	et I 20 aga	le H	is Le tta	tct	ys A: 5: cca	rg T 25 atg	nr 1	t ctt	ttc	1870
gag caa Glu Glr	cta Leu	aag Lys	agt Ser	gtt Val 535	ttt Phe	et I 20 999 Gly ato	le H caa Gln	tta Leu gtc	tct Ser 540	cca Pro	atg Met	aat Asr	c ctt	ttc Phe 545 a tat	
gag caa Glu Glr 530	cta Leu atc	aag Lys ctt Leu	agt Ser gtg Val 550	gtt Val 535 999 Gly	ttt Phe gtt Val	ggg ggg Gly ato Ile	caa Gln gct Ala	tta Leu gtc Val 555	tct Ser 540 tta Leu gat Asp	cca Pro ccg Pro	atg Met aca Thr	aat Asr acc Thr	t ctt t Lev gga r Gly 560	ttc Phe 545 a tat y Tyr	1918
gag caa Glu Glr 530 tta att Leu Ile	cta Leu atc Elle tgta e Val	aag Lys ctt Leu ctg Leu 565 act	agt Ser gtg Val 550 aat Asn	gtt Val 535 ggg Gly gga Gly	ttt Phe gtt Val ctt Leu	ggg Gly ato Ile	caa Gln gct Ala cgt Arg 570	tta Leu gtc Val 555 aca Thr	tct Ser 540 tta Leu gat Asp	cca Pro ccg Pro	aca Thr	aat Asr Asr Thr	c ctt c ctt c gga r Gl; 560 a aga s Ar	ttc Phe 545 a tat y Tyr O g tat g Tyr	1918 1966
gag caa Glu Glr 530 tta att Leu Ile gac ttt Asp Phe	a cagu Gln 580 t ggc y Gly	aag Lys ctt Leu ctg Leu 565 act Thr	agt Ser gtg Val 550 aat Asn agt	gtt Val 535 ggg Gly gga Gly tgg	ttt Phe gtt Val ctt Leu tgt	ggg Gly atc Ile tta Lev atc 589 Gl;	caa Gln gct Ala cgt 570 caace Asr	tta Leu gtc Val 555 aca Thr	tct Ser 540 tta Leu gat Asp	cca Pro ccg Pro aaa Lys	aca Thr ago Ser Asr 590	aat Asr acc Thi	t ctt t Lev c gga r Gly 560 a ag s Ar 50 u Se	ttc Phe 545 a tat y Tyr D g tat g Tyr a gga r Gly	1918 1966 2014

WO 99/42588

_				63	0	u se	ı Pi	.e 11	.e se	er Va	ai I.	le A	la Le	eu I. 64		
			64	5		u by	s Ai	a se 65	r va O	I As	зр Ту	r Ty	yr Ty 65	r Le 55	g gta u Val	
		66	0		1 110	c ly	66:	e Pr 5	o va	1 11	e Ty	r Tr 67	rp Il '0	e Se	t ggt r Gly	2302
	675	5			J Iy.	686	0	y As	o Me	t Pr	o Se 68	r Se 5	r Th	r Ar	t ata g Ile	2350
690		•			695	5	- F11e	: G11	ıırı	70	0 O CA	s Al	a Al	a Al	a gca a Ala 705	2398
				710)	. пес	, Mec	. G13	715	HI:	s Le	u Pr	o Vai	1 Ty:		2446
			725		. Cys	. 116	GIY	730	Ala	≀ Va.	L G1	y Ile	e Va] 735	l Ser	ctt Leu	2494
		740	1	200	Cly	361	745	GIU	Leu	. Val	. Lei	2 Phe 750	Thr	Gly		2542
gct Ala	755		1			760	GIU	1111	vaı	val	765	Trp) Leu	Leu	Leu	2590
tat Tyr 770				-7-	775	116	116	PIO	Pne	780	Ala	Gly	Ile	Tyr	Phe 785	2638
ttt (- 1 -	790	Cly	261	GIII	iie	795	GIn	Arg	Tyr	Glu	Asn 800	Val	2686
ccg a	•		805		Der	1111	vai	810	GIN	Thr	Met	Val	Ser 815	His	Leu	2734
atg o	egt Arg	att Ile 820	tta Leu	ggt Gly	gca Ala	ttc Phe	tta Leu 825	ata Ile	ttt Phe	tca Ser	aca Thr	gca Ala 830	ttt Phe	ttt Phe	gaa Glu	2782
aat a Asn I 8	ltt a le 1	act Thr	tat Tyr	att Ile		tgg Trp 840	ttg Leu	cag Gln	aag Lys	cta Leu	ggc Gly 845	ttg Leu	gac Asp	cca Pro	tta Leu	2830

caa gaa caa Gln Glu Gln 850	atg tta Met Leu	tgg cag Trp Gln 855	ttt cca Phe Pro	GIY L	ta ttg eu Leu 60	ctg ggg Leu Gly	gtt tgt Val Cys 865	2878
ttt att ctc Phe Ile Leu	tta gct Leu Ala 870	aga act Arg Thr	att gat Ile Asp	caa a Gln L 875	aa gtg ys Val	aaa aat Lys Asn	gct ttt Ala Phe 880	2926
cca att gct Pro Ile Ala	att atc lle Ile 885	tgg att Trp Ile	act ttg Thr Leu 890	Thr 1	tg ttt Leu Phe	tat ctt Tyr Leu 895	aat tta Asn Leu	2974
ggt cat att Gly His Ile 900	e Ser Trp	cga cta Arg Leu	tct ttc Ser Phe 905	tgg t	ttt att Phe Ile	tta cta Leu Leu 910	ttg tta Leu Leu	3022
ggc tta tta Gly Leu Let 915	a gtc att ı Val Ile	aag cca Lys Pro	Thr Let	tat a	aaa aaa Lys Lys 925	caa ttt Gln Phe	att tat Ile Tyr	3070
agc tgg ga Ser Trp Gl 930	a gag cgt u Glu Arg	att aag 3 Ile Lys 935	gat gga Asp Gl	y lle	att atc Ile Ile 940	gtt agt Val Ser	tta atg Leu Met 945	3118
gga gtt ct Gly Val Le	a ttt ta u Phe Ty: 95	r Ile Ala	gga ct Gly Le	a cta u Leu 955	ttc cct Phe Pro	atc agg	gct cat Ala His 960	3166
att aca gg Ile Thr Gl	t ggt ag y Gly Se 965	t att gaa r Ile Gli	a cgc ct 1 Arg Le 97	u His	tat ato	ata gca E Ile Ala 975	115 0	3214
ccg ata go Pro Ile Al	a ttg gc la Leu Al	t acg tt a Thr Le	g att ct u Ile Le 985	t act au Thr	ctc gtt Leu Val	tat tta l Tyr Lei 990	a tgt ttg ı Cys Leu	3262
gtt aag a' Val Lys I 995	tt tta ca le Leu Gl	n Gly Ly	a tot to s Ser Cy	gt cag ys Gln	att gg Ile Gl	y ASP Va.	g ttc aat l Phe Asn	3310
gtg gat c Val Asp A 1010	gt tat aa rg Tyr Ly	aa aaa ct ys Lys Le 1015	a ctt ca u Leu G	aa gct ln Ala	tac gg Tyr Gl 1020	t ggt tc y Gly Se	t tcg gat r Ser Asp 1025	3358
agc ggt t Ser Gly I	eu Ala Pi	tt tta aa he Leu As 030	at gat a sn Asp L	aa agg ys Arg 103	, Leu ly	c tgg ta r Trp Ty	c caa aaa r Gln Lys 1040	3406
aat gga g Asn Gly (gaa gat t Slu Asp C 1045	gc gtt go ys Val A	la Phe G	aa ttt 31n Phe .050	gta at Val Il	re var An	t aat aaa n Asn Lys 055	3454
Cys Leu	att atg g Ile Met G 1060	gg gaa c ly Glu P	ca gcc g ro Ala C 1065	ggt gat Gly Asp	t gac ac p Asp Tì	et tat at hr Tyr II 1070	t cgt gaa le Arg Glu	3502

gct att gaa tcg ttt att gat gat gct gat aag cta gac tat gac ctt Ala Ile Glu Ser Phe Ile Asp Asp Ala Asp Lys Leu Asp Tyr Asp Leu 1075 1080 1085	3550
gtt ttt tac agt att gga cag aag ttg aca cta ctt tta cat gag tat Val Phe Tyr Ser Ile Gly Gln Lys Leu Thr Leu Leu Leu His Glu Tyr 1090 1095 1100 1105	3598
ggt ttt gac ttt atg aaa gtt ggt gag gat gct tta gtt aat tta gaa Gly Phe Asp Phe Met Lys Val Gly Glu Asp Ala Leu Val Asn Leu Glu 1110 1115 1120	3646
acg tit act cit aaa ggg aat aag tac aaa cci tic aga aat gcc cta Thr Phe Thr Leu Lys Gly Asn Lys Tyr Lys Pro Phe Arg Asn Ala Leu 1125 1130 1135	3694
aat aga gtt gaa aag gat ggt ttc tat ttc gaa gtt gta caa tcg cca Asn Arg Val Glu Lys Asp Gly Phe Tyr Phe Glu Val Val Gln Ser Pro 1140 1145 1150	3742
cat agt caa gag cta cta aat agt ttg gaa gag att tct aat act tgg His Ser Gln Glu Leu Leu Asn Ser Leu Glu Glu Ile Ser Asn Thr Trp 1165	3790
tta gaa gga cgt cct gaa aaa ggt ttc tca cta gga tat ttt aat aaa Leu Glu Gly Arg Pro Glu Lys Gly Phe Ser Leu Gly Tyr Phe Asn Lys 1170 1185	3838
gat tat ttc caa caa gcc cca ata gct ttg gta aaa aat gct gaa cac Asp Tyr Phe Gln Gln Ala Pro Ile Ala Leu Val Lys Asn Ala Glu His 1190 1195 1200	3886
gaa gtt gtt gct ttt gct aat att atg cca aac tat gaa aag agt att Glu Val Val Ala Phe Ala Asn Ile Met Pro Asn Tyr Glu Lys Ser Ile 1205 1210	3934
ato tot att gat tta atg ogt cao gat aaa cag aaa att oog aat ggo Ile Ser Ile Asp Leu Met Arg His Asp Lys Gln Lys Ile Pro Asn Gly 1220 1225 1230	3982
gtt atg gat ttc ctc ttt tta tca tta ttc tct tat ta	4030
gga tac cac tat ttt gat ttg ggg atg gca cct tta tca gga gtt ggt Gly Tyr His Tyr Phe Asp Leu Gly Met Ala Pro Leu Ser Gly Val Gly 1250 1260 1265	4078
1270 1275 1280	4126
cat ttc ggt agt cat ttc tac tca ttt aat ggt tta cac aag tat aag His Phe Gly Ser His Phe Tyr Ser Phe Asn Gly Leu His Lys Tyr Lys 1285 1290 1295	4174

PCT/CA99/00114 WO 99/42588

aag aag ttt aca cca ttg tgg tcg gaa cgt tat att tct tgt tct cgt Lys Lys Phe Thr Pro Leu Trp Ser Glu Arg Tyr Ile Ser Cys Ser Arg 1300 1305 1310	4222
tcg tcc tgg tta att tgt gct att tgt gcc cta tta atg gaa gat agt Ser Ser Trp Leu Ile Cys Ala Ile Cys Ala Leu Leu Met Glu Asp Ser 1315 1320 1325	4270
aaa att aag att gtt aaa taagctttat ttggcaatta aaaagagcat Lys Ile Lys Ile Val Lys 1330 1335	4318
gtcatgcgac atgctcttt taaatcattt aataccattg attgcttgaa tctactttat aatatgatgt gctttaaat attgtttagc tactgtagct gctgatttat gctttacagc tacttggtag ttcattctt gcatttcttt ttcagtgata tgaccagcaa gtttattgag agcttttttt acttga	4378 4438 4498 4514
<210> 2 <211> 154 <212> PRT <213> Streptococcus	
<pre><400> 2 Ser Gly Lys Glu Pro Ala Asn Arg Phe Ser Trp Ala Lys Asn Lys Leu 15 10 17 18 19 19 19 19 19 19 19 19 19 19 19 19 19</pre>	
Leu Ile Asn Gly Phe Ile Ala Thr Leu Ala Ala Thr Ile Leu Phe Phe Leu Ile Asn Gly Phe Ile Ala Thr Leu Ala Ala Thr Ile Leu Phe Phe Phe Leu Ile Asn Gly Phe Ile Ala Thr Leu Ala Ala Thr Ile Leu Phe Phe Phe Phe Ile Asn Gly Phe Ile Ala Thr Leu Ala Ala Thr Ile Leu Phe Phe Phe Ile Asn Gly Phe Il	
Ala Val Gln Phe Ile Gly Leu Lys Pro Asp Tyr Pro Gly Lys Thr Tyr 45 40 45	
35 Phe Ile Ile Leu Leu Thr Ala Trp Thr Leu Met Ala Leu Val Thr Ala 60 50 50 50 50 50 50 50 50 50	
50 55 Leu Val Gly Trp Asp Asn Arg Tyr Gly Ser Phe Leu Ser Leu Leu Ile 80 70 75 80 65 70 80 70 80 80 65	
65 70 Leu Leu Phe Gln Leu Gly Ser Ser Ala Gly Thr Tyr Pro Ile Glu Leu 95 85 90 Pho Leu Pro Met Thr Tyr	
Ser Pro Lys Phe Phe Gln Thr Ile Gln Pro Phe Leu Pro Met Thr Tyr 100 105 100 The Glv Asp Val Asp	
Ser Val Ser Gly Leu Arg Glu Thr Ile Ser Leu Thr Gly Asp Val Asn 125 120 120 120 120 120 120 120 120 120 120	
His Gln Trp Arg Met Leu Val Ile Phe Leu Val Ser Ser Met Ile Leu 130 135 140	
Ala Leu Ile Tyr Arg Lys Gln Glu Asp 145	
<210> 3 <211> 118 <212> PRT <213> Streptococcus	
<pre><400> 3 Met Ser Thr Leu Thr Ile Ile Ile Ala Thr Leu Thr Ala Leu Glu His 15</pre>	
1 5 10 10 10 Phe Tyr Ile Met Tyr Leu Glu Thr Leu Ala Thr Gln Ser Asn Met Thr 20 25 30	

```
Gly Lys Ile Phe Ser Met Ser Lys Glu Glu Leu Ser Tyr Leu Pro Val
   Ile Lys Leu Phe Lys Asn Gln Gly Val Tyr Asn Gly Leu Ile Gly Leu
   Phe Leu Leu Tyr Gly Leu Tyr Ile Ser Gln Asn Gln Glu Ile Val Ala
   Val Phe Leu Ile Asn Val Leu Leu Val Ala Ile Tyr Gly Ala Leu Thr
   Val Asp Lys Lys Ile Leu Leu Lys Gln Gly Gly Leu Pro Ile Leu Ala
                            105
   Leu Leu Thr Phe Leu Phe
          115
        <210> 4
        <211> 247
        <212> PRT
        <213> Streptococcus
        <400> 4
  Met Thr Glu Asn Trp Leu His Thr Lys Asp Gly Ser Asp Ile Tyr Tyr
 Arg Val Val Gly Gln Gly Gln Pro Ile Val Phe Leu His Gly Asn Ser
 Leu Ser Ser Arg Tyr Phe Asp Lys Gln Ile Ala Tyr Phe Ser Lys Tyr
 Tyr Gln Val Ile Val Met Asp Ser Arg Gly His Gly Lys Ser His Ala
 Lys Leu Asn Thr Ile Ser Phe Arg Gln Ile Ala Val Asp Leu Lys Asp
 Ile Leu Val His Leu Glu Ile Asp Lys Val Ile Leu Val Gly His Ser
 Asp Gly Ala Asn Leu Ala Leu Val Phe Gln Thr Met Phe Pro Gly Met
 Val Arg Gly Leu Leu Asn Ser Gly Asn Leu Thr Ile His Gly Gln
 Arg Trp Trp Asp Ile Leu Leu Val Arg Ile Ala Tyr Lys Phe Leu His
Tyr Leu Gly Lys Leu Phe Pro Tyr Met Arg Gln Lys Ala Gln Val Ile
Ser Leu Met Leu Glu Asp Leu Lys Ile Ser Pro Ala Asp Leu Gln His
Val Ser Thr Pro Val Met Val Leu Val Gly Asn Lys Asp Ile Ile Lys
Leu Asn His Ser Lys Lys Leu Ala Ser Tyr Phe Pro Arg Gly Glu Phe
Tyr Ser Leu Val Gly Phe Gly His His Ile Ile Lys Gln Asp Ser His
Val Phe Asn Ile Ile Ala Lys Lys Phe Ile Asn Asp Thr Leu Lys Gly
Glu Ile Val Glu Lys Ala Asn
               245
     <210> 5
     <211> 816
     <212> PRT
     <213> Streptococcus
```

	- 4	00>	5													
Met	Ile	His	Leu													
						Met			Phe							
Val	Ile	Ala	20 Val	Leu	Pro	Thr	Thr	Gly	Tyr	Asp	Phe	Va 45	1 L	eu A	sn	Gly
Leu	Leu	35 Arg	Thr	Asp	Lys	Ser	40 Lys	Arg	Tyr	Ile	Leu 60	Gl	n T	hr S	Ser	Trp
						55 Asn				Phe						
						Phe										
						Arg							e S	er (
						Ala										
						Tyr										
Lys	Ala 130	. Ser	· Val	. Asp	TYI	135	131	0	- Cl	, ui	14 = Lv	0 s G	1 v . s	Ser	His	Tyr
Tyr 145	Phe	Pro	val	l Ile	150	135 Trp	. 116	. 56	-1	15	5 5	. G	112 1	ıal	Val	160 Ser
						Ser										
																Tyr
			y Il	e Hi												Cys
		у Су	s Al				e Va	l Se								Gly
						u Ph	e Th									240
22! Ly:	5 s Gl	u Th	r Va	ıl Va	23 1 Al	a Tr	p Le	u Le	:u Le	u Ty	r A	rg I	.eu	Ala	Ту: 25!	Tyr
								e Ty	r Ph				lis		Le	gly .
												ys (slu			l Ser
											et A	rg :				y Ala
																e Met 320
																320 u Trp 5
Tr	rp L	eu G	TU P	3: 3:	25 -	1 y 100	0) \	3	30	he T	·le	Leu	Lei	33 1 Al	5 a Arg
																e Trp
																p Arg
	eu S	er F														le Lys
					ys I	ys G										rg Ile 15
L	ys A	Asp (lle :	105 [le]	(le V	al S	Ser 1	Leu 1 425	Met	Gly	Val	Leu	2 Ph 43	е Т 0	yr Ile

11/63

```
Ala Gly Leu Leu Phe Pro Ile Arg Ala His Ile Thr Gly Gly Ser Ile
                              440
   Glu Arg Leu His Tyr Ile Ile Ala Trp Glu Pro Ile Ala Leu Ala Thr
  Leu Ile Leu Thr Leu Val Tyr Leu Cys Leu Val Lys Ile Leu Gln Gly
  Lys Ser Cys Gln Ile Gly Asp Val Phe Asn Val Asp Arg Tyr Lys Lys
  Leu Leu Gln Ala Tyr Gly Gly Ser Ser Asp Ser Gly Leu Ala Phe Leu
                                  505
  Asn Asp Lys Arg Leu Tyr Trp Tyr Gln Lys Asn Gly Glu Asp Cys Val
  Ala Phe Gln Phe Val Ile Val Asn Asn Lys Cys Leu Ile Met Gly Glu
  Pro Ala Gly Asp Asp Thr Tyr Ile Arg Glu Ala Ile Glu Ser Phe Ile
 Asp Asp Ala Asp Lys Leu Asp Tyr Asp Leu Val Phe Tyr Ser Ile Gly
 Gln Lys Leu Thr Leu Leu His Glu Tyr Gly Phe Asp Phe Met Lys
 Val Gly Glu Asp Ala Leu Val Asn Leu Glu Thr Phe Thr Leu Lys Gly
                      600
 Asn Lys Tyr Lys Pro Phe Arg Asn Ala Leu Asn Arg Val Glu Lys Asp
                        615
 Gly Phe Tyr Phe Glu Val Val Gln Ser Pro His Ser Gln Glu Leu Leu
 Asn Ser Leu Glu Glu Ile Ser Asn Thr Trp Leu Glu Gly Arg Pro Glu
 Lys Gly Phe Ser Leu Gly Tyr Phe Asn Lys Asp Tyr Phe Gln Gln Ala
 Pro Ile Ala Leu Val Lys Asn Ala Glu His Glu Val Val Ala Phe Ala
                            680
 Asn Ile Met Pro Asn Tyr Glu Lys Ser Ile Ile Ser Ile Asp Leu Met
                        695
Arg His Asp Lys Gln Lys Ile Pro Asn Gly Val Met Asp Phe Leu Phe
Leu Ser Leu Phe Ser Tyr Tyr Gln Glu Lys Gly Tyr His Tyr Phe Asp
Leu Gly Met Ala Pro Leu Ser Gly Val Gly Arg Val Glu Thr Ser Phe
Ala Lys Glu Arg Met Ala Tyr Leu Val Tyr His Phe Gly Ser His Phe
Tyr Ser Phe Asn Gly Leu His Lys Tyr Lys Lys Phe Thr Pro Leu
Trp Ser Glu Arg Tyr Ile Ser Cys Ser Arg Ser Ser Trp Leu Ile Cys
Ala Ile Cys Ala Leu Leu Met Glu Asp Ser Lys Ile Lys Ile Val Lys
                                   810
     <210> 6
     <211> 518
     <212> PRT
```

<213> Streptococcus <400> 6

Met A																		
l Asn I																		
Gln G			Met															
Phe I	le	Leu																
Pro I	le																	
65 Gly H																		
Gly L									1 1 1 5									
Ser T																		
Gly V																		
Ile 7																		
145 Pro																		
Val :				ı Glı	n Gl					Glı	ı Il							
Val .			Ty:	r Ly														
Ser		Lev	ı Al				<u>ا</u>					- 4						
Asn	Gly	glı,																
225 Cys																		
			~ ~	r Ph	e I				<i>/</i> n ·	~						-		
				r Il														
				ie Me														
	Ph	e Th		eu Ly														
				Lu Ly 3:	7 F						5 U						-	
			_	3. lu L 40					3.4	. n						_		
			ly A	rg P				101	y Ph	ne S					~			
		r P	he G	ln G			375						201	,				
	ı Va	al V		la P														
				.sp L	eu l	Met					ys (Gln	Ly.					
				he I	eu					eu I	he							Lys
Gly	у Т		is 7	Syr I	he	Asp	Leu	1 Gl 44	у М :0	et A	Ala	Pro	Le	u Se 44	er G 15	ly V	al	Gly

```
Arg Val Glu Thr Ser Phe Ala Lys Glu Arg Met Ala Tyr Leu Val Tyr
   His Phe Gly Ser His Phe Tyr Ser Phe Asn Gly Leu His Lys Tyr Lys
   Lys Lys Phe Thr Pro Leu Trp Ser Glu Arg Tyr Ile Ser Cys Ser Arg
   Ser Ser Trp Leu Ile Cys Ala Ile Cys Ala Leu Leu Met Glu Asp Ser
                                       490
                                   505
  Lys Ile Lys Ile Val Lys
          515
        <210> 7
        <211> 5126
        <212> DNA
        <213> Streptococcus
        <220>
        <221> CDS
        <222> (1)...(687)
        <221> CDS
        <222> (701)...(2557)
        <221> CDS
        <222> (2566)...(3036)
       <221> CDS
       <222> (3106)...(4842)
       <221> CDS
       <222> (4850)...(5125)
       <400> 7
 aat ttt gat atc gaa aca act ttt gag gca atg aaa aag cac gcg
 Asn Phe Asp Ile Glu Thr Thr Phe Glu Ala Met Lys Lys His Ala
                                                                      48
 tca tta ttg gag aaa ata tct gtt gag cgt tct ttt att gaa ttt gat
 Ser Leu Leu Glu Lys Ile Ser Val Glu Arg Ser Phe Ile Glu Phe Asp
                                                                      96
aaa ctt cta tta gca cct tat tgg cgt aaa gga atg ctg gca cta ata
Lys Leu Leu Ala Pro Tyr Trp Arg Lys Gly Met Leu Ala Leu Ile
                                                                     144
gat agt cat gct ttt aat tat cta cca tgc tta aaa aat agg gaa tta
Asp Ser His Ala Phe Asn Tyr Leu Pro Cys Leu Lys Asn Arg Glu Leu
                                                                     192
caa tta agc gcc ttt ttg tcc cag tta gat aaa gat ttt tta ttt gag
Gln Leu Ser Ala Phe Leu Ser Gln Leu Asp Lys Asp Phe Leu Phe Glu
                                                                    240
aca tca gaa caa gct tgg gca tca ctc atc ttg agt atg gaa gtt gaa
Thr Ser Glu Gln Ala Trp Ala Ser Leu Ile Leu Ser Met Glu Val Glu
                                                                    288
```

cac aca aag act ttt tta aaa aaa tgg aag aca tca act cac ttt caa His Thr Lys Thr Phe Leu Lys Lys Trp Lys Thr Ser Thr His Phe Gln 100 105 110	336
aaa gat gtt gag cat ata gtg gat gtt tat cgt att cgt gaa caa atg Lys Asp Val Glu His Ile Val Asp Val Tyr Arg Ile Arg Glu Gln Met 115 120 125	384
gga ttg gct aaa gaa cat ctt tat cgt tat gga aaa act ata ata aaa Gly Leu Ala Lys Glu His Leu Tyr Arg Tyr Gly Lys Thr Ile Ile Lys 130 135	432
caa gcg gaa ggt att cgc aaa gca aga ggc ttg atg gtt gat ttc gaa Gln Ala Glu Gly Ile Arg Lys Ala Arg Gly Leu Met Val Asp Phe Glu 145 150 160	480
aaa ata gaa caa cta gat agt gag tta gca atc cat gat agg cat gag Lys Ile Glu Gln Leu Asp Ser Glu Leu Ala Ile His Asp Arg His Glu 165 170	528
ata gtt gtc aat ggt ggc acc tta atc aag aaa tta gga ata aaa cct Ile Val Val Asn Gly Gly Thr Leu Ile Lys Lys Leu Gly Ile Lys Pro 180 185	576
ggt cca cag atg gga gat att atc tct caa att gaa tta gcc att gtt Gly Pro Gln Met Gly Asp Ile Ile Ser Gln Ile Glu Leu Ala Ile Val 195 200 205	624
tta gga caa ctg att aat gaa gaa gag gct att tta cat ttt gtt aag Leu Gly Gln Leu Ile Asn Glu Glu Glu Ala Ile Leu His Phe Val Lys 210 215 220	672
cag tac ttg atg gat tagagaggat tat atg agc gat ttt tta gta gat Gln Tyr Leu Met Asp 230 235	721
gga ttg act aag tcg gtt ggt gat aag acg gtc ttt agt aat gtt tca Gly Leu Thr Lys Ser Val Gly Asp Lys Thr Val Phe Ser Asn Val Ser 240 245	769
ttt atc atc cat agt tta gac cgt att ggg att att ggt gtc aat gga Phe Ile Ile His Ser Leu Asp Arg Ile Gly Ile Ile Gly Val Asn Gly 255 260 265	817
act gga aag aca aca cta tta gat gtt att tcg ggt gaa tta ggt ttt Thr Gly Lys Thr Thr Leu Leu Asp Val Ile Ser Gly Glu Leu Gly Phe 270 275 280	865
gat ggt gat cgt tcc cct ttt tca tca gct aat gat tat aag att gct Asp Gly Asp Arg Ser Pro Phe Ser Ser Ala Asn Asp Tyr Lys Ile Ala 285 290 295 300	913
tat tta aaa caa gaa cca gac ttt gat gat tct cag aca att ttg gac Tyr Leu Lys Gln Glu Pro Asp Phe Asp Asp Ser Gln Thr Ile Leu Asp 305 310 315	961

acc gta ctt tct tct gac tta aga gag atg gct tta att aaa gaa tat Thr Val Leu Ser Ser Asp Leu Arg Glu Met Ala Leu Ile Lys Glu Tyr 320 325 330	1009
gaa tta ttg ctt aat cac tac gaa gaa agt aag caa tca cgt cta gag Glu Leu Leu Asn His Tyr Glu Glu Ser Lys Gln Ser Arg Leu Glu 335 340 345	1057
aaa gta atg gca gaa atg gat tot tta gat got tgg tot att gag ago Lys Val Met Ala Glu Met Asp Ser Leu Asp Ala Trp Ser Ile Glu Ser 350 355	1105
gaa gtc aaa aca gta tta tcc aaa tta ggt att act gat ttg cag ttg Glu Val Lys Thr Val Leu Ser Lys Leu Gly Ile Thr Asp Leu Gln Leu 365 370 375 380	1153
tcg gtt ggt gaa tta tca gga gga tta cga aga cgt gtt caa tta gcg Ser Val Gly Glu Leu Ser Gly Gly Leu Arg Arg Arg Val Gln Leu Ala 385 390 395	1201
caa gta tta tta aat gat gca gat tta ttg ctc tta gac gaa cct act Gln Val Leu Leu Asn Asp Ala Asp Leu Leu Leu Leu Asp Glu Pro Thr 400 405 410	1249
aac cac tta gat att gac act att gca tgg tta acg aat ttt ttg aaa Asn His Leu Asp Ile Asp Thr Ile Ala Trp Leu Thr Asn Phe Leu Lys 420 425	1297
aat agt aaa aag aca gtg ctt ttt ata act cat gat cgt tat ttt cta Asn Ser Lys Lys Thr Val Leu Phe Ile Thr His Asp Arg Tyr Phe Leu 430 435 440	1345
gac aat gtt gca aca cgt att ttt gaa tta gat aag gca cag att aca Asp Asn Val Ala Thr Arg Ile Phe Glu Leu Asp Lys Ala Gln Ile Thr 450 455 460	1393
gaa tat caa ggc aat tat cag gat tat gtc cga ctt cgt gca gaa caa Glu Tyr Gln Gly Asn Tyr Gln Asp Tyr Val Arg Leu Arg Ala Glu Gln 465 470 475	1441
480 485 Lys Lys Gln Leu Tyr Lys	1489
495 500 S05	1537
510 515 SIN ASN Leu Lys Asn Asp Leu His	1585
Caa aca agc gat aca agc gat ttg gaa atg aca ttt gaa aca agt cga Gln Thr Ser Asp Thr Ser Asp Leu Glu Met Thr Phe Glu Thr Ser Arg 525 530 535 540	.633

att ggg aaa aag gtt att aat ttt gaa aat gtc tct ttt tct tac cca Ile Gly Lys Lys Val Ile Asn Phe Glu Asn Val Ser Phe Ser Tyr Pro 555	1681
gat aaa tot ato ttg aaa gao ttt aat ttg tta att caa aat aaa gao Asp Lys Ser Ile Leu Lys Asp Phe Asn Leu Leu Ile Gln Asn Lys Asp 560 570	1729
cgt att ggc atc gtt gga gat aat ggt gtt gga aag tca acc tta ctt Arg Ile Gly Ile Val Gly Asp Asn Gly Val Gly Lys Ser Thr Leu Leu 575 580 585	1777
aat tta att gtt caa gat tta cag ccg gat tcg ggt aat gtc tct att Asn Leu Ile Val Gln Asp Leu Gln Pro Asp Ser Gly Asn Val Ser Ile 590 595 600	1825
ggt gaa acg ata cgt gta ggt tac ttt tca caa caa ctt cat aat atg Gly Glu Thr Ile Arg Val Gly Tyr Phe Ser Gln Gln Leu His Asn Met 605 610 615	1873
gat ggc tca aaa cgt gtt att aat tat ttg caa gag gtt gca gat gag Asp Gly Ser Lys Arg Val Ile Asn Tyr Leu Gln Glu Val Ala Asp Glu 635	1921
gtt aaa act agt gtc ggt aca aca agt gtg aca gaa cta ttg gaa caa Val Lys Thr Ser Val Gly Thr Thr Ser Val Thr Glu Leu Leu Glu Gln 640 645	1969
ttt ctc ttt cca cgt tcg aca cat gga aca caa att gca aaa tta tca Phe Leu Phe Pro Arg Ser Thr His Gly Thr Gln Ile Ala Lys Leu Ser 655 660	2017
ggt ggt gag aaa aaa aga ctt tac ctt tta aaa atc ctg att gaa aag Gly Gly Glu Lys Lys Arg Leu Tyr Leu Leu Lys Ile Leu Ile Glu Lys 670 680	2065
cct aat gtg tta cta ctt gat gag ccg aca aat gac tta gat att gct Pro Asn Val Leu Leu Asp Glu Pro Thr Asn Asp Leu Asp Ile Ala 690 695 700	2113
aca tta act gtt ctt gaa aat ttt tta caa ggc ttt ggt ggt cct gtg Thr Leu Thr Val Leu Glu Asn Phe Leu Gln Gly Phe Gly Gly Pro Val 705 710	2161
att aca gtt agt cac gat cgt tac ttt tta gat aaa gtg gct aat aaa Ile Thr Val Ser His Asp Arg Tyr Phe Leu Asp Lys Val Ala Asn Lys 720 725 730	2209
att att gcg ttt gaa gat aac gat atc cgt gaa ttt ttt ggt aat tat Ile Ile Ala Phe Glu Asp Asn Asp Ile Arg Glu Phe Phe Gly Asn Tyr 735 740 745	2257
act gat tat tta gat gaa aaa gca ttt aat gag caa aat aat gaa gtt Thr Asp Tyr Leu Asp Glu Lys Ala Phe Asn Glu Gln Asn Asn Glu Val 750 755	2305

atc agt aaa aaa gag agt acc aag aca agt cgt gaa aag caa agt cgt Ile Ser Lys Lys Glu Ser Thr Lys Thr Ser Arg Glu Lys Gln Ser Arg 770 780	2353
aaa aga atg tct tac ttt gaa aaa caa gaa tgg gcg aca att gaa gac Lys Arg Met Ser Tyr Phe Glu Lys Gln Glu Trp Ala Thr Ile Glu Asp 785 790	2401
gat att atg ata ttg gaa aat act atc act cgt ata gaa aat gat atg Asp Ile Met Ile Leu Glu Asn Thr Ile Thr Arg Ile Glu Asn Asp Met 800 805	2449
caa aca tgt ggt agt gat ttt aca agg tta tct gat tta caa aag gaa Gln Thr Cys Gly Ser Asp Phe Thr Arg Leu Ser Asp Leu Gln Lys Glu 815 820 825	2497
tta gat gca aaa aat gaa gca ctt cta gaa aag tat gac cgt tat gag Leu Asp Ala Lys Asn Glu Ala Leu Leu Glu Lys Tyr Asp Arg Tyr Glu 830 835	2545
tac ctt agt gag ttagacac atg att atc cgt ccg att att aaa aat gat Tyr Leu Ser Glu LeuAspThrMet Ile Ile Arg Pro Ile Ile Lys Asn Asp 845 850 855	2595
865 870 875	2643
880 885 Reu Asp His Leu 890	2691
900 905 Phe Phe Val Ile Glu	2739
915 920 Pro Leu Lys Asn	2787
930 935 935	835
aag ggg ctt gct act gat tta gtg aaa atg att gaa gta gaa gct cga 28 Lys Gly Leu Ala Thr Asp Leu Val Lys Met Ile Glu Val Glu Ala Arg 945 950	883
aaa att ggg tat aga caa ctt tat tta gag aca gcc agt act ttg agt 29 Lys Ile Gly Tyr Arg Gln Leu Tyr Leu Glu Thr Ala Ser Thr Leu Ser 960 965 970	931
agg gca act gcg gtt tat aag cat atg gga tat tgt gcc tta tcg caa 29 Arg Ala Thr Ala Val Tyr Lys His Met Gly Tyr Cys Ala Leu Ser Gln 980 985	79

cca ata gca aat gat caa ggt cat aca gct atg gat att tgg atg atg Pro Ile Ala Asn Asp Gln Gly His Thr Ala Met Asp Ile Trp Met Ile Pro Ile Ala Asn Asp Gln Gly His Thr Ala Met Asp Ile Trp Met Ile	3027
aaa gat tta taagttgaaa gtggattagt gaacatggat taattatttt Lys Asp Leu	3076
gagataagag gaaagaaaag gagacatat atg gca tat att tgg tct tat ttg Met Ala Tyr Ile Trp Ser Tyr Leu 1010	3129
aaa agg tac ccc aat tgg tta tgg ctt gat tta cta gga gct atg ctt Lys Arg Tyr Pro Asn Trp Leu Trp Leu Asp Leu Leu Gly Ala Met Leu 1020 1025 1030	3177
ttt gtg acg gtt atc cta gga atg ccc aca gcc tta gcg ggt atg att Phe Val Thr Val Ile Leu Gly Met Pro Thr Ala Leu Ala Gly Met Ile 1035 1040 1045	3225
gat aat ggc gtt aca aaa ggt gat cgg act gga gtt tat ctg tgg acg Asp Asn Gly Val Thr Lys Gly Asp Arg Thr Gly Val Tyr Leu Trp Thr 1050 1055	3273
ttc atc atg ttt ata ttt gtt gta cta ggt att att ggg cgt att acg Phe Ile Met Phe Ile Phe Val Val Leu Gly Ile Ile Gly Arg Ile Thr 1080 1065	3321
atg gct tac gca tct agt cgc tta acg aca aca atg att aga gat atg atg gct tac gca tct agt cgc tta acg aca aca atg att aga gat atg Met Ala Tyr Ala Ser Ser Arg Leu Thr Thr Met Ile Arg Asp Met 1095 1090 1095	3369
cgt aat gat atg tat gct aag ctt caa gaa tac tcc cat cat gaa tat Arg Asn Asp Met Tyr Ala Lys Leu Gln Glu Tyr Ser His His Glu Tyr 1100 1105 1110	3417
gaa cag ata ggt gta tct tca cta gtg aca cgt atg aca agc gat act Glu Gln Ile Gly Val Ser Ser Leu Val Thr Arg Met Thr Ser Asp Thr 1115	3465
ttt gtt ttg atg caa ttt gct gaa atg tct tta cgt tta ggc cta gta Phe Val Leu Met Gln Phe Ala Glu Met Ser Leu Arg Leu Gly Leu Val	3513
act cct atg gta atg att ttt agc gtg gtt atg ata cta att acg agt Thr Pro Met Val Met Ile Phe Ser Val Val Met Ile Leu Ile Thr Ser 1145 1150 1155 1160	3561
cca tct ttg gct tgg ctt gta gcg gtt gcg atg cct ctt ttg gta gga pro Ser Leu Ala Trp Leu Val Ala Val Ala Met Pro Leu Leu Val Gly 1175	3609
gtc gtt tta tat gta gct ata aaa aca aaa cct tta tct gaa aga caa Val Val Leu Tyr Val Ala Ile Lys Thr Lys Pro Leu Ser Glu Arg Glr 1180 1185 1190	3657

cag act atg ctt gat aaa atc aat caa tat gtt cgt gaa aat tta aca Gin Thr Met Leu Asp Lys Ile Asn Gln Tyr Val Arg Glu Asn Leu Thr 1200 1205	3705
ggg tta cgc gtt gtt aga gcc ttt gca aga gag aat ttt caa tca caa l210 l215 l220	3753
aaa ttt caa gtc gct aac caa cgt tac aca gat act tca act ggt ctt Lys Phe Gln Val Ala Asn Gln Arg Tyr Thr Asp Thr Ser Thr Gly Leu 1225 1230 1240	3801
ttt aaa tta aca ggg cta aca gaa cca ctt ttc gtt caa att att att Phe Lys Leu Thr Gly Leu Thr Glu Pro Leu Phe Val Gln Ile Ile 1245 1250 1255	3849
gca atg att gtg gct atc gtt tgg ttt gct ttg gat ccc tta caa aga Ala Met Ile Val Ala Ile Val Trp Phe Ala Leu Asp Pro Leu Gln Arg 1260 1265 1270	3897
ggt gct att aaa ata ggg gat tta gtt gct ttt atc gaa tat agc ttc Gly Ala Ile Lys Ile Gly Asp Leu Val Ala Phe Ile Glu Tyr Ser Phe 1275 1280 1285	3945
cat gct ctc ttt tca ttt ttg cta ttt gcc aat ctt ttt act atg tat His Ala Leu Phe Ser Phe Leu Leu Phe Ala Asn Leu Phe Thr Met Tyr 1290 1295	3993
cct cgt atg gtg gta tca agc cat cgt att aga gag gtg atg gat atg Pro Arg Met Val Val Ser Ser His Arg Ile Arg Glu Val Met Asp Met 1305 1310 1320	4041
Pro Ile Ser Ile Asn Pro Asn Ala Glu Gly Val Thr Asp Thr Lys Leu 1325 1330	4089
aaa ggg cat tta gaa ttt gat aat gta aca ttc gct tat cca gga gaa Lys Gly His Leu Glu Phe Asp Asn Val Thr Phe Ala Tyr Pro Gly Glu 1340 1345	4137
1360 Lys Pro Gly	4185
1370 1375 1380 Lys Ser Ser Leu	4233
1390 1395 Leu Gly Lys Ile Leu	1281
Gta gat gga gtt gat gta aga gat tat aac ctt aaa tca ctt aan	329

aag att gga ttt atc ccc caa aaa gct ctt tta ttt aca ggg aca ata 4 Lys Ile Gly Phe Ile Pro Gln Lys Ala Leu Leu Phe Thr Gly Thr Ile 1420 1425 1430	4377
gga gag aat tta aaa tat gga aaa gct gat gct act att gat gat ctt Gly Glu Asn Leu Lys Tyr Gly Lys Ala Asp Ala Thr Ile Asp Asp Leu 1435 1440 1445	4425
aga caa gcg gtt gat att tct caa gct aaa gag ttt att gag agt cac Arg Gln Ala Val Asp Ile Ser Gln Ala Lys Glu Phe Ile Glu Ser His 1450 1455 1460	4473
caa gaa gcc ttt gaa acg cat tta gct gaa ggt ggg agc aat ctt tct Gln Glu Ala Phe Glu Thr His Leu Ala Glu Gly Gly Ser Asn Leu Ser 1480	4521
ggg ggt caa aaa caa cgg tta tct att gct agg gct gtt gtt aaa gat Gly Gly Gln Lys Gln Arg Leu Ser Ile Ala Arg Ala Val Val Lys Asp 1495	4569
cca gat tta tat att ttt gat gat tca ttt tct gct ctc gat tat aag Pro Asp Leu Tyr Ile Phe Asp Asp Ser Phe Ser Ala Leu Asp Tyr Lys 1500 1505	4617
aca gac gct act tta aga gcg cgt cta aaa gaa gta acc ggt gat tct Thr Asp Ala Thr Leu Arg Ala Arg Leu Lys Glu Val Thr Gly Asp Ser 1515 1520 1525	4665
aca gtt ttg ata gtt gct caa agg gtg ggt acg att atg gat gct gat Thr Val Leu Ile Val Ala Gln Arg Val Gly Thr Ile Met Asp Ala Asp 1530 1535 1540	4713
cag att att gtc ctt gat gaa ggc gaa att gtc ggt cgt ggt acc cac Gln Ile Ile Val Leu Asp Glu Gly Glu Ile Val Gly Arg Gly Thr His	4761
gct caa tta ata gaa aat aat gct att tat cgt gaa atc gct gag tca Ala Gln Leu Ile Glu Asn Asn Ala Ile Tyr Arg Glu Ile Ala Glu Ser 1565 1570 1575	4809
caa ctg aag aac caa aac tta tca gaa gga gag tgattgt atg aga aaa Gln Leu Lys Asn Gln Asn Leu Ser Glu Gly Glu Met Arg Lys 1580 1585	4858
aaa tot git tit tig aga tia tigg tot tac ota act ogo tac aaa got Lys Ser Val Phe Leu Arg Leu Trp Ser Tyr Leu Thr Arg Tyr Lys Ala 1595 1600 1605	4906
act ctt ttc tta gcg att ttt ttg aaa gtt tta tct agt ttt atg agt Thr Leu Phe Leu Ala Ile Phe Leu Lys Val Leu Ser Ser Phe Met Ser 1610 1615 1620	495 4
gtt ctg gag cct ttt att tta ggg tta gcg ata aca gag ttg act gct Val Leu Glu Pro Phe Ile Leu Gly Leu Ala Ile Thr Glu Leu Thr Ala 1635	5002

```
aac ctt gtt gat atg gct aag gga gtt tct ggg gca gaa ttg aac gtt
  Asn Leu Val Asp Met Ala Lys Gly Val Ser Gly Ala Glu Leu Asn Val
                                                                     5050
                         1645
  cct tat att gct ggt att ttg att att tat ttt ttc aga ggt gtt ttc
  Pro Tyr Ile Ala Gly Ile Leu Ile Ile Tyr Phe Phe Arg Gly Val Phe
                                                                     5098
                                        1665
  tat gaa tta ggt tot tat ggo toa aat t
  Tyr Glu Leu Gly Ser Tyr Gly Ser Asn
                                                                    5126
        <210> 8
       <211> 229
       <212> PRT
       <213> Streptococcus
       <400> 8
 Asn Phe Asp Ile Glu Thr Thr Phe Glu Ala Met Lys Lys His Ala
 Ser Leu Leu Glu Lys Ile Ser Val Glu Arg Ser Phe Ile Glu Phe Asp
                              10
 Lys Leu Leu Ala Pro Tyr Trp Arg Lys Gly Met Leu Ala Leu Ile
 Asp Ser His Ala Phe Asn Tyr Leu Pro Cys Leu Lys Asn Arg Glu Leu
 Gln Leu Ser Ala Phe Leu Ser Gln Leu Asp Lys Asp Phe Leu Phe Glu
Thr Ser Glu Gln Ala Trp Ala Ser Leu Ile Leu Ser Met Glu Val Glu
His Thr Lys Thr Phe Leu Lys Lys Trp Lys Thr Ser Thr His Phe Gln
Lys Asp Val Glu His Ile Val Asp Val Tyr Arg Ile Arg Glu Gln Met
Gly Leu Ala Lys Glu His Leu Tyr Arg Tyr Gly Lys Thr Ile Ile Lys
Gln Ala Glu Gly Ile Arg Lys Ala Arg Gly Leu Met Val Asp Phe Glu
Lys Ile Glu Gln Leu Asp Ser Glu Leu Ala Ile His Asp Arg His Glu
Ile Val Val Asn Gly Gly Thr Leu Ile Lys Lys Leu Gly Ile Lys Pro
                               185
Gly Pro Gln Met Gly Asp Ile Ile Ser Gln Ile Glu Leu Ala Ile Val
                           200
Leu Gly Gln Leu Ile Asn Glu Glu Glu Ala Ile Leu His Phe Val Lys
Gln Tyr Leu Met Asp
                                           220
225
     <210> 9
     <211> 622
     <212> PRT
     <213> Streptococcus
```

													_
<400 Met Ser As	p Phe	Leu	Val	Asp	Gly	Leu	Thr 10	Lys	Ser	Val	Gly	Asp 15	Lys
1 Thr Val Ph	e Ser	5 Asn	Val	Ser	Phe	Ile	Ile	His	Ser	Leu	Asp 30	Arg	Ile
Gly Ile II	20 e Gly	Val	Asn	Gly	Thr	25 Gly	Lys	Thr	Thr	Leu 45	Leu	Asp	Val
3! Ile Ser G	; Ly Glu	Leu	Gly	Phe	40 Asp	Gly	Asp	Arg	Ser	Pro	Phe	Ser	Ser
50 Ala Asn A	o Tyr	· Lys	Ile	55 Ala	Tyr	Leu	Lys	Gln	60 Glu	Pro	Asp	Phe	Asp 80
65 Asp Ser G	ln Thr	Ile	70 Leu	Asp	Thr	Val	Leu	75 Ser	Ser	Asp	Leu	Arg	Glu
Met Ala L	eu Ile	85 Lys	Glu	Tyr	Glu	Leu	90 Leu	Leu	Asn	His	Tyr	Glu	Glu
Ser Lys G	100	n Arc	. Leu	Glu	Lys	105 Val	5 L Met	: Ala	Glu	Met	Asp	Ser	Leu
Ser Lys C 1 Asp Ala T	15 25 Se	r Tle	Glu	. Ser	120 Glu	va.	l Lys	s Thr	. Val	125 Let	s 1 Ser	Lys	Leu
Asp Ala 1 130 Gly Ile 1	ייי אר יייי ד'ר פר	~ T ~ 1	. Glr	135	i Ser	· Vai	1 Gl	y Gli	140 Let) ı Sei	c Gly	y Gly	Leu
Gly Ile 1 145 Arg Arg A	nr As	י בי	150) 1 201	a Glr	ı Va	l Le	u Lei	a Asr	n Asj	o Ala	a Asp	160 Leu
Arg Arg i	Arg Va	1 G1:	, ње 5	A ALC	× 201	n Hi	17	0 u Asi	o Ile	e As	p Thi	179 r Ile	Ala
Leu Leu :	Leu As 18	p GI	u Pro	5 III.	- Asi	18	5 <u>5</u> 5 x I.V	e Lv	s Thi	r Va	19 l Le	0 u Phe	e Ile
Trp Leu	Thr As 195	n Ph	e Le	и гу	20	0	: 11y	ומו.	a Th	20 r Ar	5 a Il	e Ph	e Glu
Thr His	Asp Aı	rg Ty	r Ph	е Le 21	u As 5	p A:	GJ	בת בו	22 v As	0 n Tv	r Gl	n As	p Tyr
210 Leu Asp 225	Lys A	la Gl	in II 23	e Tn 0	r GI	u 1)	71 63	23	5 5	ر. د. ا (۵ م	a Se	er Le	240 u His
225 Val Arg	Leu A	rg Al	la Gl 45	u Gl	n As	sp G.	1u Ai 2!	rg As	b wr	.a A.		25	5 r Gln
Lys Lys	Lys G	ln Lo	eu Ty	r L	rs G]	Ln G. 2	lu L 65	eu Al	la II	p Me	2°	70 rg Ph	e Gln
Pro Gln	Ala A	rg A	la Ti	ar Ly	/s Gl 28	ln G 80	ln A	la Ai	rg II	Le A	sn A. 85	.g	an Glu
Asn Leu	Lys A	sn A	sp L	eu H. 2	is G: 95	ln T	hr S	er A	sp Ti	nr S	er A	sp ne	a Glu
290 Met Thr	Phe C	3lu T	hr S	er A 10	rg I	le G	ly L	ys L 3	ys V 1 5	aı I	ie A	P	320
305 Asn Val	Ser !	Phe S	er T	yr P	ro A	.sp I	Jys S	er I 30	le L	eu L	ys A	sp P	35
Leu Leu	Ile	Gln A	Asn L	ys A	sp A	rg :	Ile (345	Bly I	le V	al G	lly A	sp A 50	sn Gly
Val Gly	Lys	340 Ser :	Thr I	seu I	eu A	sn 1	Leu :	Ile V	/al G	ln A	Asp I 365	Jeu G	In Pro
Asp Se	355 Gly	Asn '	Val S	Ser :	le C	Gly '	Glu'	Thr :	lle A	Arg ¹ 380	Jal (Gly T	yr Phe
379 Ser Gl:	n Gln	Leu	His A	Asn I	Met A	Asp	Gly	Ser 1	Lys <i>l</i> 395	Arg '	Val :	Ile A	Asn Tyr 400
385 Leu Gl	n Glu	Val	Ala	Asp	Glu '	Val	Lys	Thr	Ser '	Val	Gly '	Thr :	Thr Ser
Val Th	r Glu	Leu 420	405 Leu	Glu	Gln	Phe	Leu 425	Phe	Pro	Arg	Ser	Thr :	His Gly
		120											

WO 99/42588 PCT/CA99/00114

```
Thr Gln Ile Ala Lys Leu Ser Gly Gly Glu Lys Lys Arg Leu Tyr Leu
  Leu Lys Ile Leu Ile Glu Lys Pro Asn Val Leu Leu Asp Glu Pro
  Thr Asn Asp Leu Asp Ile Ala Thr Leu Thr Val Leu Glu Asn Phe Leu
  Gln Gly Phe Gly Gly Pro Val Ile Thr Val Ser His Asp Arg Tyr Phe
  Leu Asp Lys Val Ala Asn Lys Ile Ile Ala Phe Glu Asp Asn Asp Ile
  Arg Glu Phe Phe Gly Asn Tyr Thr Asp Tyr Leu Asp Glu Lys Ala Phe
                                  505
                              520
  Asn Glu Gln Asn Asn Glu Val Ile Ser Lys Lys Glu Ser Thr Lys Thr
  Ser Arg Glu Lys Gln Ser Arg Lys Arg Met Ser Tyr Phe Glu Lys Gln
  Glu Trp Ala Thr Ile Glu Asp Asp Ile Met Ile Leu Glu Asn Thr Ile
 Thr Arg Ile Glu Asn Asp Met Gln Thr Cys Gly Ser Asp Phe Thr Arg
                                     570
                                 585
 Leu Ser Asp Leu Gln Lys Glu Leu Asp Ala Lys Asn Glu Ala Leu Leu
                            600
 Glu Lys Tyr Asp Arg Tyr Glu Tyr Leu Ser Glu Leu Asp Thr
                      615
       <210> 10
       <211> 157
       <212> PRT
       <213> Streptococcus
      <400> 10
 Met Ile Ile Arg Pro Ile Ile Lys Asn Asp Asp Gln Ala Val Ala Gln
 Leu Ile Arg Gln Ser Leu Arg Ala Tyr Asp Leu Asp Lys Pro Asp Thr
Ala Tyr Ser Asp Pro His Leu Asp His Leu Thr Ser Tyr Tyr Glu Lys
                                25
Ile Glu Lys Ser Gly Phe Phe Val Ile Glu Glu Arg Asp Glu Ile Ile
Gly Cys Gly Gly Phe Gly Pro Leu Lys Asn Leu Ile Ala Glu Met Gln
Lys Val Tyr Ile Ala Glu Arg Phe Arg Gly Lys Gly Leu Ala Thr Asp
Leu Val Lys Met Ile Glu Val Glu Ala Arg Lys Ile Gly Tyr Arg Gln
Leu Tyr Leu Glu Thr Ala Ser Thr Leu Ser Arg Ala Thr Ala Val Tyr
                               105
                        120
Lys His Met Gly Tyr Cys Ala Leu Ser Gln Pro Ile Ala Asn Asp Gln
Gly His Thr Ala Met Asp Ile Trp Met Ile Lys Asp Leu
                   150
     <210> 11
     <211> 579
     <212> PRT
     <213> Streptococcus
```

<pre><400> 11 Met Ala Tyr Ile Trp Ser Tyr Leu Lys Arg Tyr Pro Asn Trp Leu Trp</pre>
10 10 10 10 10 10 10 10 10 10 10 10 10 1
25 20 20 Pro Thr Ala Leu Ala Gly Met Ile Asp Asn Gly Val Thr Lys Gly Asp 45
Pro Thr Ala Leu Ala Gly Met 11e Asp 135 45
35 Arg Thr Gly Val Tyr Leu Trp Thr Phe Ile Met Phe Ile Phe Val Val 60
Leu Gly Ile Ile Gly Arg Ile Thr Met Ala Tyr Ala Ser Ser Arg Leu 80
65 The The Met Ile Arg Asp Met Arg Asp Met Tyr Ala Lys Leu
85 Gln Glu Tyr Ser His His Glu Tyr Glu Gln Ile Gly Val Ser Ser Leu 105 110
Gin Giu Tyr Ser his Art 105 100 100 100 100 100 Val Thr Arg Met Thr Ser Asp Thr Phe Val Leu Met Gln Phe Ala Glu 120 125
Val Thr Arg Met Thr Ser Asp 111 File Val 25 125 115 120 125 Not Yel Met The Phe Ser
115 120 120 Met Val Met Ile Phe Ser Met Ser Leu Arg Leu Gly Leu Val Thr Pro Met Val Met Ile Phe Ser 135 140
Val Val Met Ile Leu Ile Thr Ser Pro Ser Leu Ala Trp Leu Val Ala 160
145 Val Na Met Pro Leu Leu Val Gly Val Val Leu Tyr Val Ala Ile Lys 175
165 Thr Lys Pro Leu Ser Glu Arg Gln Gln Thr Met Leu Asp Lys Ile Asn 185 185 190
180 180 185 187 188 Gln Tyr Val Arg Glu Asn Leu Thr Gly Leu Arg Val Val Arg Ala Phe 200 205
Gln Tyr Val Arg Glu Ash Bed 1112 205 205 200 195 200 Ash Bed 1112 200 Ash
195 200 Ala Arg Glu Asn Phe Gln Ser Gln Lys Phe Gln Val Ala Asn Gln Arg 220 210 210 210 210 210 210 21
210 215 Tyr Thr Asp Thr Ser Thr Gly Leu Phe Lys Leu Thr Gly Leu Thr Glu 235 240
230 225 230 255 Pro Leu Phe Val Gln Ile Ile Ile Ala Met Ile Val Ala Ile Val Trp 250 255
pro Leu Phe var Gin 116 125 250 255 245 245 250 250 Leu
245 Phe Ala Leu Asp Pro Leu Gln Arg Gly Ala Ile Lys Ile Gly Asp Leu 260 260 260 260 260 260 260 260
Val Ala Phe Ile Glu Tyr Ser Phe His Ala Leu Phe Ser Phe Leu Leu 280 285
Phe Ala Asn Leu Phe Thr Met Tyr Pro Arg Met Val Val Ser Ser His
290 295 Arg Ile Arg Glu Val Met Asp Met Pro Ile Ser Ile Asn Pro Asn Ala 315 320
Arg Ile Arg Glu Val Acc 210 315 320 305 310 315 Glu Phe Asp Asn
305 310 310 Glu Gly Val Thr Asp Thr Lys Leu Lys Gly His Leu Glu Phe Asp Asn 335 330 335
325 Val Thr Phe Ala Tyr Pro Gly Glu Thr Glu Ser Pro Val Leu His Asp 345 330 345
340 The Ser Phe Lys Ala Lys Pro Gly Glu Thr Ile Ala Phe Ile Gly Ser
355 Thr Gly Ser Gly Lys Ser Ser Leu Val Asn Leu Ile Pro Arg Phe Tyr 380 380
370 373 Asp Gly Val Asp Val Arg Asp
Asp Val Thr Leu Gly Lys Ile Leu Val Asp Gly 400
385 Tyr Asn Leu Lys Ser Leu Arg Gln Lys Ile Gly Phe Ile Pro Gln Lys 415
405 Ala Leu Leu Phe Thr Gly Thr Ile Gly Glu Asn Leu Lys Tyr Gly Lys 430 425

WO 99/42588 PCT/CA99/00114

```
Ala Asp Ala Thr Ile Asp Asp Leu Arg Gln Ala Val Asp Ile Ser Gln
  Ala Lys Glu Phe Ile Glu Ser His Gln Glu Ala Phe Glu Thr His Leu
  Ala Glu Gly Gly Ser Asn Leu Ser Gly Gly Gln Lys Gln Arg Leu Ser
  Ile Ala Arg Ala Val Val Lys Asp Pro Asp Leu Tyr Ile Phe Asp Asp
  Ser Phe Ser Ala Leu Asp Tyr Lys Thr Asp Ala Thr Leu Arg Ala Arg
  Leu Lys Glu Val Thr Gly Asp Ser Thr Val Leu Ile Val Ala Gln Arg
                             520
 Val Gly Thr Ile Met Asp Ala Asp Gln Ile Ile Val Leu Asp Glu Gly
 Glu Ile Val Gly Arg Gly Thr His Ala Gln Leu Ile Glu Asn Asn Ala
 Ile Tyr Arg Glu Ile Ala Glu Ser Gln Leu Lys Asn Gln Asn Leu Ser
                                    570
 Glu Gly Glu
       <210> 12
       <211> 92
       <212> PRT
      <213> Streptococcus
      <400> 12
Met Arg Lys Lys Ser Val Phe Leu Arg Leu Trp Ser Tyr Leu Thr Arg
Tyr Lys Ala Thr Leu Phe Leu Ala Ile Phe Leu Lys Val Leu Ser Ser
Phe Met Ser Val Leu Glu Pro Phe Ile Leu Gly Leu Ala Ile Thr Glu
Leu Thr Ala Asn Leu Val Asp Met Ala Lys Gly Val Ser Gly Ala Glu
Leu Asn Val Pro Tyr Ile Ala Gly Ile Leu Ile Ile Tyr Phe Phe Arg
Gly Val Pne Tyr Glu Leu Gly Ser Tyr Gly Ser Asn
     <210> 13
     <211> 5215
     <212> DNA
     <213> Streptococcus
     <220>
     <221> CDS
     <222> (3)...(122)
     <221> CDS
     <222> (133)...(2511)
    <221> CDS
    <222> (367)...(2511)
    <221> CDS
```

<222> (2946)(2716) <223> of complementary strand	
<221> CDS <222> (3252)(2995) <223> of complementary strand	
<221> CDS <222> (3676)(3299) <223> of complementary strand	
<221> CDS <222> (4124)(3837) <223> of complementary strand	
<221> CDS <222> (5214)(4351) <223> of complementary strand	
<pre></pre>	47
gaa gaa aac ata tgg tta tat cgg ctc agt tgc tgc cat ttt act agc Glu Glu Asn Ile Trp Leu Tyr Arg Leu Ser Cys Cys His Phe Thr Ser 20 25 30	95
tac tca tat tgg aag tta cca act tgg taagcatcat atg ggt cta gca Tyr Ser Tyr Trp Lys Leu Pro Thr Trp Met Gly Leu Ala 35	144
aca aag gac aat cag att gcc tat att gat gac agc aaa ggt aag gca Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser Lys Gly Lys Ala 45 50 55 60	192
aaa gcc cct aaa aca aac aaa acg atg gat caa atc agt gct gaa gaa Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile Ser Ala Glu Glu 65	240
ggc atc tct gct gaa cag atc gta gtc aaa att act gac caa ggc tat Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr Asp Gln Gly Tyr 80 85	288
gtg acc tca cac ggt gac cat tat cat ttt tac aat ggg aaa gtt cct Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn Gly Lys Val Pro 95 100 105	336
tat gat gcg att att agt gaa gag ttg ttg atg acg gat cct aat tac Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr Asp Pro Asn Tyr 110 115	384
cgt ttt aaa caa tca gac gtt atc aat gaa atc tta gac ggt tac gtt Arg Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu Asp Gly Tyr Val 125 130 135	432

att aaa gtc aat ggc aac tat tat gtt tac ctc aag cca ggt agt aag Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr Leu Lys Pro Gly Ser Lys 145 150 155	480
cgc aaa aac att cga acc aaa caa caa att gct gag caa gta gcc aaa Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile Ala Glu Gln Val Ala Lys 160 165 170	528
gga act aaa gaa gct aaa gaa ada ggt tta gct caa gtg gcc cat ctc Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu Ala Gln Val Ala His Leu 175 180 185	576
agt aaa gaa gat gcg gca gtc aat gaa gca aaa aga caa gga cgc Ser Lys Glu Glu Val Ala Ala Val Asn Glu Ala Lys Arg Gln Gly Arg 190 195 200	624
tat act aca gac gat ggc tat att ttt agt ccg aca gat atc att gat Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser Pro Thr Asp Ile Ile Asp 210 215 220	672
gat tta gga gat gct tat tta gta cct cat ggt aat cac tat cat tat Asp Leu Gly Asp Ala Tyr Leu Val Pro His Gly Asn His Tyr His Tyr 225 230 235	720
att cct aaa aag gat ttg tct cca agt gag cta gct gct gca caa gcc Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu Leu Ala Ala Ala Gln Ala 240 245 250	768
tac tgg agt caa aaa caa ggt cga ggt gct aga ccg tct gat tac cgc Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala Arg Pro Ser Asp Tyr Arg 255 260 265	816
ccg aca cca gcc cca ggt cgt agg aaa gcc cca att cct gat gtg acg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala Pro Ile Pro Asp Val Thr 275 280	864
cct aac cct gga caa ggt cat cag cca gat aac ggt ggc tat cat cca Pro Asn Pro Gly Gln Gly His Gln Pro Asp Asn Gly Gly Tyr His Pro 295 300	912
gcg cct cct agg cca aat gat gcg tca caa aac aaa cac caa aga gat Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln Asn Lys His Gln Arg Asp 305 310 315	960
gag tit aaa gga aaa acc tit aag gaa cit tia gat caa ata a	1008
ctt gat ttg aaa tac cgt cat gtg gaa gaa gat ggg ttg att bat	L0 5 6
Pro Thr Classes and the age to the ggg tat gtg gtg are	104

gga gat cat tat cat att atc cca aga agt cag tta tca cct ctt gaa Gly Asp His Tyr His Ile Ile Pro Arg Ser Gln Leu Ser Pro Leu Glu 365 370 375 380	1152
atg gaa tta gca gat cga tac tta gct ggc caa act gag gac aat gac Met Glu Leu Ala Asp Arg Tyr Leu Ala Gly Gln Thr Glu Asp Asn Asp 385 390 395	1200
tca ggt tca gag cac tca aaa cca tca gat aaa gaa gtg aca cat acc Ser Gly Ser Glu His Ser Lys Pro Ser Asp Lys Glu Val Thr His Thr 400 405 410	1248
ttt ctt ggt cat cgc atc aaa gct tac gga aaa ggc tta gat ggt aaa Phe Leu Gly His Arg Ile Lys Ala Tyr Gly Lys Gly Leu Asp Gly Lys 415 420 425	1296
cca tat gat acg agt gat gct tat gtt ttt agt aaa gaa tcc att cat Pro Tyr Asp Thr Ser Asp Ala Tyr Val Phe Ser Lys Glu Ser Ile His 430 435	1344
tca gtg gat aaa tca gga gtt aca gct aaa cac gga gat cat ttc cac Ser Val Asp Lys Ser Gly Val Thr Ala Lys His Gly Asp His Phe His 445 450 450	1392
tat ata gga ttt gga gaa ctt gaa caa tat gag ttg gat gag gtc gct Tyr Ile Gly Phe Gly Glu Leu Glu Gln Tyr Glu Leu Asp Glu Val Ala 465 470	1440
aac tgg gtg aaa gca aaa ggt caa gct gat gag ctt gct gct gt ttg Asn Trp Val Lys Ala Lys Gly Gln Ala Asp Glu Leu Ala Ala Leu 480 485	1488
gat cag gaa caa ggc aaa gaa aaa cca ctc ttt gac act aaa aaa gtg Asp Gln Glu Gln Gly Lys Glu Lys Pro Leu Phe Asp Thr Lys Lys Val 495 500	1536
agt cgc aaa gta aca aaa gat ggt aaa gtg ggc tat atg atg cca aaa Ser Arg Lys Val Thr Lys Asp Gly Lys Val Gly Tyr Met Met Pro Lys 510 515	1584
gat ggt aag gac tat ttc tat gct cgt gat caa ctt gat ttg act cag Asp Gly Lys Asp Tyr Phe Tyr Ala Arg Asp Gln Leu Asp Leu Thr Gln 525 530 540	1632
att gcc ttt gcc gaa caa gaa cta atg ctt aaa gat aag aag cat tac Ile Ala Phe Ala Glu Gln Glu Leu Met Leu Lys Asp Lys Lys His Tyr 545 550 555	1680
cgt tat gac att gtt gac aca ggt att gag cca cga ctt gct gta gat Arg Tyr Asp Ile Val Asp Thr Gly Ile Glu Pro Arg Leu Ala Val Asp 560 565	1728
gtg toa agt ctg ccg atg cat gct ggt aat gct act tac gat act ggs Val Ser Ser Leu Pro Met His Ala Gly Asn Ala Thr Tyr Asp Thr Gly 575 580 585	a 1776

agt tcg ttt gtt atc cca cat att gat cat atc cat gtc gtt ccg tat Ser Ser Phe Val Ile Pro His Ile Asp His Ile His Val Val Pro Tyr 590 595 600	1824
tca tgg ttg acg cgc gat cag att gca aca gtc aag tat gtg atg caa Ser Trp Leu Thr Arg Asp Gln Ile Ala Thr Val Lys Tyr Val Met Gln 610 615 620	1872
cac ccc gaa gtt cgt ccg gat gta tgg tct aag cca ggg cat gaa gag His Pro Glu Val Arg Pro Asp Val Trp Ser Lys Pro Gly His Glu Glu 625 630 635	1920
tca ggt tcg gtc att cca aat gtt acg cct ctt gat aaa cgt gct ggt Ser Gly Ser Val Ile Pro Asn Val Thr Pro Leu Asp Lys Arg Ala Gly 640 645 650	1968
atg cca aac tgg caa att atc cat tct gct gaa gaa gtt caa aaa gcc Met Pro Asn Trp Gln Ile Ile His Ser Ala Glu Glu Val Gln Lys Ala 655 660 665	2016
Cta gca gaa ggt cgt ttt gca aca cca gac ggc tat att ttc gat cca Leu Ala Glu Gly Arg Phe Ala Thr Pro Asp Gly Tyr Ile Phe Asp Pro 670 675 680	2064
cga gat gtt ttg gcc aaa gaa act ttt gta tgg aaa gat ggc tcc ttt Arg Asp Val Leu Ala Lys Glu Thr Phe Val Trp Lys Asp Gly Ser Phe 695 700	2112
agc atc cca aga gca gat ggc agt tca ttg aga acc att aat aaa tct Ser Ile Pro Arg Ala Asp Gly Ser Ser Leu Arg Thr Ile Asn Lys Ser 710 715	2160
gat cta tcc caa gct gag tgg caa caa gct caa gag tta ttg gca aag Asp Leu Ser Gln Ala Glu Trp Gln Gln Ala Gln Glu Leu Leu Ala Lys 720 725	2208
aaa aat act ggt gat gct act gat acg gat aaa ccc aaa gaa aag caa Lys Asn Thr Gly Asp Ala Thr Asp Thr Asp Lys Pro Lys Glu Lys Gln 735 740 745	2256
750 755 760	2304
765 770 775 The Tie Asp Ser Leu Pro Asp Tyr Gly	2352
Cta gat aga gca acc cta gaa gat cat atc aat caa tta gca caa aaa 2 Leu Asp Arg Ala Thr Leu Glu Asp His Ile Asn Gln Leu Ala Gln Lys 785 790 795	2400
gct aat atc gat cct aag tat ctc att ttc caa cca gaa ggt gta aa	448

```
ttt tat aat aaa aat ggt gaa ttg gta act tat gat atc aag aca ctt
                                                                  2496
Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp Ile Lys Thr Leu
        815
caa caa ata aac cct taaccaaaag aagatctcat tgttaaagca ctgctttgtc
                                                                  2551
Gln Gln Ile Asn Pro
    830
aaagcaagtt acggtgattt tgaagtcatt ctatgtaacg agtagtgata aaagttggat
                                                                  2611
aatagcggtt ttcttttgca aagaaatggt atccatgtta gaatagtaaa aaaagaggag
                                                                  2671
gattettgga etaatgteaa ataagtagae agaaaactgt gttattttattgegt
taaaataatt ttcttctttc tgattagggg ttagtcctag attagccgta tgtgggttgt
aattgttata aaaattetea atgtatteaa ageagtetaa ttgaacetgt ttgatatttt
gataatgttt teggttgatt tgtctatgct ttaaatactt gaaaaatgct tcagttacgg
cattatcata aggatatcca ggattagaaa aagaatgcat gatattggca ctgcacccta
atagtgagac gcaagaaaaa cacttttaggcaatcagtt ttctgtactg tacaggcgac
                                                                   3025
3085
atattigtta tactatcttt gttgtatttt ctcctattat ggaaataaaa ggtttcagtc 3145
tttaggacgg tgtgaaacca ttcaatacag gcattatctg caggtgttcc ttttcgagac
attgagcgga taatgtettt tteegtgcaa geetggtagt aageeataga agtatacaet 3265
gageettggt cactgtgtaa gattgeteet ttatttaggeaatt ttaactgatt
 aagggtgtct agtacaaaat ccgtgtcctg acaatctgag atagtgtaag ctataatttc 3379
 toggttatag agattcataa ttgatgagag atacaattta cagttaccga aatataggta 3439
 ggtaatatet gttacgaget ttteettagg ettateggea tggaaateee gaeteaattt 3499
 attatctgtt aaataataag ctttacccaa attgggaact ttcttggtac gtgtccgaca 3559
 aagccagcca ttatttttca tgatacgata gactttcttt gtattaacag tcaatccgtg 3619
 gatttttttg agcaatcgtg taatggtacg atagccataa ataaagtgat tctccataca 3679
 gagetgttca attaattcaa taaggtcate tttttttgcg gettetcata eteetttttc 3739
 caacggtaat aggtcgaccg cttgacctta aaacagtcta gaatgaaaac tatcgggtag 3799
 ttgtttttat agtcttccac aagcttgata agacttactttatcgatt tccttatcaa
 gcctcgatac ttttttaaga ggtcaacctg taattgtaat tgttccactt cagacagatg 3917
 ttccaagcct ttaccgtagg tatattgctt gccaacacct tgatgaaaac gataaagctc
 ctcgttttcg taccatttca tccaagtata gatttgacta ttatttttga tgcctaaagt
 ctccataata actctgttag acttgcctgc tttcttcata tcgatgcaag ccagcttagt
                                                                   4097
 ttcccatgaa tatgctttt taaccataat aaaacattcc tgtttctagt ttactaaatt 4157
 tcaacaggag tgttttctt ttgtctcatt ttagggattc agtgcctatt gttgtcatca 4217
 attatttttc taaattcccc ggacttaaat tgtgaccctt ggtcggaatg aaagagaagt 4277
 gttccttcaa tctttcttt attaagtgaa aaggcaacac ttttctgtac aacatttata 4337
  aagtgttttt ctaggcaattaatc ttttagtcat tggtgtttgg tagttgagac
  taccatgaat geggtggtaa ttecaccaat gaacatagte tttagtetta agagetagtt 4451
  cttccagcaa ttgaaaggtt tcttgataaa caaattcaat tttgaaagca cgatacgtac 4511
  tttcagctac ggcattgtca taaggataac cagcctgact aagcgaacgt gtgattccaa 4571
  aggettecaa tattteatea attaactgat tateaaacte tetgeeacga tetgaatgga 4631
  acatettgae tttggtcagg gegtaaggga tgetttgtat ggettgetta acgagttcag 4691
  cggtcttgtg ccaaccaaga gacaggccga tgatttcacg gttgtatagg tcaatgatga 4751
  cggtcttgtg ccaaccaaga gacaggccga tgactatagg gacataggt taagtcagtg actaaggctt 4811 ggcaaacata agcccaacga ttgcctacac gacataggt taagtcagtg actaaggc 4871
  gragtggtet trettgetta aartgeetgt craagtggtt gggaataggg getteattet
  tgcctctaga atgtggtttg aaggtggctt tctgataaac agaaaccaaa ttgagtcgct 4931
  tcataatgcg tcgaatccga cgacgtgaaa gtgtgatacc ttcgttattc aagcatattt 4991
  tgatttttct ggatccgtat ctagactcgc tatcgagaaa aattctttta atagtttctt 5051
  caaactccgt ttcagatact gactccacgg cttgatagta ataacttgag tgtggcatat 5111
  tragcageg acacatettt gaaatgetgt atttateett attagcagtg attattteec 5171
   tttttgtgcc ataatcaccg ctgcttgctt taggatatct aatt
         <210> 14
         <211> 40
         <212> PRT
```

```
<213> Streptococcus
```

<400> 14 Phe Gly Ser Ala Leu Ser Thr Val Glu Val Lys Glu Ile Ile Ser Glu 10 Glu Asn Ile Trp Leu Tyr Arg Leu Ser Cys Cys His Phe Thr Ser Tyr Ser Tyr Trp Lys Leu Pro Thr Trp 35 <210> 15 <211> 793 <212> PRT <213> Streptococcus <400> 15

Met Gly Leu Ala Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser Lys Gly Lys Ala Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile Ser Ala Glu Glu Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr Asp Gln Gly Tyr Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn Gly Lys Val Pro Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr Asp Pro Asn Tyr Arg Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu Asp Gly Tyr Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr Leu Lys 105 Pro Gly Ser Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile Ala Glu Gln Val Ala Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu Ala Gln Val Ala His Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu Ala Lys Arg Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser Pro Thr Asp Ile Ile Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His Gly Asn His Tyr His Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu Leu Ala 185 Ala Ala Gln Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala Arg Pro Ser Asp Tyr Arg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala Pro Ile Pro Asp Val Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp Asn Gly Gly Tyr His Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln Asn Lys 250 His Gln Arg Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu Leu Asp 265 Gln Leu His Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu Asp Gly Leu Ile Phe Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe Gly Tyr 315

Val V																		
Ser P				Met														
Glu A			Asp															
Val T	hr	His					ly I	His										
Leu A	sp					r A	sp '											
385 Glu S					Va	l A												
Asp H			420	Ту	- Il				42	5								
Asp C		455	Ala	Ası				440						7	7.7			
Ala A		Ala				- 1							40	U				
Thr 1	Lys																	
465 Met 1				40							470							
Asp				_					—	15								
Lys																		
Leu							535						J-					
Tyr 545																		
Val				/							1 L	,					-	
Tyr				. ^					_	ж 5							-	
Gly			-					- 60	n						002			
				Ly M														
				la L														
Ile				ro A 6														
				6 he S 60														
				er A				← }	∢()						00.	_		
		_		ys I			~ ~ ~	_										
	_					710						,	エン					Ser 720 Leu
					, , ,						- 1	5 ()						
				2 4 A						14	~							Gln
Le	u A.		ln 1 55	, sv	Ala	Asn	ıIl	le A 7	sp 60	rr	о <u>н</u>	ys 1	λŢ	اتاند	76	55.	`	 Pro

```
Glu Gly Val Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp
   Ile Lys Thr Leu Gln Gln Ile Asn Pro
   785
                   790
        <210> 16
        <211> 715
        <212> PRT
        <213> Streptococcus
        <400> 16
  Met Thr Asp Pro Asn Tyr Arg Phe Lys Gln Ser Asp Val Ile Asn Glu
  Ile Leu Asp Gly Tyr Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr
  Leu Lys Pro Gly Ser Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile
                                  25
  Ala Glu Gln Val Ala Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu
 Ala Gln Val Ala His Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu
 Ala Lys Arg Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser
 Pro Thr Asp Ile Ile Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His
                                 105
 Gly Asn His Tyr His Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu
 Leu Ala Ala Gln Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala
 Arg Pro Ser Asp Tyr Arg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala
 Pro Ile Pro Asp Val Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp
 Asn Gly Gly Tyr His Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln
                                     170
                                185
 Asn Lys His Gln Arg Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu
                            200
 Leu Asp Gln Leu His Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu
Asp Gly Leu Ile Phe Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe
Gly Tyr Val Val Pro His Gly Asp His Tyr His Ile Ile Pro Arg Ser
Gln Leu Ser Pro Leu Glu Met Glu Leu Ala Asp Arg Tyr Leu Ala Gly
Gln Thr Glu Asp Asn Asp Ser Gly Ser Glu His Ser Lys Pro Ser Asp
Lys Glu Val Thr His Thr Phe Leu Gly His Arg Ile Lys Ala Tyr Gly
Lys Gly Leu Asp Gly Lys Pro Tyr Asp Thr Ser Asp Ala Tyr Val Phe
Ser Lys Glu Ser Ile His Ser Val Asp Lys Ser Gly Val Thr Ala Lys
                                  330
His Gly Asp His Phe His Tyr Ile Gly Phe Gly Glu Leu Glu Gln Tyr
                               345
```

```
Glu Leu Asp Glu Val Ala Asn Trp Val Lys Ala Lys Gly Gln Ala Asp
                         360
Glu Leu Ala Ala Ala Leu Asp Gln Glu Gln Gly Lys Glu Lys Pro Leu
                     375
Phe Asp Thr Lys Lys Val Ser Arg Lys Val Thr Lys Asp Gly Lys Val
                                    395
                 390
Gly Tyr Met Met Pro Lys Asp Gly Lys Asp Tyr Phe Tyr Ala Arg Asp
                                410
                                                  415
Gln Leu Asp Leu Thr Gln Ile Ala Phe Ala Glu Gln Glu Leu Met Leu
                             425
Lys Asp Lys Lys His Tyr Arg Tyr Asp Ile Val Asp Thr Gly Ile Glu
                         440
                                           445
Pro Arg Leu Ala Val Asp Val Ser Ser Leu Pro Met His Ala Gly Asn
                                        460
                     455
Ala Thr Tyr Asp Thr Gly Ser Ser Phe Val Ile Pro His Ile Asp His
                                    475
                  470
Ile His Val Val Pro Tyr Ser Trp Leu Thr Arg Asp Gln Ile Ala Thr
                                 490
              485
Val Lys Tvr Val Met Gln His Pro Glu Val Arg Pro Asp Val Trp Ser
                            505
          500
Lys Pro Gly His Glu Glu Ser Gly Ser Val Ile Pro Asn Val Thr Pro
                         520
    515
Leu Asp Lys Arg Ala Gly Met Pro Asn Trp Gln Ile Ile His Ser Ala
           535
Glu Glu Val Gln Lys Ala Leu Ala Glu Gly Arg Phe Ala Thr Pro Asp
        550 555 560
Gly Tyr Ile Phe Asp Pro Arg Asp Val Leu Ala Lys Glu Thr Phe Val
                    570
             565
Trp Lys Asp Gly Ser Phe Ser Ile Pro Arg Ala Asp Gly Ser Ser Leu
     580 585
Arg Thr Ile Asn Lys Ser Asp Leu Ser Gln Ala Glu Trp Gln Gln Ala
 595 600
Gln Glu Leu Leu Ala Lys Lys Asn Thr Gly Asp Ala Thr Asp Thr Asp
                      615
                                        620
Lys Pro Lys Glu Lys Gln Gln Ala Asp Lys Ser Asn Glu Asn Gln Gln
                                     635
Pro Ser Glu Ala Ser Lys Glu Glu Lys Glu Ser Asp Asp Phe Ile Asp
                                 650
               645
Ser Leu Pro Asp Tyr Gly Leu Asp Arg Ala Thr Leu Glu Asp His Ile
                             665
Asn Gln Leu Ala Gln Lys Ala Asn Ile Asp Pro Lys Tyr Leu Ile Phe
                         680
Gln Pro Glu Gly Val Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr
                     695
Tyr Asp Ile Lys Thr Leu Gln Gln Ile Asn Pro
                  710
      <210> 17
      <211> 77
      <212> PRT
      <213> Streptococcus
     <400> 17
Met His Ser Phe Ser Asn Pro Gly Tyr Pro Tyr Asp Asn Ala Val Thr
```

10

WO 99/42588 PCT/CA99/00114

35 / 63

```
Glu Ala Phe Phe Lys Tyr Leu Lys His Arg Gln Ile Asn Arg Lys His
             20
                                 25
 Tyr Gln Asn Ile Lys Gln Val Gln Leu Asp Cys Phe Glu Tyr Ile Glu
                             40
 Asn Phe Tyr Asn Asn Tyr Asn Pro His Thr Ala Asn Leu Gly Leu Thr
                        55
 Pro Asn Gln Lys Glu Glu Asn Tyr Phe Asn Ala Ile Lys
      <210> 18
       <211> 86
       <212> PRT
       <213> Streptococcus
       <400> 18
Met Ala Tyr Tyr Gln Ala Cys Thr Glu Lys Asp Ile Ile Arg Ser Met
                                     10
Ser Arg Lys Gly Thr Pro Ala Asp Asn Ala Cys Ile Glu Trp Phe His
Thr Val Leu Lys Thr Glu Thr Phe Tyr Phe His Asn Arg Arg Lys Tyr
                            40
Asn Lys Asp Ser Ile Thr Asn Ile Val Lys Asn Tyr Ile Thr Phe Tyr
                                            60
Asn Glu Thr Arg Ile Gln Gln Arg Leu Asn Asp Gln Ser Pro Val Gln
Tyr Arg Lys Leu Ile Ala
      <210> 19
      <211> 126
      <212> PRT
      <213> Streptococcus
      <400> 19
Met Glu Asn His Phe Ile Tyr Gly Tyr Arg Thr Ile Thr Arg Leu Leu
                                   10
Lys Lys Ile His Gly Leu Thr Val Asn Thr Lys Lys Val Tyr Arg Ile
Met Lys Asn Asn Gly Trp Leu Cys Arg Thr Arg Thr Lys Lys Val Pro
Asn Leu Gly Lys Ala Tyr Tyr Leu Thr Asp Asn Lys Leu Ser Arg Asp
                       55
Phe His Ala Asp Lys Pro Lys Glu Lys Leu Val Thr Asp Ile Thr Tyr
                                       75
Leu Tyr Phe Gly Asn Cys Lys Leu Tyr Leu Ser Ser Ile Met Asn Leu
                                   90
Tyr Asn Arg Glu Ile Ile Ala Tyr Thr Ile Ser Asp Cys Gln Asp Thr
                             105
Asp Phe Val Leu Asp Thr Leu Asn Gln Leu Lys Leu Pro Lys
     <210> 20
     <211> 96
```

BNSDOCID: <WO___9942588A2_1_>

<212> PRT

<213> Streptococcus

<400> 20 Met Val Lys Lys Ala Tyr Ser Trp Glu Thr Lys Leu Ala Cys Ile Asp Met Lys Lys Ala Gly Lys Ser Asn Arg Val Ile Met Glu Thr Leu Gly 25 Ile Lys Asn Asn Ser Gln Ile Tyr Thr Trp Met Lys Trp Tyr Glu Asn 40 Glu Glu Leu Tyr Arg Phe His Gln Gly Val Gly Lys Gln Tyr Thr Tyr 60 55 Gly Lys Gly Leu Glu His Leu Ser Glu Val Glu Gln Leu Gln Leu Gln 75 Val Asp Leu Leu Lys Lys Tyr Arg Gly Leu Ile Arg Lys Ser Ile Lys <210> 21 <211> 288 <212> PRT <213> streptococus <400> 21 Ile Arg Tyr Pro Lys Ala Ser Ser Gly Asp Tyr Gly Thr Lys Arg Glu 10 Ile Ile Thr Ala Asn Lys Asp Lys Tyr Ser Ile Ser Lys Met Cys Arg 25 Trp Leu Asn Met Pro His Ser Ser Tyr Tyr Tyr Gln Ala Val Glu Ser 40

Val Ser Glu Thr Glu Phe Glu Glu Thr Ile Lys Arg Ile Phe Leu Asp 60 Ser Glu Ser Arg Tyr Gly Ser Arg Lys Ile Lys Ile Cys Leu Asn Asn 75 70 Glu Gly Ile Thr Leu Ser Arg Arg Ile Arg Arg Ile Met Lys Arg 90 85 Leu Asn Leu Val Ser Val Tyr Gln Lys Ala Thr Phe Lys Pro His Ser 105 Arg Gly Lys Asn Glu Ala Pro Ile Pro Asn His Leu Asp Arg Gln Phe 120 115 Lys Gln Glu Arg Pro Leu Gln Ala Leu Val Thr Asp Leu Thr Tyr Val 135 Arg Val Gly Asn Arg Trp Ala Tyr Val Cys Leu Ile Ile Asp Leu Tyr 155 150 Asn Arg Glu Ile Ile Gly Leu Ser Leu Gly Trp His Lys Thr Ala Glu 170 165 Leu Val Lys Gln Ala Ile Gln Ser Ile Pro Tyr Ala Leu Thr Lys Val 190 185 180 Lys Met Phe His Ser Asp Arg Gly Lys Glu Phe Asp Asn Gln Leu Ile 200 Asp Glu Ile Leu Glu Ala Phe Gly Ile Thr Arg Ser Leu Ser Gln Ala 220 215 Gly Tyr Pro Tyr Asp Asn Ala Val Ala Glu Ser Thr Tyr Arg Ala Phe 235 230 Lys Ile Glu Phe Val Tyr Gln Glu Thr Phe Gln Leu Leu Glu Glu Leu 250 245

Ala Leu Lys Thr Lys Asp Tyr Val His Trp Trp Asn Tyr His Arg Ile

265 His Gly Ser Leu Asn Tyr Gln Thr Pro Met Thr Lys Arg Leu Ile Ala 280

260

		<211 <212	> 22 > 50 > DN > st	58 A	0000	cus										
			> CD		(663)										
			> CD > (7		(1	344)										
<221> CDS <222> (1362)(1739) <221> CDS																
<221> CDS <222> (2266)(5058)																
aat Asr 1	tto	400: Jaaa Lys	a gca	a gaa a Glu 5	a tta ı Lei	a tct 1 Ser	gta Val	a gaa l Glu	gat Asp	GIU	g caa 1 Glr	tat Tyi	aca Thr	a gca Ala 15	aca Thr	48
gtt Val	tat Tyr	ggt Gly	aaa Lys 20		gct Ala	cat His	ggt Gly	tca Ser 25	Inr	cca Pro	. caa Gln	gaa Glu	ggt Gly 30	Val	aat Asn	96
ggg Gly	gcg Ala	act Thr 35	- 2 -	tta Leu	gct Ala	ctt Leu	tat Tyr 40	cta Leu	agt Ser	caa Gln	ttt Phe	gat Asp 45	Phe	gaa Glu	ggt Gly	144
cct Pro	gct Ala 50	cgt Arg	gct Ala	ttc Phe	tta Leu	gat Asp 55	gtt Val	aca Thr	gcc Ala	aac Asn	att Ile 60	att Ile	cac His	gaa Glu	gac Asp	192
ttc Phe 65	tca Ser	ggt Gly	gaa Glu	aaa Lys	ctt Leu 70	gga Gly	gta Val	gct Ala	tat Tyr	gaa Glu 75	gat Asp	gac Asp	tgt Cys	atg Met	gga Gly 80	240
cca Pro	ttg Leu	agc Ser	atg Met	aat Asn 85	gca Ala	ggt Gly	gtc Val	ttc Phe	cag Gln 90	ttt Phe	gat Asp	gaa Glu	act Thr	aat Asn 95	gat Asp	288
gat Asp	aat Asn	act Thr	atc Ile 100	gct Ala	ctt Leu	aat Asn	ttc Phe	cgt Arg 105	tac Tyr	cca Pro	caa Gln	gly ggg	aca Thr 110	gat Asp	gct Ala	336
-		115			2,3	Deu	120	Lys	Leu	Asn	GIA	Val 125	gaa Glu	Lys	Val	384
act Thr	ctt Leu 130	tct Ser	gac Asp	cat His	gaa Glu	cac His 135	aca Thr	cca Pro	cac His	tat Tyr	gta Val 140	cct Pro	atg Met	gac Asp	gat Asp	432

gaa tta Glu Leu 145	gta : Val :	tca Ser	Thr I	ta c Leu L 150	ta g eu A	ict i	gtc Val	tat Tyr	gaa Glu 155	aag Lys	ca: Gl:	a ac n Th	et (ggt Gly	ctt Leu 160		480
aaa gga Lys Gly	cat His	gaa Glu	cag 9 Gln 1 165	gtt a Val I	itt g	ggt Gly	ggt Gly	ggg Gly 170	aca Thr	ttt Phe	gg Gl	t co	- 5	tta Leu 175	ctt Leu		528
gaa cgg Glu Arg	ggt Gly	gtt Val 180	gca Ala	tac g Tyr (ggt g Bly i	gcc Ala	atg Met 185	ttc Phe	cca	gga	a ga Y As	P -	aa lu 90	aac Asn	act Thr		576
atg cat Met His	caa Gln 195	gct Ala	aat Asn	gag 1 Glu 1	ryr	atg Met 200	cct Pro	tta Leu	gaa Glu	aa 1 Asi	t at n Il 20		tc he	cgt Arg	tcg Ser		624
gct gct Ala Ala 210	Ile	tac Tyr	gca Ala	Glu.	gct Ala 215	atc Ile	tat Tyr	gaa Glu	tta Lei	a at 1 Il 22	ر بد	aa t ⁄s	aaa	ata	atc		673
cttaaac cttttca	taa a	atat ggtt	gtgat agatt	c aa t gg	tgat agac	aaaq ttt	atu	act	. ua		u G				ttgc att		733 786
aaa gca Lys Ala 230	a ata a Ile	aaa Lys	agt Ser	gat Asp 235	tca Ser	cag Gln	aat Asn	caa Gli	a aa n As 24	11 T.	it a	ca g hr (gaa Glu	aat	ggt Gly 245		834
att gat Ile Asi	t cct p Pro	ttg Lev	ttt Phe 250	gct Ala	gct Ala	cct	aaa Lys	aca Th: 25	LAI	t ag .a Ai	gg a rg I	tc a	aat Asn	att Ile 260	-	ī. 1	882
ggc ca Gly Gl	a gca n Ala	a cct a Pro 265	o Gly	tta Leu	aaa Lys	act Thr	caa Glr 270	1 61	a go u Al	a a	ga c rg L	ic u	tat Tyr 275	:	g aa p Ly	a s	930
gat aa Asp Ly	a tct rs Se: 28	r Gl	a gat y Asp	cgt Arg	cta Leu	cg Arg 28	g Gli	g tg n Tr	g ct	t g eu G	TÀ	gtt /al 290	gat Asp	ga Gl	a ga u Gl	g u	978
aca tt Thr Ph	ne Ty	c ca r Hi	t tct s Sei	gga Gly	aaa Lys	: Ph	t gc e Al	t gt a Va	t t	eu F	ro I	tta Leu	gat Asp	t tt p Ph	t ta e Ty	r	1026
tac co Tyr Pr 310	ca gg ro Gl	c aa y Ly	a gg s Gl	a aaa y Lys 315	s Sei	a gg c Gl	a ga y As	t tt p Le	eu P	cc c ro E 20	ect Pro	aga Arg	aa. Ly	a gg s Gl		t ne 25	1074
gcg g Ala G	ag aa lu Ly	a to /s Tr	gg ca rp Hi 33	s Pro	cti Lei	t at u Il	t tt e Le	eu L	aa g ys G 35	jaa a Slu I	atg Met	cct Pro	aa As		al G	aa ln	1122
ttg a Leu T	cc tt hr Le	eu Le	ia gt eu Va 45	t gg .l Gl:	t ca y Gl	g ta n Ty	r A.	ct c la G 50	ag a ln I	aaa Lys	tat Tyr	tat Tyr	ct Le 35	u Ç	ga a ly S	gc er	1170

	3 6	at aaa is Lys 50				365	IIII	va.	г гу.	s Ala	a Ty:	r Ly 0	s As	p Tyr	1218
3	375	at tat sp Tyr		3	80		nış	Pro	se:	385	o Arg	g Ası	n Gli	l lle	1266
tgg c Trp L 390	ta aa .eu Ly	g aag s Lys	aat Asn	cca t Pro I 395	gg t rp F	tt he	gaa Glu	aaa Lys	gat Asp 400	Leu	ato Ile	gtt Val	gat L Asp	tta Leu 405	1314
		a gta e Val	410		10 11	eu	ьys	415					M	et	1364
aga g Arg A	-	420				yr .	425	ser	Tyr	Asp	Cys	Gln 430	Thr	Ala	1412
ttt ga Phe Gl	435	5			4	10	TIIT	GIY	Glu	Phe	Ile 445	Thr	Thr	Glu	1460
cat tt His Ph 45	50			45	5	/ L]	. 111	GIY	GIN	Asp 460	Asp	Val	Pro	Asp	1508
tat ag Tyr Se 465		•	4	70	5 11	. С Р	ъÞ	lyr	ьец 475	Asn	Gln	Lys	Tyr	Gly 480	1556
aat cg Asn Ar		4	185	-,	C G1	uı	16 (490	Tyr	Phe	Lys	Asp	Arg 495	Glu	1604
tca ga Ser Asj	_	500	-	,	т шу	5 A	05	Jys (Jlu	Phe .	qzA	Leu 510	Lys	Leu	1652
ttg tca Leu Sei	515			01	520	0	Y I	sp.	ryr .	Leu (Gln (525	Glu	Glu Z	Ala	1700
ctg aaa Leu Lys 530		cca a Pro T	ca aa hr Ly	ag gga /s Gly 535	ATC	tt a Ph	t a ne S	gc a Ser A	arg 1	tta d Leu I	ctt (Leu	taat	cgtat	g	1749
gaatttg aagttaa ataaaga gggaatg tactcta caaggtc taaaaaa	itgt t gaaa a itag g	atcta acttta ctctga	aggg atcg acgg	gttag	cttt	t g	aac	taaa tact attt	ta o	gca <i>a</i> caaa acag ttat	ittga itcco icttg igaat	aa go et tt gg tt et te	egcat atct gtaa gatag	tttc atat acaa actt	1809 1869 1929 1989 2049 2109 2169

atttcaaaaa aataa tttattggta acaa	agaaa tcattt tcatt aaaaaa	actt gttgo ggag aatga	at atg aaa	gcgtaaa ttgttatg. aga aaa gac tta Arg Lys Asp Leu 545	2229 2283
ttt ggt gat aaa Phe Gly Asp Lys 550	caa act caa Gln Thr Gln	tac acg at Tyr Thr Il 555	tt aga aag le Arg Lys	tta agt gtt gga Leu Ser Val Gly 560	2331
gta gct tca gtt Val Ala Ser Val 565	aca aca ggg Thr Thr Gly 570	gta tgt at Val Cys II	tt ttt ctt le Phe Leu 575	cat agt cca cag His Ser Pro Gln	2379
gta ttt gct gaa Val Phe Ala Glu 580	gaa gta agt Glu Val Ser 585	gtt tct co Val Ser P	ct gca act ro Ala Thr 590	aca gcg att gca Thr Ala Ile Ala 595	•
gag tcg aat att Glu Ser Asn Ile	aat cag gtt Asn Gln Val 600	Asp Asn G	aa caa tct ln Gln Ser 05	act aat tta aas Thr Asn Leu Lys 610	2475
gat gac ata aac Asp Asp Ile Asi 619	Ser Asn Ser	gag acg g Glu Thr V 620	gtt gtg aca Val Val Thr	e ccc tca gat atg r Pro Ser Asp Med 625	2523
ccg gat acc aag Pro Asp Thr Ly: 630	g caa tta gta s Gln Leu Val	tca gat g Ser Asp G 635	gaa act gac Glu Thr Asp	e act caa aag gg o Thr Gln Lys Gl 640	a 2571 Y
gtg aca gag cc Val Thr Glu Pr 645	g gat aag gcg o Asp Lys Ala 650	Thr Ser I	ctg ctt gaa Leu Leu Gli 659	a gaa aat aaa gg u Glu Asn Lys Gl 5	t 2619 Y
cct gtt tca ga Pro Val Ser As 660	t aaa aat acc p Lys Asn Thi 665	tta gat t Leu Asp l	tta aaa gta Leu Lys Va 670	a gca cca tct ac l Ala Pro Ser Th 67	.±
ttg caa aat ac Leu Gln Asn Th	t ccc gac aaa r Pro Asp Ly: 680	Thr Ser	caa gct at Gln Ala Il 685	a ggt gct cca ag e Gly Ala Pro Se 690	gc 2715 er
cct acc ttg as Pro Thr Leu Ly 69	s Val Ala As	caa gct n Gln Ala 700	cca cgg at Pro Arg Il	t gaa aat ggt ta e Glu Asn Gly Ty 705	ac 2763 /r
ttt agg cta ca Phe Arg Leu H. 710	it ctt aaa ga .s Leu Lys Gl	a ttg cct u Leu Pro 715	caa ggt ca Gln Gly Hi	at cct gta gaa ag is Pro Val Glu S 720	gc 2811 er
act gga ctt t Thr Gly Leu T 725	gg ata tgg gg rp Ile Trp Gl 73	y Asp Val	Asp Gin Pi	eg tet agt aat t ro Ser Ser Asn T 35	gg 2859 rp
cca aat ggt g Pro Asn Gly A 740	ct atc cct at la Ile Pro Me 745	g act gat t Thr Asp	gct aag aa Ala Lys Ly 750	aa gat gat tac g ys Asp Asp Tyr G 7	gt 2907 ly 55

WO 99/42588

	•			76	50	. Б. Д.	-u 5e	:1 6.	1u L 7	ys (65	GIn	Ar	g r ^y	/s G	ln 1	11e		2955
			77	5	2		u Gi	· 78	11 A	sn 1	Jeu	Sei	c Gl	y As 78	5p H 35	lis		3003
		790	D		<i>J</i>	0 01	g at u Me 79	5 5	11 6.	ın v	/al	Trp	80 80	e As	p G	lu	Lys	3051
tac Tyr	ggt Gly 805	ata Ile	a cat	t ac	t ta r Ty	t ca r Gl: 81	a cc n Pro	c ct o Le	c aa u Ly	aa g /s G	ıυ	999 Gly 815	Ту	t gt r Va	с с 1 А:	gt rg	att Ile	3099
aac Asn 820	-				82	5	. ASI	ı ıy:	r As	н q: 8	1s 30	Leu	Se	r Al	a Ti	-p	Leu 835	3147
ttt Phe	aaa Lys	gat Asp	gtt Val	90a Ala 840		c ccy Xaa	/ tca a Ser	a aca	a ac r Th 84	r 1	gg rp	cca Pro	gat Asp	gg Gl	t ag y Se 85	er	aat Asn	3195
ttt Phe	gtg Val	aat Asn	caa Gln 855	gga Gly	cta Lei	tat Tyr	gga Gly	agg Arg 860	Ty	t ai r Ii	tt q le A	gat Asp	gt <i>a</i> Val	tca Sea	Le	a u	aaa Lys	3243
act a	aac Asn	gcc Ala 870	aaa Lys	gag Glu	att	ggt Gly	ttt Phe 875	cta Leu	ate Ile	c tt e Le	a g eu <i>P</i>	gat Asp	gaa Glu 880	agt Ser	aa Ly	g s	aca Thr	3291
gga g Gly A	gat Asp 385	gca Ala	gtg Val	aaa Lys	gtt Val	caa Gln 890	ccc Pro	aac Asn	gad Asp	ta Ty	rv	gtt Zal 195	ttt Phe	aga Arg	ga As	t t p I	ta Leu	3339
gct a Ala A 900	ac (cat His	aac Asn	caa Gln	att Ile 905	ttt Phe	gta Val	aaa Lys	gat Asp	aa Ly 91	s A	at .sp	cca Pro	aag Lys	gt! Val	1 7	at Yr 915	3387
aat a Asn A	at d	Pro	tat Tyr	tac Tyr 920	att Ile	gat Asp	caa Gln	gtg Val	cag Gln 925	re.	a a u L	ag y	gat Asp	gcc Ala	caa Glr 930	ı G	aa In	3435
att g Ile A	at t sp I		aca Thr 935	agt Ser	att Ile	caa Gln	gca Ala	agt Ser 940	ttt Phe	aca Th:	a ao	ct o	cta Leu	gat Asp 945	gly ggg	, A	ta al	3483
gat a Asp L	aa a ys T 9	hr 50	gaa Glu	att Ile	tta Leu	aaa Lys	gaa Glu 955	ttg Leu	aaa Lys	gtg Va]	g ac	nr A	gat Asp 960	aaa Lys	aat Asn	c G	a a ln	3531
aat go Asn Al	ct a la I 65	ta (caa Gln	att Ile	tct Ser	gat Asp 970	atc Ile	act Thr	ctc Leu	gat Asp	ac Th	ır s	igt Ser	aaa Lys	tct Ser	C:	t t eu	3579

tta ata atc aaa ggc gac ttt aat cct aaa caa ggt cat ttc aac ata Leu Ile Ile Lys Gly Asp Phe Asn Pro Lys Gln Gly His Phe Asn Ile 980 985 990 995	3627
tot tat aat ggt aac aat gto atg aca agg caa tot tgg gaa ttt aaa Ser Tyr Asn Gly Asn Asn Val Met Thr Arg Gln Ser Trp Glu Phe Lys 1000 1005 1010	3675
gac caa ctt tat gct tat agt gga aat tta ggt gca gtt ctc aat caa Asp Gln Leu Tyr Ala Tyr Ser Gly Asn Leu Gly Ala Val Leu Asn Gln 1015 1020 1025	3723
gat ggt tca aaa gtt gaa gcc agc ctc tgg tca ccg agt gct gat agt Asp Gly Ser Lys Val Glu Ala Ser Leu Trp Ser Pro Ser Ala Asp Ser 1030 1035 1040	3771
gtc act atg att att tat gac aaa gat aac caa aac agg gtt gta gcg Val Thr Met Ile Ile Tyr Asp Lys Asp Asn Gln Asn Arg Val Val Ala 1045 1050 1055	3819
act acc ccc ctt gtg aaa aat aat aaa ggt gtt tgg cag acg ata ctt Thr Thr Pro Leu Val Lys Asn Asn Lys Gly Val Trp Gln Thr Ile Leu 1060 1065 1070 1075	3867
gat act aaa tta ggt att aaa aac tat act ggt tac tat tat ctt tac Asp Thr Lys Leu Gly Ile Lys Asn Tyr Thr Gly Tyr Tyr Tyr Leu Tyr 1080 1085 1090	3915
gaa ata aaa aga ggt aag gat aag gtt aag att tta gat cct tat gca Glu Ile Lys Arg Gly Lys Asp Lys Val Lys Ile Leu Asp Pro Tyr Ala 1095 1100 1105	3963
aag toa tta goa gag tgg gat agt aat act gtt aat gat gat att aaa Lys Ser Leu Ala Glu Trp Asp Ser Asn Thr Val Asn Asp Asp Ile Lys 1110 1115 1120	4011
acg gct aaa gca gct ttt gta aat cca agt caa ctt gga cct caa aat Thr Ala Lys Ala Ala Phe Val Asn Pro Ser Gln Leu Gly Pro Gln Asn 1125 1130 1135	4059
tta agt ttt gct aaa att gct aat ttt aaa gga aga caa gat gct gtt Leu Ser Phe Ala Lys Ile Ala Asn Phe Lys Gly Arg Gln Asp Ala Val 1140 1145 1150 1155	4107
ata tac gaa gca cat gta aga gac ttc act tct gat cga tct ttg gat Ile Tyr Glu Ala His Val Arg Asp Phe Thr Ser Asp Arg Ser Leu Asp 1160 1165 1170	4155
gga aaa tta aaa aat caa ttt ggt acc ttt gca gcc ttt tca gag aaa Gly Lys Leu Lys Asn Gln Phe Gly Thr Phe Ala Ala Phe Ser Glu Lys 1175 1180 1185	4203
cta gat tat tta cag aaa tta gga gtt aca cac att cag ctt tta ccg Leu Asp Tyr Leu Gln Lys Leu Gly Val Thr His Ile Gln Leu Leu Pro 1190 1195 1200	4251

gta ttg agt tat ttt tat gtt aat gaa atg gat aag tca cgc tca aca Val Leu Ser Tyr Phe Tyr Val Asn Glu Met Asp Lys Ser Arg Ser Thr 1205 1210 1215	4299
gct tac act tcc tca gac aat aat tac aat tgg ggc tat gac cca cag Ala Tyr Thr Ser Ser Asp Asn Asn Tyr Asn Trp Gly Tyr Asp Pro Gln 1220 1225 1230 1235	4347
1240 1245 1250	4395
1255 1260 The His Asp Ile His Lys	4443
1270 1275 1280	4491
act tat ctc ttt gag gat ata gaa cct aat tat tat cac ttt atg aat 4 Thr Tyr Leu Phe Glu Asp Ile Glu Pro Asn Tyr Tyr His Phe Met Asn 1285 1290 1295	1539
1300 1305 Phe Gly Gly Arg Leu Gly Thr 1315	1587
1320 1325 Ser Ile Lys Tyr Leu	635
1335 Phe Arg Phe Asp Met Met Gly Asp	683
1350 1355 1360	731
1365 1370 1375	779
1380 1385 Pro Ala Asp Gln Asp Trp Met Lys Ser 1390 1395	327
1400 1405 1410	375
tct ggt ttt cca aat gaa ggt act cca gct ttc atc aca ggt ggc cca 49 Ser Gly Phe Pro Asn Glu Gly Thr Pro Ala Phe Ile Thr Gly Gly Pro 1415 1420 1425	23

```
caa tot tta caa ggt att ttt aaa aat atc aaa gca caa cot ggg aat
                                                                4971
Gln Ser Leu Gln Gly Ile Phe Lys Asn Ile Lys Ala Gln Pro Gly Asn
                           1435
ttt gaa gca gat tcg cca gga gat gtg gtg cag tat att gct gca cat
                                                                  5019
Phe Glu Ala Asp Ser Pro Gly Asp Val Val Gln Tyr Ile Ala Ala His
                       1450
                                                                  5058
gat aac ctt acc ttg cat gat gtg att gca aaa tca att
Asp Asn Leu Thr Leu His Asp Val Ile Ala Lys Ser Ile
                  1465
      <210> 23
      <211> 221
      <212> PRT
      <213> streptococcus
      <400> 23
Asn Leu Lys Ala Glu Leu Ser Val Glu Asp Glu Gln Tyr Thr Ala Thr
                            10
Val Tyr Gly Lys Ser Ala His Gly Ser Thr Pro Gln Glu Gly Val Asn
                                25
Gly Ala Thr Tyr Leu Ala Leu Tyr Leu Ser Gln Phe Asp Phe Glu Gly
                           40
 Pro Ala Arg Ala Phe Leu Asp Val Thr Ala Asn Ile Ile His Glu Asp
                        55
 Phe Ser Gly Glu Lys Leu Gly Val Ala Tyr Glu Asp Asp Cys Met Gly
                    70
 Pro Leu Ser Met Asn Ala Gly Val Phe Gln Phe Asp Glu Thr Asn Asp
                                    90
 Asp Asn Thr Ile Ala Leu Asn Phe Arg Tyr Pro Gln Gly Thr Asp Ala
                                105
 Lys Thr Ile Gln Thr Lys Leu Glu Lys Leu Asn Gly Val Glu Lys Val
                                                125
                            120
 Thr Leu Ser Asp His Glu His Thr Pro His Tyr Val Pro Met Asp Asp
                                            140
                        135
 Glu Leu Val Ser Thr Leu Leu Ala Val Tyr Glu Lys Gln Thr Gly Leu
                                        155
                     150
 Lys Gly His Glu Gln Val Ile Gly Gly Gly Thr Phe Gly Arg Leu Leu
                                                       175
                                    170
                 165
 Glu Arg Gly Val Ala Tyr Gly Ala Met Phe Pro Gly Asp Glu Asn Thr
                                            190
                                185
 Met His Gln Ala Asn Glu Tyr Met Pro Leu Glu Asn Ile Phe Arg Ser
                            200
 Ala Ala Ile Tyr Ala Glu Ala Ile Tyr Glu Leu Ile Lys
                        215
     210
       <210> 24
       <211> 194
       <212> PRT
       <213> streptococcus
```

<400> 24

WO 99/42588 PCT/CA99/00114

45 / 63

Met Thr Asp Leu Glu Lys Ile Ile Lys Ala Ile Lys Ser Asp Ser Gln 10 Asn Gln Asn Tyr Thr Glu Asn Gly Ile Asp Pro Leu Phe Ala Ala Pro Lys Thr Ala Arg Ile Asn Ile Val Gly Gln Ala Pro Gly Leu Lys Thr Gln Glu Ala Arg Leu Tyr Trp Lys Asp Lys Ser Gly Asp Arg Leu Arg 55 Gln Trp Leu Gly Val Asp Glu Glu Thr Phe Tyr His Ser Gly Lys Phe Ala Val Leu Pro Leu Asp Phe Tyr Tyr Pro Gly Lys Gly Lys Ser Gly 85 Asp Leu Pro Pro Arg Lys Gly Phe Ala Glu Lys Trp His Pro Leu Ile 105 Leu Lys Glu Met Pro Asn Val Gln Leu Thr Leu Leu Val Gly Gln Tyr 120 Ala Gln Lys Tyr Tyr Leu Gly Ser Ser Ala His Lys Asn Leu Thr Glu 135 140 Thr Val Lys Ala Tyr Lys Asp Tyr Leu Pro Asp Tyr Leu Pro Leu Val 150 155 His Pro Ser Pro Arg Asn Gln Ile Trp Leu Lys Lys Asn Pro Trp Phe 165 170 Glu Lys Asp Leu Ile Val Asp Leu Gln Lys Ile Val Ala Asp Ile Leu Lys Asp

<210> 25 <211> 126 <212> PRT

<213> streptococcus

<400> 25

 Met
 Arg
 Asp
 Asn
 His
 Leu
 His
 Thr
 Tyr
 Phe
 Ser
 Tyr
 Asp
 Cys
 Gln
 Thr

 Ala
 Phe
 Glu
 Asp
 Tyr
 Ile
 Asn
 Gly
 Phe
 Thr
 Gly
 Glu
 Phe
 Ile
 Thr
 Thr
 Gly
 Glu
 Phe
 Asp
 Asp
 Val
 Pro

 Asp
 Tyr
 Ser
 Ala
 Tyr
 Cys
 Glu
 Tyr
 Tyr
 Leu
 Asp
 Asp
 Tyr
 Phe
 Lys
 Asp
 Arg
 Arg
 Tyr
 Phe
 Lys
 Asp
 Arg
 Arg
 Tyr
 Asp
 Tyr
 Leu
 Lys
 Arg
 Tyr
 Arg
 Tyr
 Leu
 Leu
 Lys
 Arg
 Tyr
 Arg
 Tyr
 Leu
 Leu
 Leu
 Leu
 Leu
 Leu
 Leu
 L

<210> 26 <211> 931 <212> PRT <213> streptococcus

<400> 26

Met I				5					10					7.2	
Arg I			2.0					25					30		
Phe I		25					40					45			
Ala 5	50					55					60				
Gln S	Ser				70					75					80
Val 7				85					90					75	
Thr A			100					105					110		
Leu		115					120					125			
Lys	130					135					140				
Ala	Ile	Gly	Ala	Pro		Pro	Thr	Leu	Lys	Val	Ala	Asn	Gin	Ala	160
145 Arg	~ 7	a 1	N	~1··	150	Dhe	λra	Len	Hie	155		Glu	Leu	Pro	
Arg	116	GIU	ASII	165	IĀI	FIIC	A. 9	пси	170		-1-			175	
			180	Glu				185					190		
		195		Asn			200					205			
_	210			Tyr		215					220				
225				Ile	230					235	•				240
				245					250)				255	
			260)				265	,				2/0	1	Lys
		275	5				280)				285)		Asp
	290					295	5				300)			Thr
) Ası	o Gly	y Sei	Asr. 310		e Val	L Asr	1 GII	315	у пет 5	ı ıyı	. 61)	ALS	320
	Asp			329	ı Lys	Thi			330	s Gli	u Ile			33:	
Leu	Asp	Gl	u Se: 34	r Lys	5 Thi	Gly	y Asp	Ala 345		l Ly	s Vai	l Glr	n Pro	ASI O	n Asp
Tyr	Val	l Ph 35	e Ar	g As	, Le	Ala د	a Ası 36	n His	s Ası	n Gl:	n Ile	e Phe 36!	e Vai	l Lys	g Asp
	370	p Pr	o Ly			37:	n Asi	n Pro			38	U			l Gln
Leu	Lys	- s As	p Al	a Gl	n Gli	n Il	e As	p Le	u Th	r Se	r Il	e Gl:	n Al	a Se	r Phe
3 8 5					3.9	0				39	5				400
				4.0	5				41	0				4 1	
			42	0				42	5				43	U	r Leu
Asp	Th	r Se 43		's Se	r Le	u Le	u Il 44	e Il O	e Ly	s Gl	y As	p Ph 44	e As 5	n Pr	o ràs

WO 99/42588

	100					455	5				160	1			r Arg
					4 / 0	,				475	Туг	Sei			n Leu
				400					497	s Val	Glu			401	480 1 Trp
			200					505	: Ile	e Ile			E 3 6		Asn
		2 + 2					520)				E つ E	Asr	Lys	Gly
	220					235					E 4 A	Lys	Asr		Thr
212					220					555	Lys	Asp			Lys 560
				202					570	Glu					Thr
			200					585	Ala	Ala			E 0 0	Pro	Ser
		223					600			Lys		6 N E	Asn	Phe	
	010					0 T 2				His	620	Arg			
023					030					Asn 635					
				043					650	Gln				~	Thr
			000					665		Phe			C 7 0	Glu	
		0,5					680			Ser		COL			
	000					695				Leu	700				
, 0 5					/ T U					Ala 715					
				123					730	Val					
			, -					745		Glu			750		
		/ 2 2					760			Pro		765			
	, , ,					//5				Ser	700				
, 0 5					790					Lys 795					000
Phe				000					810					015	
Lys			020					825					020		
Trp .		000					840					RAE			
	000					855					860				
Ile A					8/0					875					000
Phe :	116	TILE (gry (885	PTO (GIN	ser	Leu	Gln 890	Gly	Ile	Phe	Lys	Asn 895	Ile

· · · · · · · · · · · · · · · · · · ·	
Lys Ala Gln Pro Gly Asn Phe Glu Ala Asp Ser Pro Gly Asp Val Val	
Gln Tyr Ile Ala Ala His Asp Asn Leu Thr Leu His Asp Val Ile Ala	
913	
Lys Ser Ile 930	
<210> 27	
<211> 5607	
<212> DNA	
<213> streptococcus	
<220>	
<221> CDS <222> (2)(301)	
<2225 (2)(301)	
<400> 27	49
a att caa agt ttg aca gaa ggt caa ctt cgt tct gat atc cct gag ttc Ile Gln Ser Leu Thr Glu Gly Gln Leu Arg Ser Asp Ile Pro Glu Phe	
1 5 10 15	
-	0.77
egt get ggt gat act gta egt gtt cae get aaa gtt gtt gaa ggt act	97
Arg Ala Gly Asp Thr Val Arg Val His Ala Lys Val Val Glu Gly Thr	
20 25 30	
ege gaa egt att eag ate tit gaa ggt gtt gtt ate tea egt aaa ggt	145
Arg Glu Arg Ile Gln Ile Phe Glu Gly Val Val Ile Ser Arg Lys Gly	
35 40 45	
and and and att tot got att	193
caa gga atc tca gaa atg tac aca gta cgt aaa att tct ggt ggt atc Gln Gly Ile Ser Glu Met Tyr Thr Val Arg Lys Ile Ser Gly Gly Ile	
Gin Gly He Ser Glu Met Tyr IIII var III y 27	
	247
ggt gta gag cgt aca ttc cca att cac act cct cgt gtt gat aaa atc	241
Gly Val Glu Arg Thr Phe Pro Ile His Thr Pro Arg Val Asp bys 110	
65 70 /5	
gaa gtt gtt cgt tat ggt aaa gta cgt cgt gct aaa ctt tac tac tta	289
Glu Val Val Arg Tyr Gly Lys Val Arg Arg Ala Lys Led Tyr Tyr Ded	
85 90 95	
and a second contract of the second contract the	341
cgc gca ttg caa ggtaaagctg cacgtattaa agaaatccgt cgttaatttt	
Arg Ala Leu Gln 100	
	401
gatgatcaga ttttaaaaat gcttggttgt ttgaggatag taactatgtt ttaaaactgg	461
acaaccaaga cgtaaaaaat ctgcctgtgg gcagtttttt tactaggtcc ccttagttca	521
atggatataa caactccctc ctaaggagta attgctggtt cgattccggc aggggacata ttcattgcat gtaaatagcg gtttagagct attttgcccc aaatttctct gattaagttt	581
atagttagta tottettatt ottotaatto atotogaa accididaday igatattaa	641
atterests retargaett gagagatgga aattagatag ettgeaaatg tatgeegag	701
nangtacact catacctcac gaccaqttat ttttcggata gttltallga cigcactate	761 821
tganagette togaataato totoottiti attititgia aattoatgod adadadadaa	881
tgtatcattg tcaattggta tatttctgat actacttttg ttttttgttg gcaggtatct	941
ttggttgaaa tgataatccc aagttttatt aattgataaa tatttgttag tgtaatcaat atcattaact gttaaaccta aacattcagc gaagcgcatg ccagttttag cgatgaggta	1001
attattaatt yttaaattta aattattaga gaagagaaa	

WO 99/42588

taacqctqca tagaatt					
taacgctgca tacgattg	at gttgtgatt	t ttctttaca	a atttttatc	a agcgtaagta	1061
JJ counguat	ice ecalectica	L DEACGCCC	t tottttt	a	
3 3	,alala	L CCCTCGTGA	2 C2GCC2tGG	2 *20000	
	icy cittactor	a Ecttocaca	t acatttala		
- J J garacee	gr gyaaytaat	a trocasaot	a atatatec.	~ +	
5 5-5-4-6	Le claccide	a reacarres.	c ccasataca		
Transfer goldwage	ac addatation	a addetacet	t		
J	eg acattttaa	3 FCGCECECE	+		
- 55	ugaagttta	2	~ ~~~~~~~		
J J J JJ	eg geteatade	,	- ~~~~~~~~		
	og uguttgagt	i actitaacta	~~++~~~		
5 5	ww codaddcta	J [[[ACT333:			1781
	ge geelalida	i uccerator			1901
tcaggctatt acaagtgg	ct caatcotcaa	aaaacacatt	ttanana-	ggggtctcgt	1961
ctaatggcta aaatcaag	ga acttogtaga	ctctacaate	ctyayacaaa	aaatacaaag	2021
atgacaacat ttattaat	cg tcaacttgg	acaacttaa:	g gracettage	ttatcgccgt	2081
ttgatgaaca ttctgggg	at tagttcagt	; attentent	acaagaaac	gattcgttga	2141
gctggtgaca gattttac	a agaaaaratt	: cttaatogtc	, cragecarge	ttgtacaaaa	2201
aaccagaaat ggtgcaca	ga totcacctat	cttaategeg	aatttacago	cacageteat	2261
aaccagaaat ggtgcaca	rt grataaccat	totattatac	gtctgggagc	taaagcttat	2321
ctcagtgcga ttaaagac	o algerate	colattato	cttatgagat	tagtcacaac	2381
aatgaaatcc acttgtta	st tagactacta	aaaaggggct	agageteaat	ccaggagcca	2441
tacaacaage togtetga	c ttatecatet	adlatacttc	: caaagaatac	cgttatatca	2501
tacaacaago tggtotgad	o ttattcange	ceeggattgg	caaatgtatt	gataatgcac	2561
caactgaaag tttctttgg	et cataraga	ctgagtetta	ccaccttaag	aaatacaact	2621
cttatgatga gttggtcaa	c gargraggeac	gttatatcga	attctacaac	acacaacgtt	2681
	ve elaciticit	Lagaarrcac			2741
	· · · · · · · · · · · · · · · · · · ·		~~~++~~++~		2801
J	'a yaaaacuadc	Carraatoo			2861
J	· · · · · · · · · · · · · · · · · · ·	urgagggfff	++~++~~+		2921
	e gulluludad	adccarcaaa	actteatte	~~+ ~~ + +	2981
	LagadaLadi	araraaaaa	300tccc		3041
	u cuccuccaa	aadaacorta	ataaaaaa		3101
5 5	· · · · · · · · · · · · · · · · · · ·	LIFCATATAA	2000000000		3161
J gaacageee	- LLLUadadla	aaaaaattaa	- tataatata		3221
	a aagglalula	accragrate	F 20000 2000		3281
JJ-J geaucetat	a yattuataat	FFFACFACES			3341
J.J	- yeadyclaaa	LLaggaaaata	22Ctt2tata	22244244	3401
	- Gallattuaa	acadecadea	TOO SECOLO		3461
5	a accadadate	agrication	****	_	3521
Jees ou ducturate	a LLaudiadiri	rrrations	~~~~		3581
Jan	- Licalaalua	GEFAFFFGag			3641
- January Guguuccu	v alalalaaan	CCCCCCCCC	++~~~~	· ·	3701
	L auttilaaaa	acattacttc	t > < < < < < < < < < < < < < < < < < <		3761
J-JJJ-uacacaca	L GCGGGGLAAA	2222020200	~~+ ~~+ ~~-		3821
Jee- goulded	a ccadadaaa	aaaramaaca	~++~+~~~~		3881
	L LULALLCATO	FFFAACSSES	2502225		
J J J J J J J J J J J J J J J J J J J	a Hilliaalic	TTCAATATCA	2++2-2-2-		3941
accuaccaa	- Llaagaalat	rdaaaaaata	2220200++-		4001
gatggatta	4 Cadadiloaa	adateteass	ataattaat.		4061
	i Cidacdaatt	Taaaaatott	atttalate	A	4121
agaaacce	L LALLLAULAU	ragagraft	201111		4181
tatagaagaa aatgataag	a attcaattct	tattcatcas	gaatttaaag	aaggaaaaaa	4241
actaaaattg ggtgatgaa	a ttgatctros	attactacat	gaattegeta	aacaaaacaa	4301
	Jacoba	uccayat	acyyaaaaaa	ycggaaaaat	4361

4721

4781

```
aaaaagtcat aaatttaaaa ttataggaat cttttctggt aaaaaacagg aaacatatac 4421
aggattatca totgatttta gogaaaatat ggtttttgta gattattcaa otagocaaga 4481
aatattaaat aaatcagaga ataatagaat tgcaaataaa attttaatgt attctggtag 4541
tttagaatct acagagettg cettaaacaa attgaaagae tttaaaattg ataagtcaaa
gtattctatt aagaaagata ataaagcatt cgaagagtct ttagagtcag tgagtggaat
aaaacatata attaaaataa tgacttattc gattatgtta ggtggaatag ttgttctttc
attaatottg attotatggt taagagaaag aatttatgaa ataggtatat ttttatotat
tggaacaact aagatacaaa ttataaggca atttatattt gagttaatat tcatatcaat 4841
accaagtata atateeteet tatttttagg gaatetaeta ttaaaagtaa ttgtagaagg 4901
atttattaac tcagagaact caatgatttt cggtggaagt ttaataaata aaagcagttt
tatgttaaac ataacaacac ttgcagaaag ttatttaata ttaataagta ttattgtttt 5021
atcagttgta atggcctctt cattaatatt atttaagaaa ccacaagaaa tattatcaaa 5081
aataagttag gagcaaataa tggatatatt agaaataaag aatgtaaatt acagttacgc 5141
aaattctaaa gaaaaagttt tgtcaggagt aaatcaaaaa tttgaacttg gaaagtttta 5201
tgcgatagta gggaagtcag gaacaggaaa atccacactt ctttccttac ttgcaggact 5261
tgataaagtt caaacaggaa aaatcttgtt taagaatgaa gatatagaaa agaaaggata 5321
tagtaatcac agaaaaaata atatatcttt ggtatttcaa aattataatt taatagatta 5381
tttatcgccg attgaaaata ttagactagt aaataaatca gtagatgaga gtatcttgtt 5441 cgaattaggt ttagataaaa aacaaataaa aagaaatgtt atgaaaattat ctggtggtca 5501
gcaacaaagg gtagctattg ctagggcact ggtatcagat gccccaataa tactagctga 5561
tgagcctacc ggtaacctag acagtgttac tgctggagaa ataatt
<210> 28
       <211> 111 .
       <212> PRT
       <213> streptococcus
       <400> 28
 Ile Gln Ser Leu Thr Glu Gly Gln Leu Arg Ser Asp Ile Pro Glu Phe
                                      10
                  5
 Arg Ala Gly Asp Thr Val Arg Val His Ala Lys Val Val Glu Gly Thr
                                  25
             20
 Arg Glu Arg Ile Gln Ile Phe Glu Gly Val Val Ile Ser Arg Lys Gly
                              40
         35
 Gln Gly Ile Ser Glu Met Tyr Thr Val Arg Lys Ile Ser Gly Gly Ile
                          55
 Gly Val Glu Arg Thr Phe Pro Ile His Thr Pro Arg Val Asp Lys Ile
                                           75
                      70
 Glu Val Val Arg Tyr Gly Lys Val Arg Arg Ala Lys Leu Tyr Tyr Leu
                                       90
                  85
  Arg Ala Leu Gln Gly Lys Ala Ala Arg Ile Lys Glu Ile Arg Arg
                                   105
              100
        <210> 29
        <211> 173
        <212> PRT
        <213> streptococcus
        <400> 29
  Met Arg Phe Ala Glu Cys Leu Gly Leu Thr Val Asn Asp Ile Asp Tyr
                                                            15
                                       10
  Thr Asn Lys Tyr Leu Ser Ile Asn Lys Thr Trp Asp Tyr His Phe Asn
                                                        3.0
                                   25
              20
  Gln Arg Tyr Leu Pro Thr Lys Asn Lys Ser Ser Ile Arg Asn Ile Pro
                                                    45
                               40
  Ile Asp Asn Asp Thr Leu Phe Phe Leu His Glu Phe Thr Lys Asn Lys
```

WO 99/42588 PCT/CA99/00114

```
55
 Asn Asp Arg Leu Phe Asp Lys Leu Ser Asn Asn Ala Val Asn Lys Thr
 Ile Arg Lys Ile Thr Gly Arg Glu Val Arg Val His Ser Leu Arg His
                 85
                                     90
 Thr Phe Ala Ser Tyr Leu Ile Ser Ile Ser Gln Val Leu Asp His Glu
                                 105
 Asn Leu Asn Ile Thr Leu Glu Val Tyr Ala His Gln Leu Gln Glu Gln
                             120
 Lys Asp Arg Asn Asp Lys Leu Asn Gln Arg Asn Leu Gly Gln Asn Ser
                        135
                                            140
 Ser Lys Pro Leu Phe Thr Cys Asn Glu Tyr Val Pro Cys Arg Asn Arg
          150
 Thr Ser Asn Tyr Ser Leu Gly Gly Ser Cys Tyr Ile His
       <210> 30
       <211> 389
       <212> PRT
       <213> streptococcus
      <400> 30
 Met Lys Ser Ser Asn Glu Ile Glu Lys Ala Leu Tyr Glu Ser Ser Asn
                                   10
 Ser Ser Ile Ser Ile Thr Lys Lys Asp Gly Lys Tyr Phe Asn Ile Asn
Gln Phe Lys Asn Ile Glu Lys Ile Lys Glu Val Glu Glu Lys Ile Phe
Gln Tyr Asp Gly Leu Ala Lys Leu Lys Asp Leu Lys Val Val Ser Gly
                        55
Glu Gln Ser Ile Asn Arg Glu Asp Leu Ser Asp Glu Phe Lys Asn Val
                    70
Val Ser Leu Glu Ala Thr Ser Asn Thr Lys Arg Asn Leu Leu Phe Ser
                85
                                    90
Ser Gly Val Phe Ser Phe Lys Glu Gly Lys Asn Ile Glu Glu Asn Asp
                                105
Lys Asn Ser Ile Leu Val His Glu Glu Phe Ala Lys Gln Asn Lys Leu
        115
                           120
Lys Leu Gly Asp Glu Ile Asp Leu Glu Leu Leu Asp Thr Glu Lys Ser
                        135
Gly Lys Ile Lys Ser His Lys Phe Lys Ile Ile Gly Ile Phe Ser Gly
                    150
                                       155
Lys Lys Gln Glu Thr Tyr Thr Gly Leu Ser Ser Asp Phe Ser Glu Asn
                165
                                   170
Met Val Phe Val Asp Tyr Ser Thr Ser Gln Glu Ile Leu Asn Lys Ser
                                185
Glu Asn Asn Arg Ile Ala Asn Lys Ile Leu Met Tyr Ser Gly Ser Leu
                           200
Glu Ser Thr Glu Leu Ala Leu Asn Lys Leu Lys Asp Phe Lys Ile Asp
                       215
Lys Ser Lys Tyr Ser Ile Lys Lys Asp Asn Lys Ala Phe Glu Glu Ser
                   230
                                       235
Leu Glu Ser Val Ser Gly Ile Lys His Ile Ile Lys Ile Met Thr Tyr
                                   250
Ser Ile Met Leu Gly Gly Ile Val Val Leu Ser Leu Ile Leu Ile Leu
            260
```

WO 99/42588 PCT/CA99/00114

```
Trp Leu Arg Glu Arg Ile Tyr Glu Ile Gly Ile Phe Leu Ser Ile Gly
                            280
       275
Thr Thr Lys Ile Gln Ile Ile Arg Gln Phe Ile Phe Glu Leu Ile Phe
                        295
Ile Ser Ile Pro Ser Ile Ile Ser Ser Leu Phe Leu Gly Asn Leu Leu
                                       315
                   310
Leu Lys Val Ile Val Glu Gly Phe Ile Asn Ser Glu Asn Ser Met Ile
                                    330
               325
Phe Gly Gly Ser Leu Ile Asn Lys Ser Ser Phe Met Leu Asn Ile Thr
                                345
            340
Thr Leu Ala Glu Ser Tyr Leu Ile Leu Ile Ser Ile Ile Val Leu Ser
                            360
Val Val Met Ala Ser Ser Leu Ile Leu Phe Lys Lys Pro Gln Glu Ile
                     375
Leu Ser Lys Ile Ser
      <210> 31
      <211> 169
      <212> PRT
      <213> streptococcus
      <400> 31
Met Asp Ile Leu Glu Ile Lys Asn Val Asn Tyr Ser Tyr Ala Asn Ser
                                    10
Lys Glu Lys Val Leu Ser Gly Val Asn Gln Lys Phe Glu Leu Gly Lys
 Phe Tyr Ala Ile Val Gly Lys Ser Gly Thr Gly Lys Ser Thr Leu Leu
                            40
 Ser Leu Leu Ala Gly Leu Asp Lys Val Gln Thr Gly Lys Ile Leu Phe
                        55
 Lys Asn Glu Asp Ile Glu Lys Lys Gly Tyr Ser Asn His Arg Lys Asn
                     70
 Asn Ile Ser Leu Val Phe Gln Asn Tyr Asn Leu Ile Asp Tyr Leu Ser
                85
 Pro Ile Glu Asn Ile Arg Leu Val Asn Lys Ser Val Asp Glu Ser Ile
            100
                                 105
 Leu Phe Glu Leu Gly Leu Asp Lys Lys Gln Ile Lys Arg Asn Val Met
                             120
        115
 Lys Leu Ser Gly Gly Gln Gln Gln Arg Val Ala Ile Ala Arg Ala Leu
                        135
 Val Ser Asp Ala Pro Ile Ile Leu Ala Asp Glu Pro Thr Gly Asn Leu
                                         155
                    150
 Asp Ser Val Thr Ala Gly Glu Ile Ile
       <210> 32
       <211> 4171
       <212> DNA
       <213> Streptococcus
       <400> 32
 catatgacaa tatttttcaa agtctacatc acttactcgc ctgtcgtgga aaatctggca
                                                                      60
                                                                      120
 atacattaat cgaccaatta gttgctgatg gtttacttca tgcagataat cactaccatt
 ttttcaatgg gaagtctctg gccactttca atactaacca attgattcgc gaagttgtct
                                                                      180
                                                                      240
  atgttgaaat atccttagat actatgtcta gtggtgaaca tgatttagta aaagttaaca
```

WO 99/42588

ttatcagacc	Cactaccas					
aaggtatcaa	taataataa	calactate	c ccacgatga	t gacagctag	c ccctatcatc	300
			u aaagettes.	~ ~~~~		
J J	<u> </u>	accadeddd	U AFFACCAAC)		
		- uccalcua	, <u>daaaroooci</u>	- +	·	
		9 - L L L L L L L L L L L L L L L L L L	a aarraacar:	2 CtCCCCC		
		garractar	: aagcartoti	- aaat <i>a</i> aaaa		
		ucaaccaa	. acrodeards			
		9 Lage Lace	: crcarogact	. コクコペペットト~~		1080
			TOCCECSSSC	. ^^+^		_
		- cacacacaca	i arrogeante	. ペコヤトペットャー		1200
		- quactattt	I UCATTOACAS			
		- uccuaucaa	CEEGGGAAGE			1260
	,	LLAUGLUBER		· + > + + ~ > +		1320
		aaauaci	- FCAAFGEGEE		and the same and a	1380
						1440
						1500
						1560
						1620
						1680
						1740
						1800
						1860
						1920
						1980
						2040
						2100
						2160
						2220
						2280
						2340
						2400
						2460
						2520
ctgcttcttt accactaaq a	gaaatcctt	cacqttqcta	Cattaatoon	teateatet	aagaaaatcg	2580
						2640
						2700
						2760
						2820
						2880
						2940
						3000
aggatttaac ac	aaggcgtt 1	tacageette	CtCtacttac	atttaataag	cctgtcttag	3060
						3120
						3180
ttactgagaa ac	Ctattagt o	Jacataaata	aggtagaagg	tcgccatcta	gctcgtaaat	3240
ttactgagaa ac	ictaattac /	cttttaaaac	ayetacccca	gaactctgca	aaaaacagt	3300
						3360
						3420
						3480
						3540
tcagcatgtt ca		gugalyt	gradiccaaa	ctaaggtctt :	accttccaat	3600

```
tettteataa ataeeettag taaggettgt teagtaatag gateaagtee aacagttgge 3660
tcatctaaga taacaattgg gacatctttt agtaagattc tagccaaagc aattctatgc 3720
ctttcgccac ctgaaaacct aagtccagct tcatcaacca ttgtatagag accatctgat 3780 aaatcagtga ccatctcttt caatccaact cgttcaagaa ctttccatac atcttcttca 3840
ctagcatctt ggtttccaat gcgaatgtta tttagcaggg ttgtattaaa aaggtagggc 3900
gettgttgta teactecaat atagttagaa atgeaateae caactattga aacateagea 3960
cegectaggg taatetteee ttgacttget ttcaagtege caegaagtag actagetaag 4020
gtactcttgc cagaaccact ccgccctaaa atagcaattt tttctccttc tttaatatcc 4080
aaatctaaat gatgcaaaac ccatttetet tgtggettat actggaaact taaattettg 4140
acggaaaaat catatggctt attaggcaat t
      <210> 33
      <211> 649
      <212> PRT
      <213> Streptococus
      <400> 33
Tyr Asp Asn Ile Phe Gln Ser Leu His His Leu Leu Ala Cys Arg Gly
                                     10
Lys Ser Gly Asn Thr Leu Ile Asp Gln Leu Val Ala Asp Gly Leu Leu
                                 25
             20
His Ala Asp Asn His Tyr His Phe Phe Asn Gly Lys Ser Leu Ala Thr
                             40
         35
Phe Asn Thr Asn Gln Leu Ile Arg Glu Val Val Tyr Val Glu Ile Ser
                        55
                                            60
Leu Asp Thr Met Ser Ser Gly Glu His Asp Leu Val Lys Val Asn Ile
                                         75
                    70
 Ile Arg Pro Thr Thr Glu His Thr Ile Pro Thr Met Met Thr Ala Ser
                                     90
                85
 Pro Tyr His Gln Gly Ile Asn Asp Pro Ala Ala Asp Gln Lys Thr Tyr
                                 105
 Gln Met Glu Gly Ala Leu Ala Val Lys Gln Pro Lys His Ile Gln Val
                             120
 Asp Thr Lys Pro Phe Lys Glu Glu Val Lys His Pro Ser Lys Leu Pro
                                              140
                         135
 Ile Ser Pro Ala Thr Glu Ser Phe Thr His Ile Asp Ser Tyr Ser Leu
                                          155
                     150
 Asn Asp Tyr Phe Leu Ser Arg Gly Phe Ala Asn Ile Tyr Val Ser Gly
                                      170
                 165
 Val Gly Thr Ala Gly Ser Thr Gly Phe Met Thr Ser Gly Asp Tyr Gln
                                                      190
                                  185
 Gln Ile Gln Ser Phe Lys Ala Val Ile Asp Trp Leu Asn Gly Lys Val
                              200
 Thr Ala Phe Thr Ser His Lys Arg Asp Lys Gln Val Lys Ala Asp Trp
                                              220
                          215
 Ser Asn Gly Leu Val Ala Thr Thr Gly Lys Ser Tyr Leu Gly Thr Met
                                           235
                      230
 Ser Thr Gly Leu Ala Thr Thr Gly Val Glu Gly Leu Lys Val Ile Ile
                                      250
                  245
 Ala Glu Ala Ala Ile Ser Thr Trp Tyr Asp Tyr Tyr Arg Glu Asn Gly
                                  265
              260
 Leu Val Cys Ser Pro Gly Gly Tyr Pro Gly Glu Asp Leu Asp Val Leu
                              280
         275
  Thr Glu Leu Thr Tyr Ser Arg Asn Leu Leu Ala Gly Asp Tyr Ile Lys
```

295

Asn Asn Asp Cys Tyr Gln Ala Leu Leu Asn Glu Gln Ser Lys Ala Ile

WO 99/42588 PCT/CA99/00114

55 / 63

```
310
                                        315
 Asp Arg Gln Ser Gly Asp Tyr Asn Gln Tyr Trp His Asp Arg Asn Tyr
                325
                                    330
 Leu Thr His Val Asn Asn Val Lys Ser Arg Val Val Tyr Thr His Gly
                                 345
 Leu Gln Asp Trp Asn Val Lys Pro Arg His Val Tyr Lys Val Phe Asn
                            360
 Ala Leu Pro Gln Thr Ile Lys Lys His Leu Phe Leu His Gln Gly Gln
                         375
 His Val Tyr Met His Asn Trp Gln Ser Ile Asp Phe Arg Glu Ser Met
                    390
                                       395
 Asn Ala Leu Leu Ser Gln Glu Leu Leu Gly Ile Asp Asn His Phe Gln
                405
                                    410
 Leu Glu Glu Val Ile Trp Gln Asp Asn Thr Thr Glu Gln Thr Trp Gln
            420
                                425
 Val Leu Asp Ala Phe Gly Gly Asn His Gln Glu Gln Ile Gly Leu Gly
                             440
 Asp Ser Lys Lys Leu Ile Asp Asn His Tyr Asp Lys Glu Ala Phe Asp
                        455
                                            460
Thr Tyr Cys Lys Asp Phe Asn Val Phe Lys Asn Asp Leu Phe Lys Gly
                   470
                                       475
Asn Asn Lys Thr Asn Gln Ile Thr Ile Asn Leu Pro Leu Lys Lys Asn
                485
                                   490
Tyr Leu Leu Asn Gly Gln Cys Lys Leu His Leu Arg Val Lys Thr Ser
                               505
Asp Lys Lys Ala Ile Leu Ser Ala Gln Ile Leu Asp Tyr Gly Pro Lys
        515
                            520
Lys Arg Phe Lys Asp Thr Pro Thr Ile Lys Phe Leu Asn Ser Leu Asp
Asn Gly Lys Asn Phe Ala Arg Glu Ala Leu Arg Glu Leu Pro Phe Thr
                    550
                                       555
Lys Asp His Tyr Arg Val Ile Ser Lys Gly Val Leu Asn Leu Gln Asn
                                    570
Arg Thr Asp Leu Leu Thr Ile Glu Ala Ile Glu Pro Glu Gln Trp Phe
                               585
Asp Ile Glu Phe Ser Leu Gln Pro Ser Ile Tyr Gln Leu Ser Lys Gly
                           600
Asp Asn Leu Arg Ile Ile Leu Tyr Thr Thr Asp Phe Glu His Thr Ile
                       615
                                          620
Arg Asp Asn Ala Ser Tyr Ser Ile Thr Val Asp Leu Ser Gln Ser Tyr
                   630
                                       635
Leu Thr Ile Pro Thr Asn Gln Gly Asn
               645
     <210> 34
      <211> 119
      <212> PRT
      <213> Streptococus
      <400> 34
Met Lys Leu Leu Thr Lys Glu Arg Phe Asp Asp Ser Gln His Phe Trp
Tyr Gln Ile Asn Leu Leu Gln Glu Ser Asn Phe Gly Ala Val Phe Asp
                               25
```

His Asp Asn Lys Asn Ile Pro Gln Val Val Ala Thr Ile Val Asp Asp

56 / 63 Leu Gln Gly Ser Gly Ser Ser Asn His Phe Trp Tyr Phe Gly Asn Thr Thr Asp Thr Ser Ile Leu Met Ile Ala His Leu Asn Arg Lys Phe Tyr 75 70 Ile Gln Val Asn Leu Lys Asp Phe Asp Phe Ala Leu Asn Leu Ile Ala 90 Ile Asn Asn Trp Lys Ser Leu Leu Gln Thr Gln Leu Glu Ala Leu Asn 105 Asp Thr Leu Ala Ile Phe Gln 115 <210> 35 <211> 326 <212> PRT <213> Streptococus <400> 35 Met Ser Ser Tyr Trp Asn Asn Tyr Pro Glu Leu Lys Lys Asn Ile Asp 10 Glu Thr Asn Gln Leu Ile Gln Glu Arg Ile Gln Val Arg Asn Lys Asp 20 Ile Glu Ala Ala Leu Ser Gln Leu Thr Ala Ala Gly Gly Lys Gln Leu 40 35 Arg Pro Ala Phe Phe Tyr Leu Phe Ser Gln Leu Gly Asn Lys Glu Asn 55 Gln Asp Thr Gln Gln Leu Lys Lys Ile Ala Ala Ser Leu Glu Ile Leu 70 His Val Ala Thr Leu Ile His Asp Asp Val Ile Asp Asp Ser Pro Leu 90 85 Arg Arg Gly Asn Met Thr Ile Gln Ser Lys Phe Gly Lys Asp Ile Ala 105 Val Tyr Thr Gly Asp Leu Leu Phe Thr Val Phe Phe Asp Leu Ile Leu 120 Glu Ser Met Thr Asp Thr Pro Phe Met Arg Ile Asn Ala Lys Ser Met 135 Arg Lys Ile Leu Met Gly Glu Leu Asp Gln Met His Leu Arg Tyr Asn 155 150 Gln Gln Gln Gly Ile His His Tyr Leu Arg Ala Ile Ser Gly Lys Thr 170 165

Ala Glu Leu Phe Lys Leu Ala Ser Lys Glu Gly Ala Tyr Phe Gly Gly 185 Ala Glu Lys Glu Val Val Arg Leu Ala Gly His Ile Gly Phe Asn Ile

200

Gly Met Thr Phe Gln Ile Leu Asp Asp Ile Leu Asp Tyr Thr Ala Asp 220 215 Lys Lys Thr Phe Asn Lys Pro Val Leu Glu Asp Leu Thr Gln Gly Val

230 235 Tyr Ser Leu Pro Leu Leu Leu Ala Ile Glu Glu Asn Pro Asp Ile Phe

250 245 Lys Pro Ile Leu Asp Lys Lys Thr Asp Met Ala Thr Glu Asp Met Glu 265

Lys Ile Ala Tyr Leu Val Val Ser His Arg Gly Val Asp Lys Ala Arg 280

His Leu Ala Arg Lys Phe Thr Glu Lys Ala Ile Ser Asp Ile Asn Lys 295 Leu Pro Gln Asn Ser Ala Lys Lys Gln Leu Leu Gln Leu Thr Asn Tyr WO 99/42588 PCT/CA99/00114

57 / 63

```
310
                                         315
                                                             320
 Leu Leu Lys Arg Lys Ile
       <210> 36
       <211> 247
       <212> PRT
       <213> Streptococus
       <400> 36
 Leu Pro Asn Lys Pro Tyr Asp Phe Ser Val Lys Asn Leu Ser Phe Gln
                                     10
 Tyr Lys Pro Gln Glu Lys Trp Val Leu His His Leu Asp Leu Asp Ile
                                 25
 Lys Glu Gly Glu Lys Ile Ala Ile Leu Gly Arg Ser Gly Ser Gly Lys
                             40
 Ser Thr Leu Ala Ser Leu Leu Arg Gly Asp Leu Lys Ala Ser Gln Gly
Lys Ile Thr Leu Gly Gly Ala Asp Val Ser Ile Val Gly Asp Cys Ile
 65
                     70
Ser Asn Tyr Ile Gly Val Ile Gln Gln Ala Pro Tyr Leu Phe Asn Thr
                85
                                    90
Thr Leu Leu Asn Asn Ile Arg Ile Gly Asn Gln Asp Ala Ser Glu Glu
                                105
Asp Val Trp Lys Val Leu Glu Arg Val Gly Leu Lys Glu Met Val Thr
        115
                            120
Asp Leu Ser Asp Gly Leu Tyr Thr Met Val Asp Glu Ala Gly Leu Arg
                        135
Phe Ser Gly Gly Glu Arg His Arg Ile Ala Leu Ala Arg Ile Leu Leu
                    150
                                       155
Lys Asp Val Pro Ile Val Ile Leu Asp Glu Pro Thr Val Gly Leu Asp
                165
                                    170
Pro Ile Thr Glu Gln Ala Leu Leu Arg Val Phe Met Lys Glu Leu Glu
                                185
                                                  190
Gly Lys Thr Leu Val Trp Ile Thr His His Leu Lys Gly Ile Glu His
                            200
                                                205
Ala Asp Arg Ile Leu Phe Ile Glu Asn Gly Gln Leu Glu Leu Glu Gly
Ser Pro Gln Glu Leu Ser Gln Ser Ser Gln Arg Tyr Arg Gln Leu Lys
                    230
                                       235
Ala Ala Asp Asp Gly Asp Leu
                245
      <210> 37
      <211> 3480
      <212> DNA
      <213> Streptococcus
      <400> 37
aattetattt ggaggttttt ettgaataaa tggttagtta aggeaagtte ettagttgtt
ttaggtggta tggttttatc tgcgggttcc cgagttttag cggatactta tgtccgtcca
attgataatg gtagaattac aacaggtttc aatggttatc ctggacattg tggggtggat 180
tatgetgtte egaetggaae gattattagg geagtggeag atggtaetgt gaaatttgea 240
ggagctggag ccaacttttc ttggatgaca gacttagcag gaaattgtgt catgattcaa 300
catgoggatg gaatgoatag tggttacgot catatgtcac gtgtggtggc taggactggg
gaaaaagtca aacaaggaga tatcatcggt tacgtaggag caactggtat ggcgacggga
```

cotcaccttc	attttgaatt	tttaccagct	aaccctaatt	ttcaaaatgg	tttccatgga	480
cotatoaato	caacgtcact	aattgctaac	gttgcgacct	ttagtggaaa	aacgcaagca	540
tragetreaa	gcattaagcc	attacaatca	gctcctgtac	agaatcaatc	tagtaaatta	600
aaagtgtatC	gagtagatga	attacaaaag	gttaatggtg	tttggttagt	caaaaataac	660
accetaacee	cgactgggtt	tgattggaac	gataatggta	taccagcatc	agaaattyat	720
gaggttgatg	ctaatggtaa	tttgacagct	gaccaggttc	ttcaaaaagg	Eggttacttt	780
arcttraatc	ctaaaactct	taaqactgta	gaaaaaccca	tccaaggaac	agetggttta	840
acttgggcta	agacacgctt	tgctaatggt	agttcagttt	ggcttcgcgt	tgacaacagt	900
caagaactgc	tttacaaata	qtttgaggta	ttgattcatt	gttttaaatg	acagettege	960
tactaactaa	gtacaatttc	tttaaaccgt	ctgaaaataa	ttttatagtc	Cagtaaagtg	1020
tgatattata	gtctcggact	aataaaaagg	aaataggaat	tgaagcaatg	aaaatgaata	1080
aaaaggtact	attgacatcg	acaatggcag	cttcgctatt	atcagtcgca	agtgttcaag	1140
cacaagaaac	agatacgacg	tqqacagcac	gtactgtttc	agaggtaaag	gergarrigg	1200
taaagcaaga	caataaatca	tcatatactg	tgaaatatgg	tgatacacta	agegilatii	1260
cagaagcaat	gtcaattgat	atgaatgtct	tagcaaaaat	taataacatt	gcagatatea	1320
atcttattta	tcctgagaca	acactgacag	taacttacga	tcagaagagt	Catactgcca	1380
cttcaatgaa	aatagaaaca	ccaqcaacaa	atgctgctgg	tcaaacaaca	getactgtgg	1440
atttqaaaac	caatcaaqtt	tctqttqcag	accaaaaagt	tteteteaat	acaattttgg	1500
aaggtatgac	accagaagca	qcaacaacqa	ttgtttcgcc	aatgaagaca	tattettetg	1560
caccaacttt	gaaatcaaaa	gaagtattag	cacaagagca	agctgttagt	caagcagcag	1620
ctaatgaaca	ggtatcaaca	gctcctgtga	agtcgattac	ttcagaagtt	Coagoagoca	1680
aagaggaagt	taaaccaact	cagacgtcag	tcagtcagtc	aacaacagta	teaccagett	1740
ctattaccac	tgaaacacca	gctccagtag	ctaaagtagc	accggtaaga	actgtagcag	1800
cccctagagt	ggcaagtgtt	aaagtagtca	ctcctaaagt	agaaactggt	geateaceag	1860
agcatgtatc	agetecagea	gttcctgtga	ctacgacttc	aacagctaca	gacagtaagt	1920
tacaagcgac	tgaagttaag	agcgttccgg	tagcacaaaa	agctccaaca	gcaacaccgg	1980
tagcacaacc	agcttcaaca	acaaatgcag	tagctgcaca	tcctgaaaat	geagggetee	2040
aacctcatqt	tacaacttat	aaagaaaaag	tagcgtcaac	ttatggagtt	aatgaattca	2100
gracataccg	tacadataat	ccaggtgatc	atggtaaagg	tttagcagtc	gactitating	2160
raggtaaaaa	ccaagcactt	qqtaatgaag	ttgcacagta	ctctacacaa	aatatggcag	2220
caaataacat	ttcatatqtt	atctggcaac	aaaagtttta	ctcaaataca	aatagtattt	2280
atggacctgc	taatacttqq	aatgcaatgc	cagatcgtgg	tggcgttact	gccaaccatt	2340
atraccatot	tcacqtatca	tttaacaaat	aatataaaaa	. aggaagctat	EEggeeteete	2400
ttttatatgo	cttgaataga	ctttcaaggt	tcttatctaa	tttttattaa	attgaggaga	2460
ttaadctata	agtetgaaac	tactttcacg	ı ttaaccgtga	ctaaatcaaa	acgilaaaac	2520
taaaatotaa	gtctgtaaag	attattgaaa	. acgctttaaa	aacagatata	ataaggtttg	2580
tagatatota	a aaattaaaaa	aqataaggaa	ı gtgagaatat	gecacateta	agtaaagaag	2640
cttttaaaaa	gcaaataaaa	aatqqcatta	i ttgtgtcatg	, tcaagctity	CCLGGGGagc	2700
ctctttatac	tgaaagtgga	ggtgttatgo	ctcttttage	tttggcagct	caagaagcag	2760
gagggttgg	tataaqaqcc	aatagtgtco	gcgacattaa	a ggaaattcaa	gaagttatta	2820
atttacctat	catcoocatt	attaaacgtg	g aatatcctco	c acaagaacca	tttattattg	2880
ctacgatgag	agaggtggat	. caattagcta	a gtttagatat	t tgcagtaata	geettagatt	2940
gtagacttag	n agagogtoat	gatggtttga	a gtgtagctga	a gtttattcaa	aayacaaaay	3000
ggaaatatco	tgaacagttg	ctaatggctg	g atataagtad	: ttttgaagaa	ggtadaaatg	3060
cttttgaag	- aggagttgat	: tttqtqqqta	a caactctato	tggatacaca	gattadaged	3120
gccaagaag	a aggaccggat	atagaactco	: ttaataagc1	t ttgtcaagco	ggtalagalg	3180
tgattgcgg	a aggtaaaatt	: catactccta	a agcaagcta:	a tgaaattaat	: catataggig	3240
ttgcaggaa'	t tataattaat	gqtqctatca	a ctagaccaa:	a agaaatagc	gagegillea	3300
tctcaggac:	t tagttaaaac	tottactca:	a aaatcaaaa	t caaaataaaa	a aaggggaata	3360
attatoagt.	a tcaaaaaaaa	r tataattaa	t ttttgcctc	g gagetgeage	attattaaty	3420
tttgcttgt	g tagacagtag	g tcaatctgt	t atggctgcc	g agaaggataa	a agtcgaaatt	3480

<210> 38

<211> 306 <212> PRT

<213> Streptococcus

59 / 63

```
<400> 38
Asn Ser Ile Trp Arg Phe Phe Leu Asn Lys Trp Leu Val Lys Ala Ser
                                   10
Ser Leu Val Val Leu Gly Gly Met Val Leu Ser Ala Gly Ser Arg Val
                                25
Leu Ala Asp Thr Tyr Val Arg Pro Ile Asp Asn Gly Arg Ile Thr Thr
                           40
Gly Phe Asn Gly Tyr Pro Gly His Cys Gly Val Asp Tyr Ala Val Pro
                                            60
Thr Gly Thr Ile Ile Arg Ala Val Ala Asp Gly Thr Val Lys Phe Ala
                   70
Gly Ala Gly Ala Asn Phe Ser Trp Met Thr Asp Leu Ala Gly Asn Cys
                                    90
Val Met Ile Gln His Ala Asp Gly Met His Ser Gly Tyr Ala His Met
                                105
Ser Arg Val Val Ala Arg Thr Gly Glu Lys Val Lys Gln Gly Asp Ile
                           120
Ile Gly Tyr Val Gly Ala Thr Gly Met Ala Thr Gly Pro His Leu His
                       135
Phe Glu Phe Leu Pro Ala Asn Pro Asn Phe Gln Asn Gly Phe His Gly
                                     155
Arg Ile Asn Pro Thr Ser Leu Ile Ala Asn Val Ala Thr Phe Ser Gly
               165
                                   170
Lys Thr Gln Ala Ser Ala Pro Ser Ile Lys Pro Leu Gln Ser Ala Pro
                               185
Val Gln Asn Gln Ser Ser Lys Leu Lys Val Tyr Arg Val Asp Glu Leu
        195
                           200
Gln Lys Val Asn Gly Val Trp Leu Val Lys Asn Asn Thr Leu Thr Pro
                       215
Thr Gly Phe Asp Trp Asn Asp Asn Gly Ile Pro Ala Ser Glu Ile Asp
                   230
                                        235
Glu Val Asp Ala Asn Gly Asn Leu Thr Ala Asp Gln Val Leu Gln Lys
               245
                                    250
Gly Gly Tyr Phe Ile Phe Asn Pro Lys Thr Leu Lys Thr Val Glu Lys
                               265
Pro Ile Gln Gly Thr Ala Gly Leu Thr Trp Ala Lys Thr Arg Phe Ala
                         280
Asn Gly Ser Ser Val Trp Leu Arg Val Asp Asn Ser Gln Glu Leu Leu
                      295
Tyr Lys
305
     <210> 39
      <211> 434
      <212> PRT
     <213> Streptococcus
     <400> 39
Met Lys Met Asn Lys Lys Val Leu Leu Thr Ser Thr Met Ala Ala Ser
Leu Leu Ser Val Ala Ser Val Gln Ala Gln Glu Thr Asp Thr Thr Trp
                               25
Thr Ala Arg Thr Val Ser Glu Val Lys Ala Asp Leu Val Lys Gln Asp
```

35 40 45 Asn Lys Ser Ser Tyr Thr Val Lys Tyr Gly Asp Thr Leu Ser Val Ile

60 / 63

```
. 55
                                         60
Ser Glu Ala Met Ser Ile Asp Met Asn Val Leu Ala Lys Ile Asn Asn
                  70
                                     75
Ile Ala Asp Ile Asn Leu Ile Tyr Pro Glu Thr Thr Leu Thr Val Thr
                                 90
              85
Tyr Asp Gln Lys Ser His Thr Ala Thr Ser Met Lys Ile Glu Thr Pro
                             105
          100
Ala Thr Asn Ala Ala Gly Gln Thr Thr Ala Thr Val Asp Leu Lys Thr
                          120
                                             125
Asn Gln Val Ser Val Ala Asp Gln Lys Val Ser Leu Asn Thr Ile Ser
                      135
                                         140
Glu Gly Met Thr Pro Glu Ala Ala Thr Thr Ile Val Ser Pro Met Lys
                  150
                                     155
Thr Tyr Ser Ser Ala Pro Ala Leu Lys Ser Lys Glu Val Leu Ala Gln
                                 170
              165
Glu Gln Ala Val Ser Gln Ala Ala Ala Asn Glu Gln Val Ser Thr Ala
                              185
           180
Pro Val Lys Ser Ile Thr Ser Glu Val Pro Ala Ala Lys Glu Glu Val
                                  205
                          200
      195
Lys Pro Thr Gln Thr Ser Val Ser Gln Ser Thr Thr Val Ser Pro Ala
                               220
             215
Ser Val Ala Ala Glu Thr Pro Ala Pro Val Ala Lys Val Ala Pro Val
                  230
                                     235
Arg Thr Val Ala Ala Pro Arg Val Ala Ser Val Lys Val Val Thr Pro
              245
                                  250
Lys Val Glu Thr Gly Ala Ser Pro Glu His Val Ser Ala Pro Ala Val
                               265
          260
Pro Val Thr Thr Ser Thr Ala Thr Asp Ser Lys Leu Gln Ala Thr
                                             285
                          280
Glu Val Lys Ser Val Pro Val Ala Gln Lys Ala Pro Thr Ala Thr Pro
                                          300
                       295
Val Ala Gln Pro Ala Ser Thr Thr Asn Ala Val Ala Ala His Pro Glu
                                      315
                   310
Asn Ala Gly Leu Gln Pro His Val Ala Ala Tyr Lys Glu Lys Val Ala
               325
                                  330
Ser Thr Tyr Gly Val Asn Glu Phe Ser Thr Tyr Arg Ala Gly Asp Pro
                              345
Gly Asp His Gly Lys Gly Leu Ala Val Asp Phe Ile Val Gly Lys Asn
                          360
Gln Ala Leu Gly Asn Glu Val Ala Gln Tyr Ser Thr Gln Asn Met Ala
                                          380
                       375
Ala Asn Asn Ile Ser Tyr Val Ile Trp Gln Gln Lys Phe Tyr Ser Asn
                                      395
                   390
Thr Asn Ser Ile Tyr Gly Pro Ala Asn Thr Trp Asn Ala Met Pro Asp
                                  410
               405
Arg Gly Gly Val Thr Ala Asn His Tyr Asp His Val His Val Ser Phe
                        425
Asn Lys
```

<210> 40 <211> 232 <212> PRT <213> Streptococcus

<400> 40

WO 99/42588

61 / 63

```
Met Pro His Leu Ser Lys Glu Ala Phe Lys Lys Gln Ile Lys Asn Gly
 Ile Ile Val Ser Cys Gln Ala Leu Pro Gly Glu Pro Leu Tyr Thr Glu
 Ser Gly Gly Val Met Pro Leu Leu Ala Leu Ala Ala Gln Glu Ala Gly
                             40
 Ala Val Gly Ile Arg Ala Asn Ser Val Arg Asp Ile Lys Glu Ile Gln
                         55
 Glu Val Thr Asn Leu Pro Ile Ile Gly Ile Ile Lys Arg Glu Tyr Pro
 Pro Gln Glu Pro Phe Ile Thr Ala Thr Met Thr Glu Val Asp Gln Leu
                                     90
 Ala Ser Leu Asp Ile Ala Val Ile Ala Leu Asp Cys Thr Leu Arg Glu
             100
                                 105
 Arg His Asp Gly Leu Ser Val Ala Glu Phe Ile Gln Lys Ile Lys Gly
        115
                             120
                                                 125
 Lys Tyr Pro Glu Gln Leu Leu Met Ala Asp Ile Ser Thr Phe Glu Glu
                         135
                                             140
 Gly Lys Asn Ala Phe Glu Ala Gly Val Asp Phe Val Gly Thr Thr Leu
                    150
 Ser Gly Tyr Thr Asp Tyr Xaa Arg Gln Glu Glu Gly Pro Asp Ile Glu
                165
                                     170
Leu Leu Asn Lys Leu Cys Gln Ala Gly Ile Asp Val Ile Ala Glu Gly
                                185
Lys Ile His Thr Pro Lys Gln Ala Asn Glu Ile Asn His Ile Gly Val
                            200
Ala Gly Ile Val Val Gly Gly Ala Ile Thr Arg Pro Lys Glu Ile Ala
                        215
Glu Arg Phe Ile Ser Gly Leu Ser
                     230
      <210> 41
      <211> 39
      <212> PRT
      <213> Streptococcus
      <400> 41
Met Ser Ile Lys Lys Ser Val Ile Gly Phe Cys Leu Gly Ala Ala Ala
                                    10
Leu Ser Met Phe Ala Cys Val Asp Ser Ser Gln Ser Val Met Ala Ala
            20
                                25
Glu Lys Asp Lys Val Glu Ile
        35
      <210> 42
      <211> 1305
      <212> DNA
      <213> Streptococcus
      <400> 42
atgaaaatga ataaaaaggt actattgaca tcgacaatgg cagcttcgct attatcagtc
gcaagtgttc aagcacaaga aacagatacg acgtggacag cacgtactgt ttcagaggta
aaggotgatt tggtaaagca agacaataaa toatcatata otgtgaaata tggtgataca
ctaagcgtta tttcagaagc aatgtcaatt gatatgaatg tcttagcaaa aattaataac
attgcagata tcaatcttat ttatcctgag acaacactga cagtaactta cgatcagaag
agtcatactg ccacttcaat gaaaatagaa acaccagcaa caaatgctgc tggtcaaaca
```

62 / 63

```
acagctactg tggatttgaa aaccaatcaa gtttctgttg cagaccaaaa agtttctctc
aatacaattt cggaaggtat gacaccagaa gcagcaacaa cgattgtttc gccaatgaag
acatattott otgogocago tttgaaatca aaagaagtat tagcacaaga gcaagotgtt
agtcaagcag cagctaatga acaggtatca acagctcctg tgaagtcgat tacttcagaa
                                                                    600
gttccagcag ctaaagagga agttaaacca actcagacgt cagtcagtca gtcaacaaca
                                                                    660
gtatcaccag cttctgttgc cgctgaaaca ccagctccag tagctaaagt agcaccggta
                                                                    720
agaactgtag cagcccctag agtggcaagt gttaaagtag tcactcctaa agtagaaact
ggtgcatcac cagagcatgt atcagctcca gcagttcctg tgactacgac ttcaacagct
acagacagta agttacaagc gactgaagtt aagagcgttc cggtagcaca aaaagctcca
acagcaacac eggtagcaca accagettea acaacaaatg cagtagetge acateetgaa
aatgcagggc tccaacctca tgttgcagct tataaagaaa aagtagcgtc aacttatgga 1020
gttaatgaat tcagtacata ccgtgcaggt gatccaggtg atcatggtaa aggtttagca 1080
gtcgacttta ttgtaggtaa aaaccaagca cttggtaatg aagttgcaca gtactctaca 1140
caaaatatgg cagcaaataa catttcatat gttatctggc aacaaaagtt ttactcaaat 1200
                                                                   1260
acaaatagta tttatggacc tgctaatact tggaatgcaa tgccagatcg tggtggcgtt
                                                                    1305
actgccaacc attatgacca tgttcacgta tcatttaaca aataa
      <210> 43
      <211> 1230
      <212> DNA
      <213> Streptococcus
      <400> 43
caagaaacag atacgacgtg gacagcacgt actgtttcag aggtaaaggc tgatttggta
aagcaagaca ataaatcatc atatactgtg aaatatggtg atacactaag cgttatttca
                                                                     120
gaagcaatgt caattgatat gaatgtctta gcaaaaatta ataacattgc agatatcaat
                                                                     180
cttatttatc ctgagacaac actgacagta acttacgatc agaagagtca tactgccact
                                                                     240
                                                                     300
tcaatgaaaa tagaaacacc agcaacaaat gctgctggtc aaacaacagc tactgtggat
ttgaaaacca atcaagtttc tgttgcagac caaaaagttt ctctcaatac aatttcggaa
                                                                     360
ggtatgacac cagaagcagc aacaacgatt gtttcgccaa tgaagacata ttcttctgcg
                                                                     420
ccagctttga aatcaaaaga agtattagca caagagcaag ctgttagtca agcagcagct
                                                                     480
aatgaacagg tatcaacagc teetgtgaag tegattaett cagaagttee agcagetaaa
                                                                     540
                                                                     600
gaggaagtta aaccaactca gacgtcagtc agtcagtcaa caacagtatc accagcttct
gttgccgctg aaacaccagc tccagtagct aaagtagcac cggtaagaac tgtagcagcc
                                                                     660
cctagagtgg caagtgttaa agtagtcact cctaaagtag aaactggtgc atcaccagag
                                                                     720
                                                                     780
 catgtatcag ctccagcagt tcctgtgact acgacttcaa cagctacaga cagtaagtta
                                                                     840
 caagegactg aagttaagag egtteeggta geacaaaaag etecaacage aacaceggta
 gcacaaccag cttcaacaac aaatgcagta gctgcacatc ctgaaaatgc agggctccaa
                                                                     900
                                                                     960
 cetcatgttg cagettataa agaaaaagta gegtcaaett atggagttaa tgaatteagt
                                                                    1020
 acataccgtg caggtgatcc aggtgatcat ggtaaaggtt tagcagtcga ctttattgta
 ggtaaaaacc aagcacttgg taatgaagtt gcacagtact ctacacaaaa tatggcagca
                                                                    1080
 aataacattt catatgttat ctggcaacaa aagttttact caaatacaaa tagtatttat
                                                                    1140
 ggacctgcta atacttggaa tgcaatgcca gatcgtggtg gcgttactgc caaccattat
                                                                    1200
                                                                    1230
 gaccatgttc acgtatcatt taacaaataa
       <210> 44
       <211> 409
       <212> PRT
       <213> Streptococcus
       <400> 44
 Gln Glu Thr Asp Thr Thr Trp Thr Ala Arg Thr Val Ser Glu Val Lys
                                     10
  1
 Ala Asp Leu Val Lys Gln Asp Asn Lys Ser Ser Tyr Thr Val Lys Tyr
                                 25
             20
 Gly Asp Thr Leu Ser Val Ile Ser Glu Ala Met Ser Ile Asp Met Asn
```

WO 99/42588 PCT/CA99/00114

63 / 63

		35					40								
٧a	l Le	u Al	a Lv	s Ti	e λcτ		- - 10	- 33				45			
															r Pro
															a Thr
Se:	r Me	t Ly	s Il	e Gli 85	u Thr	Pro	Ala	Th	Ası	ı Ala	a Ala	Gly	y Gl	n Th	80 r Thr
			l As	p Lei											n Lys
															a Thr
			-				1/1						-		
						133					7 4 0	Pro	Ala		ı Lys
	-				100					755	Ser	Glr			a Ala
Asr	ı Glu	Glr	l Val	l Ser 165	Thr	Ala	Pro	Val	Lys	Ser	Ile	Thr	Ser	Glu	160 Val
Pro	Ala	Ala	Lys 180	Glu		Val	Lys	Pro	170 Thr	Gln	Thr	Ser	· Val	175 Ser	Gln
		Thr	Val	,			Ser	185 Val							Pro
															Ala
225	val	Lys	Val	Val	Thr 230	Pro	Lys	Val	Glu	Thr	${\tt Gl}_{Y}$	Ala	Ser	Pro	Glu
His	Val	Ser	Ala	Pro 245	Ala	Val	Pro	Val	Thr	235 Thr	Thr	Ser	Thr	Ala	240 Thr
			Leu	Gln	Ala										
					Thr										
					Pro										
					Val 310						Val				
Thr	Tyr	Arg	Ala	Gly 325	Asp	Pro	Gly	Asp	His	Gly	Lys	Gly	Leu	Ala	320 Val
Asp	Phe	Ile	Val 340	Gly	Lys	Asn	Gln	Ala	330 Leu	Gly	Asn	Glu	Val	335 Ala	Gln
					Met										
							3011					2			
					Ser	2/7					200				
Thr 385	Trp	Asn	Ala	Met	Pro .	Asp .	Arg	Gly	Gly	Val	Thr	Ala	Asn	His	Tyr
					Ser					395					400

BNSDOCID: <WO__ 9942588A2 I >

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/31, C07K 14/315, A61K 39/09, C12N 1/21

(11) International Publication Number:

WO 99/42588

A3

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/CA99/00114

(22) International Filing Date:

17 February 1999 (17.02.99)

(30) Priority Data:

60/075,425

20 February 1998 (20.02.98)

US

(71) Applicant (for all designated States except US): BIOCHEM VACCINS INC. [CA/CA]; 2323 boulevard du Parc Technologique, Sainte-Foy, Québec G1P 4R8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRODEUR, Bernard, R. [CA/CA]; 2401 rue Maritain, Sillery, Québec GIT 1N6 (CA). RIOUX, Clément [CA/CA]; 1012 Jean-Charles Cantin, Ville de Cap Rouge, Québec G1Y 2X1 (CA). BOYER, Martine [CA/CA]; Apt. 204, 25 des Mouettes, Beauport, Québec G1E 7G1 (CA). CHARLEBOIS, Isabelle [CA/CA]; 410 Mirabel, St-Nicolas, Québec G7A 2L5 (CA). HAMEL, Josée [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G rue Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9 (CA).

(74) Agents: CÔTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:

23 March 2000 (23.03.00)

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

(57) Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Senegal
ΑZ	Azerbaijan	GB	United Kingdom	MC	Моласо	3Z TD	Swaziland
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Chad
BB	Barbados	GН	Ghana	MG	Madagascar	TJ	Togo
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Tajikistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkmenistan
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Turkey
BJ	Benin	IE	Ireland	MN	Mongolia		Trinidad and Tobago
BR	Brazil	IL	Israel	MR	Mauritania	UA	Ukraine
BY	Belarus	IS	Iceland	MW	Malawi	UG	Uganda
CA	Canada	IT	Italy	MX	Mexico	US	United States of Americ
CF	Central African Republic	JP	Japan	NE	Niger	UZ	Uzbekistan
CG	Congo	KE	Kenya	NL	Netherlands	VN	Viet Nam
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	zw	Zimbabwe
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT			
CU	Cuba	KZ	Kazakstan	RO	Portugal Romania		
CZ	Czech Republic	LC	Saint Lucia	RU			
DE	Germany	LI	Liechtenstein	SD	Russian Federation Sudan		
DK	Denmark	LK	Sri Lanka	SE			
EE	Estonia	LR	Liberia	SG	Sweden		
			2.00.10	36	Singapore		

Interr nal Application No PCT/CA 99/00114

		PCT/CR 33/	
CLASSIFIC	CATION OF SUBJECT MATTER C12N15/31 C07K14/315 A61K39/0	09 C12N1/21	
	nternational Patent Classification (IPC) or to both national classifica	ution and IPC	
	FARCHED		
Minimum docu	mentation searched (classification system followed by classification	on symbols)	
IPC 6	C07K C12N A61K		
	in searched other than minimum documentation to the extent that s	uch documents are included in the fields sea	rohed
Electronic dat	a base consulted during the international search (name of data ba	se and, where practical, search terms used)	
C. DOCUME	NTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the re	levant passages	Neisvani to ciami to
	MICHEL J L ET AL: "Cloned alpha	and beta	1-48
A	C-protein antigens of group B St	reptococci	
	elicit protective immunity"	·	
	INFECTION AND IMMUNITY., vol. 59, no. 6, June 1991 (1991-	-06), pages	
	2023-2028 XP00210/260		
	AMERICAN SOCIETY FOR MICROBIOLOG	GY.	
	WASHINGTON., US ISSN: 0019-9567		
į	the whole document		
		-/	
		,	
1			
	other documents are listed in the continuation of box C.	Patent family members are lister	in annex.
			tomational filing date
1	extegories of cited documents :	"I later document published after the in or priority date and not in conflict will cited to understand the principle or t	
1 cons	ment defining the general state of the art which is not sidered to be of particular relevance	invention	claimed invention
filing	r document but published on or after the international cate	cannot be considered novel or cannot involve an inventive step when the	
1	nent which may throw doubts on priority claim(s) or this cited to establish the publication date of another	"Y" document of particular relevance; the	claimed invention inventive atep when the
l citat	ment referring to an oral disclosure, use, exhibition or	document is combined with one or i ments, such combination being obv	mare other such dood.
P docu	er means ment published prior to the international filing date but	in the art. *&* document member of the same pate	
late	r than the priority date claimed	Date of mailing of the international	
Date of th	ne actual completion of the international search	24 01 20	
	15 December 1999	24 01 20	
Name an	nd mailing address of the ISA	Authorized officer	
	European Patent Office, P.B. 5818 Patentiaan 2	lejeune P	
1	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Lejeune, R	

Form PCT/ISA/210 (second sheet) (July 1992)

PCT/CA 99/00114

		PCT/CA 99/00114
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	LACHENAUER C S ET AL: "Cloning and expression in Escherichia coli of a protective surface protein from type V group B Streptococci" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 418, 9 December 1997 (1997-12-09), pages 615-618, XP002107261 SPRING ST., NY, US ISSN: 0065-2598 the whole document	1-48
P,X	DATABASE EMBL [Online] Accession number AF062533, 11 February 1999 (1999-02-11) SPELLERBERG B ET AL: "Streptococcus agalactiae Lmb (lmb) gene, complete cds; and unknown gene." XP002125180 98.9% identity between base 1-2514 of SEQ ID NO 13 and base 988-3501 of AF062533 Translation product (AC: Q9ZHG9) has 98.5% identity in 793 AA overlap with SEQ ID NO 15 and 98.5% identity in 715 AA overlap with SEQ ID 16 & SPELLERBERG B ET AL: "Lmb, a protein with similarities to the LraI adhesin family, mediates attachment of Streptococcus agalactiae to human laminin" INFECTION AND IMMUNITY., vol. 67, no. 2, February 1999 (1999-02), pages 871-878, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON., US ISSN: 0019-9567	1-10, 16-23,26
X	DATABASE EMBL [Online] Accession Number L23843, 4 January 1994 (1994-01-04) MACRINA F L ET AL: "ISN IS199 from Streptococcus mutans IS3 (Brathal) serotype C) DNA fragment" XP002125181 79.6% identity between base 5212-4314 of SEQ ID NO 13 and base 312-1220 of L23843 Translation has 83.4% identity in 283 AA overlap with SEQ ID NO 21	1,3-7,10

Inter: nat Application No PCT/CA 99/00114

		PC1/CA 99/00114				
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Newvant to claim No.				
	DATABASE EMBL [Online] Accession Number AF026542, 15 October 1997 (1997-10-15) HYNES W L ET AL: "Streptococcus pyogenes FF22 lantibiotic (scn) gene cluster region containing: scnK, scnR, streptococcin A-FF22 precursor (scnA), scnA1, scnM, scnT, scnF, scnE, scnG genes, complete cds, and tnpA gene, partial cds." XP002125182 88.2% identity between base 2607-2953 of SEQ ID NO 13 and base 10435-10777 of AF026542 Translation product (AC: 031057) has 95.8% identity in 71 AA overlap with SEQ ID NO	1-10, 16-23,26				
P,X	DATABASE GENESEQ [Online] Accession Number V52136, 23 October 1998 (1998-10-23) BARASH S C ET AL: "Streptococcus pneumoniae genome fragment SEQ ID NO:3" XP002125183 68.5% identity between base 2539-3319 of SEQ ID NO 37 and base 18492-19271 of V52136 Translation has 74.5% identity in 231 AA overlap with SEQ ID NO 40 & WO 98 18931 A (DOUGHERTY BRIAN A ;HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A) 7 May 1998 (1998-05-07)	1,3-7,10				

3

ational application No. PCT/CA 99/00114

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
(Community of home a sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
Although claims 37-46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	_
	_
This International Searching Authority found multiple inventions in this international application, as follows:	
see additional sheet	
As a result of the prior review under R. 40.2(e) PCT, no additional fees are to be refunded.	
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
11-14,16,24,25,27,28,30,31 (completely), 1-10,15,17-23,26,29,32-48 (all partially) i.e. (group of) inventions 1, 3 and 7	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest X The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	